Priothera Limited 07/09/2024 Approve Dec 31 2022 financial statements CORPORATE GOVERNANCE ISSUER 346666.000000 0.000000 FOR 346666.000000 FOR Priothera Limited 07/09/2024 Re-appoint statutory auditors AUDIT-RELATED ISSUER 346666.000000 0.000000 FOR 346666.000000 FOR Priothera Limited 07/09/2024 Authorize directors to approve remuneration of the statutory auditors for the calendar year 2023 AUDIT-RELATED ISSUER 346666.000000 0.000000 FOR 346666.000000 FOR Jazz Pharmaceuticals plc G50871105 IE00B4Q5ZN47 07/25/2024 To elect four nominees for director named below to hold office until the 2027 Annual General Meeting of Shareholders: Laura J. Hamill DIRECTOR ELECTIONS ISSUER 22124.000000 0 FOR 22124.000000 FOR Jazz Pharmaceuticals plc G50871105 IE00B4Q5ZN47 07/25/2024 To elect four nominees for director named below to hold office until the 2027 Annual General Meeting of Shareholders: Patrick Kennedy DIRECTOR ELECTIONS ISSUER 22124.000000 0 FOR 22124.000000 FOR Jazz Pharmaceuticals plc G50871105 IE00B4Q5ZN47 07/25/2024 To elect four nominees for director named below to hold office until the 2027 Annual General Meeting of Shareholders: Kenneth W. O'Keefe DIRECTOR ELECTIONS ISSUER 22124.000000 0 FOR 22124.000000 FOR Jazz Pharmaceuticals plc G50871105 IE00B4Q5ZN47 07/25/2024 To elect four nominees for director named below to hold office until the 2027 Annual General Meeting of Shareholders: Mark D. Smith, M.D. DIRECTOR ELECTIONS ISSUER 22124.000000 0 FOR 22124.000000 FOR Jazz Pharmaceuticals plc G50871105 IE00B4Q5ZN47 07/25/2024 To ratify, on a non-binding advisory basis, the appointment of KPMG as the independent auditors of Jazz Pharmaceuticals plc for the fiscal year ending December 31, 2024 and to authorize, in a binding vote, the Board of Directors, acting through the audit committee, to determine KPMG's remuneration. AUDIT-RELATED ISSUER 22124.000000 0 FOR 22124.000000 FOR Jazz Pharmaceuticals plc G50871105 IE00B4Q5ZN47 07/25/2024 To approve, on a non-binding advisory basis, the compensation of Jazz Pharmaceuticals plc's named executive officers, as disclosed in the proxy statement. SECTION 14A SAY-ON-PAY VOTES ISSUER 22124.000000 0 AGAINST 22124.000000 AGAINST Jazz Pharmaceuticals plc G50871105 IE00B4Q5ZN47 07/25/2024 To indicate, on a non-binding advisory basis, the preferred frequency of the advisory vote on the compensation of Jazz Pharmaceuticals plc's named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 22124.000000 0 ONE YEAR 22124.000000 FOR Jazz Pharmaceuticals plc G50871105 IE00B4Q5ZN47 07/25/2024 To grant the Board of Directors authority under Irish law to allot and issue ordinary shares for cash without first offering those ordinary shares to existing shareholders pursuant to the statutory pre-emption right that would otherwise apply. CAPITAL STRUCTURE ISSUER 22124.000000 0 AGAINST 22124.000000 AGAINST Jazz Pharmaceuticals plc G50871105 IE00B4Q5ZN47 07/25/2024 To approve any motion to adjourn the Annual General Meeting, or any adjournments thereof, to another time and place to solicit additional proxies if there are insufficient votes at the time of the Annual General Meeting to approve Proposal 5. CORPORATE GOVERNANCE ISSUER 22124.000000 0 FOR 22124.000000 FOR McKesson Corporation 58155Q103 US58155Q1031 07/31/2024 Election of eleven directors for a one-year term: Richard H. Carmona, M.D. DIRECTOR ELECTIONS ISSUER 12176.000000 0 FOR 12176.000000 FOR McKesson Corporation 58155Q103 US58155Q1031 07/31/2024 Election of eleven directors for a one-year term: Dominic J. Caruso DIRECTOR ELECTIONS ISSUER 12176.000000 0 FOR 12176.000000 FOR McKesson Corporation 58155Q103 US58155Q1031 07/31/2024 Election of eleven directors for a one-year term: W. Roy Dunbar DIRECTOR ELECTIONS ISSUER 12176.000000 0 FOR 12176.000000 FOR McKesson Corporation 58155Q103 US58155Q1031 07/31/2024 Election of eleven directors for a one-year term: Deborah Dunsire, M.D. DIRECTOR ELECTIONS ISSUER 12176.000000 0 FOR 12176.000000 FOR McKesson Corporation 58155Q103 US58155Q1031 07/31/2024 Election of eleven directors for a one-year term: James H. Hinton DIRECTOR ELECTIONS ISSUER 12176.000000 0 FOR 12176.000000 FOR McKesson Corporation 58155Q103 US58155Q1031 07/31/2024 Election of eleven directors for a one-year term: Donald R. Knauss DIRECTOR ELECTIONS ISSUER 12176.000000 0 FOR 12176.000000 FOR McKesson Corporation 58155Q103 US58155Q1031 07/31/2024 Election of eleven directors for a one-year term: Bradley E. Lerman DIRECTOR ELECTIONS ISSUER 12176.000000 0 FOR 12176.000000 FOR McKesson Corporation 58155Q103 US58155Q1031 07/31/2024 Election of eleven directors for a one-year term: Maria N. Martinez DIRECTOR ELECTIONS ISSUER 12176.000000 0 FOR 12176.000000 FOR McKesson Corporation 58155Q103 US58155Q1031 07/31/2024 Election of eleven directors for a one-year term: Kevin M. Ozan DIRECTOR ELECTIONS ISSUER 12176.000000 0 FOR 12176.000000 FOR McKesson Corporation 58155Q103 US58155Q1031 07/31/2024 Election of eleven directors for a one-year term: Brian S. Tyler DIRECTOR ELECTIONS ISSUER 12176.000000 0 FOR 12176.000000 FOR McKesson Corporation 58155Q103 US58155Q1031 07/31/2024 Election of eleven directors for a one-year term: Kathleen Wilson-Thompson DIRECTOR ELECTIONS ISSUER 12176.000000 0 FOR 12176.000000 FOR McKesson Corporation 58155Q103 US58155Q1031 07/31/2024 Ratification of Appointment of Deloitte & Touche LLP as the Company's Independent Registered Public Accounting Firm for Fiscal Year 2025 AUDIT-RELATED ISSUER 12176.000000 0 AGAINST 12176.000000 AGAINST McKesson Corporation 58155Q103 US58155Q1031 07/31/2024 Advisory vote on Executive Compensation SECTION 14A SAY-ON-PAY VOTES ISSUER 12176.000000 0 AGAINST 12176.000000 AGAINST McKesson Corporation 58155Q103 US58155Q1031 07/31/2024 Approve Amendment to Certificate of Incorporation to Provide for Officer Exculpation CORPORATE GOVERNANCE ISSUER 12176.000000 0 FOR 12176.000000 FOR McKesson Corporation 58155Q103 US58155Q1031 07/31/2024 Shareholder Proposal on Independent Board Chairman CORPORATE GOVERNANCE SECURITY HOLDER 12176.000000 0 FOR 12176.000000 AGAINST McKesson Corporation 58155Q103 US58155Q1031 07/31/2024 Shareholder Proposal on Report on Risks of State Policies Restricting Reproductive Health Care OTHER SOCIAL ISSUES SECURITY HOLDER 12176.000000 0 AGAINST 12176.000000 FOR Immunovant, Inc. 45258J102 US45258J1025 08/12/2024 To elect as directors the three nominees named in the Company's proxy statement, each to hold office until our 2025 Annual Meeting of Stockholders and until their successors are duly elected and qualified: Peter Salzmann, M.D., M.B.A. DIRECTOR ELECTIONS ISSUER 263613.000000 0 WITHHOLD 263613.000000 AGAINST Immunovant, Inc. 45258J102 US45258J1025 08/12/2024 To elect as directors the three nominees named in the Company's proxy statement, each to hold office until our 2025 Annual Meeting of Stockholders and until their successors are duly elected and qualified: George Migausky DIRECTOR ELECTIONS ISSUER 263613.000000 0 WITHHOLD 263613.000000 AGAINST Immunovant, Inc. 45258J102 US45258J1025 08/12/2024 To elect as directors the three nominees named in the Company's proxy statement, each to hold office until our 2025 Annual Meeting of Stockholders and until their successors are duly elected and qualified: Douglas Hughes DIRECTOR ELECTIONS ISSUER 263613.000000 0 WITHHOLD 263613.000000 AGAINST Immunovant, Inc. 45258J102 US45258J1025 08/12/2024 To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending March 31, 2025. AUDIT-RELATED ISSUER 263613.000000 0 FOR 263613.000000 FOR Immunovant, Inc. 45258J102 US45258J1025 08/12/2024 To approve, on a non-binding, advisory basis, the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 263613.000000 0 FOR 263613.000000 FOR Roivant Sciences Ltd. G76279101 BMG762791017 09/10/2024 To elect the Board of Directors' three nominees for Class III Director to serve for a three-year term: Ilan Oren DIRECTOR ELECTIONS ISSUER 747277.000000 0 WITHHOLD 747277.000000 AGAINST Roivant Sciences Ltd. G76279101 BMG762791017 09/10/2024 To elect the Board of Directors' three nominees for Class III Director to serve for a three-year term: James C. Momtazee DIRECTOR ELECTIONS ISSUER 747277.000000 0 WITHHOLD 747277.000000 AGAINST Roivant Sciences Ltd. G76279101 BMG762791017 09/10/2024 To elect the Board of Directors' three nominees for Class III Director to serve for a three-year term: Mayukh Sukhatme DIRECTOR ELECTIONS ISSUER 747277.000000 0 FOR 747277.000000 FOR Roivant Sciences Ltd. G76279101 BMG762791017 09/10/2024 To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as Roivant's independent registered public accounting firm for Roivant's fiscal year ending March 31, 2025, to appoint Ernst & Young LLP as auditor for statutory purposes under the Bermuda Companies Act 1981, as amended, for Roivant's fiscal year ending March 31, 2025, and to authorize the Board of Directors, through the Audit Committee, to set the remuneration for Ernst & Young LLP as Roivant's auditor for Roivant's fiscal year ending March 31, 2025. AUDIT-RELATED ISSUER 747277.000000 0 FOR 747277.000000 FOR Roivant Sciences Ltd. G76279101 BMG762791017 09/10/2024 To cast a non-binding, advisory vote to approve the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 747277.000000 0 FOR 747277.000000 FOR Roivant Sciences Ltd. G76279101 BMG762791017 09/10/2024 To cast a non-binding, advisory vote on the frequency of future non-binding, advisory votes to approve the compensation of our named executive officers every: SECTION 14A SAY-ON-PAY VOTES ISSUER 747277.000000 0 ONE YEAR 747277.000000 FOR Rhythm Pharmaceuticals, Inc. 76243J105 US76243J1051 09/18/2024 Election of the Class I directors, each to serve for a three year term until the 2027 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified: Stuart A. Arbuckle DIRECTOR ELECTIONS ISSUER 74675.000000 0 WITHHOLD 74675.000000 AGAINST Rhythm Pharmaceuticals, Inc. 76243J105 US76243J1051 09/18/2024 Election of the Class I directors, each to serve for a three year term until the 2027 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified: Christophe R. Jean DIRECTOR ELECTIONS ISSUER 74675.000000 0 WITHHOLD 74675.000000 AGAINST Rhythm Pharmaceuticals, Inc. 76243J105 US76243J1051 09/18/2024 Election of the Class I directors, each to serve for a three year term until the 2027 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified: Lynn A. Tetrault DIRECTOR ELECTIONS ISSUER 74675.000000 0 WITHHOLD 74675.000000 AGAINST Rhythm Pharmaceuticals, Inc. 76243J105 US76243J1051 09/18/2024 Ratification of the appointment of Ernst & Young LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2024. AUDIT-RELATED ISSUER 74675.000000 0 FOR 74675.000000 FOR Rhythm Pharmaceuticals, Inc. 76243J105 US76243J1051 09/18/2024 Approval, on an advisory (non-binding) basis, of the compensation of the named executive officers of the Company. SECTION 14A SAY-ON-PAY VOTES ISSUER 74675.000000 0 FOR 74675.000000 FOR Rhythm Pharmaceuticals, Inc. 76243J105 US76243J1051 09/18/2024 Reapproval of the Rhythm Pharmaceuticals, Inc. 2017 Equity Incentive Plan. COMPENSATION ISSUER 74675.000000 0 AGAINST 74675.000000 AGAINST Galera Therapeutics, Inc. 36338D108 US36338D1081 10/17/2024 To approve the liquidation and dissolution of the Company and the Plan of Liquidation and Dissolution (the "Plan of Dissolution") which, if approved, will authorize the Company's Board of Directors to liquidate and dissolve the Company in accordance with the Plan of Dissolution (the "Dissolution Proposal"). EXTRAORDINARY TRANSACTIONS ISSUER 296462.000000 0 FOR 296462.000000 FOR Galera Therapeutics, Inc. 36338D108 US36338D1081 10/17/2024 To adjourn the Special Meeting, from time to time, to a later date or dates, even if a quorum is present, to solicit additional proxies in the event that there are not sufficient votes at the time of the Special Meeting to approve the Dissolution Proposal. CORPORATE GOVERNANCE ISSUER 296462.000000 0 FOR 296462.000000 FOR Medtronic Plc G5960L103 IE00BTN1Y115 10/17/2024 Electing, by separate resolutions, the ten director nominees named in the proxy statement to hold office until the 2025 Annual General Meeting of Medtronic plc (the "Company"): Craig Arnold DIRECTOR ELECTIONS ISSUER 52381.000000 0 FOR 52381.000000 FOR Medtronic Plc G5960L103 IE00BTN1Y115 10/17/2024 Electing, by separate resolutions, the ten director nominees named in the proxy statement to hold office until the 2025 Annual General Meeting of Medtronic plc (the "Company"): Scott C. Donnelly DIRECTOR ELECTIONS ISSUER 52381.000000 0 FOR 52381.000000 FOR Medtronic Plc G5960L103 IE00BTN1Y115 10/17/2024 Electing, by separate resolutions, the ten director nominees named in the proxy statement to hold office until the 2025 Annual General Meeting of Medtronic plc (the "Company"): Lidia L. Fonseca DIRECTOR ELECTIONS ISSUER 52381.000000 0 FOR 52381.000000 FOR Medtronic Plc G5960L103 IE00BTN1Y115 10/17/2024 Electing, by separate resolutions, the ten director nominees named in the proxy statement to hold office until the 2025 Annual General Meeting of Medtronic plc (the "Company"): Andrea J. Goldsmith, Ph.D. DIRECTOR ELECTIONS ISSUER 52381.000000 0 FOR 52381.000000 FOR Medtronic Plc G5960L103 IE00BTN1Y115 10/17/2024 Electing, by separate resolutions, the ten director nominees named in the proxy statement to hold office until the 2025 Annual General Meeting of Medtronic plc (the "Company"): Randall J. Hogan, III DIRECTOR ELECTIONS ISSUER 52381.000000 0 FOR 52381.000000 FOR Medtronic Plc G5960L103 IE00BTN1Y115 10/17/2024 Electing, by separate resolutions, the ten director nominees named in the proxy statement to hold office until the 2025 Annual General Meeting of Medtronic plc (the "Company"): Gregory P. Lewis DIRECTOR ELECTIONS ISSUER 52381.000000 0 FOR 52381.000000 FOR Medtronic Plc G5960L103 IE00BTN1Y115 10/17/2024 Electing, by separate resolutions, the ten director nominees named in the proxy statement to hold office until the 2025 Annual General Meeting of Medtronic plc (the "Company"): Kevin E. Lofton DIRECTOR ELECTIONS ISSUER 52381.000000 0 FOR 52381.000000 FOR Medtronic Plc G5960L103 IE00BTN1Y115 10/17/2024 Electing, by separate resolutions, the ten director nominees named in the proxy statement to hold office until the 2025 Annual General Meeting of Medtronic plc (the "Company"): Geoffrey S. Martha DIRECTOR ELECTIONS ISSUER 52381.000000 0 FOR 52381.000000 FOR Medtronic Plc G5960L103 IE00BTN1Y115 10/17/2024 Electing, by separate resolutions, the ten director nominees named in the proxy statement to hold office until the 2025 Annual General Meeting of Medtronic plc (the "Company"): Elizabeth G. Nabel, M.D. DIRECTOR ELECTIONS ISSUER 52381.000000 0 FOR 52381.000000 FOR Medtronic Plc G5960L103 IE00BTN1Y115 10/17/2024 Electing, by separate resolutions, the ten director nominees named in the proxy statement to hold office until the 2025 Annual General Meeting of Medtronic plc (the "Company"): Kendall J. Powell DIRECTOR ELECTIONS ISSUER 52381.000000 0 AGAINST 52381.000000 AGAINST Medtronic Plc G5960L103 IE00BTN1Y115 10/17/2024 Ratifying, in a non-binding vote, the appointment of PricewaterhouseCoopers LLP as the Company's independent auditor for fiscal year 2025 and authorizing, in a binding vote, the Board of Directors, acting through the Audit Committee, to set the auditor's remuneration; AUDIT-RELATED ISSUER 52381.000000 0 AGAINST 52381.000000 AGAINST Medtronic Plc G5960L103 IE00BTN1Y115 10/17/2024 Approving, on an advisory basis, the Company's executive compensation; SECTION 14A SAY-ON-PAY VOTES ISSUER 52381.000000 0 AGAINST 52381.000000 AGAINST Medtronic Plc G5960L103 IE00BTN1Y115 10/17/2024 Renewing the Board of Directors' authority to issue shares under Irish law; CAPITAL STRUCTURE ISSUER 52381.000000 0 FOR 52381.000000 FOR Medtronic Plc G5960L103 IE00BTN1Y115 10/17/2024 Renewing the Board of Directors' authority to opt out of pre-emption rights under Irish law; and CAPITAL STRUCTURE ISSUER 52381.000000 0 AGAINST 52381.000000 AGAINST Medtronic Plc G5960L103 IE00BTN1Y115 10/17/2024 Authorizing the Company and any subsidiary of the Company to make overseas market purchases of Medtronic ordinary shares. CAPITAL STRUCTURE ISSUER 52381.000000 0 FOR 52381.000000 FOR Pyxis Oncology, Inc. 747324101 US7473241013 10/23/2024 Approval of an increase in the number of shares of our common stock available for issuance under our 2021 Equity and Incentive Plan by 5,500,000 shares. COMPENSATION ISSUER 481646.000000 0 FOR 481646.000000 FOR Pyxis Oncology, Inc. 747324101 US7473241013 10/23/2024 Approval of the adjournment of the special meeting, if necessary, in the reasonable discretion of the Chairperson of the Board, to solicit additional proxies if there are insufficient votes at the time of the special meeting to approve the plan amendment. CORPORATE GOVERNANCE ISSUER 481646.000000 0 FOR 481646.000000 FOR State Street Institutional Investment Trust 857492706 US8574927062 12/06/2024 To Elect a Board of Trustees: Patrick J. Riley DIRECTOR ELECTIONS ISSUER 29295154.460000 0 FOR 29295154.460000 FOR State Street Institutional Investment Trust 857492706 US8574927062 12/06/2024 To Elect a Board of Trustees: Donna M. Rapaccioli DIRECTOR ELECTIONS ISSUER 29295154.460000 0 FOR 29295154.460000 FOR State Street Institutional Investment Trust 857492706 US8574927062 12/06/2024 To Elect a Board of Trustees: Margaret K. McLaughlin DIRECTOR ELECTIONS ISSUER 29295154.460000 0 FOR 29295154.460000 FOR State Street Institutional Investment Trust 857492706 US8574927062 12/06/2024 To Elect a Board of Trustees: George M. Pereira DIRECTOR ELECTIONS ISSUER 29295154.460000 0 FOR 29295154.460000 FOR State Street Institutional Investment Trust 857492706 US8574927062 12/06/2024 To Elect a Board of Trustees: Mark E. Swanson DIRECTOR ELECTIONS ISSUER 29295154.460000 0 FOR 29295154.460000 FOR State Street Institutional Investment Trust 857492706 US8574927062 12/06/2024 To Elect a Board of Trustees: Jeanne LaPorta DIRECTOR ELECTIONS ISSUER 29295154.460000 0 FOR 29295154.460000 FOR Becton, Dickinson and Company 075887109 US0758871091 01/28/2025 Election of Directors: William M. Brown DIRECTOR ELECTIONS ISSUER 33002.000000 0 FOR 33002.000000 FOR Becton, Dickinson and Company 075887109 US0758871091 01/28/2025 Election of Directors: Catherine M. Burzik DIRECTOR ELECTIONS ISSUER 33002.000000 0 FOR 33002.000000 FOR Becton, Dickinson and Company 075887109 US0758871091 01/28/2025 Election of Directors: Carrie Byington DIRECTOR ELECTIONS ISSUER 33002.000000 0 FOR 33002.000000 FOR Becton, Dickinson and Company 075887109 US0758871091 01/28/2025 Election of Directors: R. Andrew Eckert DIRECTOR ELECTIONS ISSUER 33002.000000 0 FOR 33002.000000 FOR Becton, Dickinson and Company 075887109 US0758871091 01/28/2025 Election of Directors: Claire M. Fraser DIRECTOR ELECTIONS ISSUER 33002.000000 0 AGAINST 33002.000000 AGAINST Becton, Dickinson and Company 075887109 US0758871091 01/28/2025 Election of Directors: Jeffrey W. Henderson DIRECTOR ELECTIONS ISSUER 33002.000000 0 FOR 33002.000000 FOR Becton, Dickinson and Company 075887109 US0758871091 01/28/2025 Election of Directors: Christopher Jones DIRECTOR ELECTIONS ISSUER 33002.000000 0 FOR 33002.000000 FOR Becton, Dickinson and Company 075887109 US0758871091 01/28/2025 Election of Directors: Thomas E. Polen DIRECTOR ELECTIONS ISSUER 33002.000000 0 FOR 33002.000000 FOR Becton, Dickinson and Company 075887109 US0758871091 01/28/2025 Election of Directors: Timothy M. Ring DIRECTOR ELECTIONS ISSUER 33002.000000 0 FOR 33002.000000 FOR Becton, Dickinson and Company 075887109 US0758871091 01/28/2025 Election of Directors: Bertram L. Scott DIRECTOR ELECTIONS ISSUER 33002.000000 0 AGAINST 33002.000000 AGAINST Becton, Dickinson and Company 075887109 US0758871091 01/28/2025 Election of Directors: Joanne Waldstreicher DIRECTOR ELECTIONS ISSUER 33002.000000 0 FOR 33002.000000 FOR Becton, Dickinson and Company 075887109 US0758871091 01/28/2025 Ratification of the selection of the independent registered public accounting firm. AUDIT-RELATED ISSUER 33002.000000 0 AGAINST 33002.000000 AGAINST Becton, Dickinson and Company 075887109 US0758871091 01/28/2025 Advisory vote to approve named executive officer compensation. SECTION 14A SAY-ON-PAY VOTES ISSUER 33002.000000 0 AGAINST 33002.000000 AGAINST Galera Therapeutics, Inc. 36338D108 US36338D1081 02/24/2025 Election of Class II Directors to serve until the 2027 Annual Meeting of Stockholders, and until their respective successors shall have been duly elected and qualified: Lawrence Alleva DIRECTOR ELECTIONS ISSUER 296462.000000 0 WITHHOLD 296462.000000 AGAINST Galera Therapeutics, Inc. 36338D108 US36338D1081 02/24/2025 Election of Class II Directors to serve until the 2027 Annual Meeting of Stockholders, and until their respective successors shall have been duly elected and qualified: Kevin Lokay DIRECTOR ELECTIONS ISSUER 296462.000000 0 WITHHOLD 296462.000000 AGAINST Galera Therapeutics, Inc. 36338D108 US36338D1081 02/24/2025 To ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024. AUDIT-RELATED ISSUER 296462.000000 0 FOR 296462.000000 FOR Arrowhead Pharmaceuticals, Inc. 04280A100 US04280A1007 03/12/2025 Election of Directors: Hongbo Lu DIRECTOR ELECTIONS ISSUER 301338.000000 0 FOR 301338.000000 FOR Arrowhead Pharmaceuticals, Inc. 04280A100 US04280A1007 03/12/2025 Election of Directors: Michael S. Perry DIRECTOR ELECTIONS ISSUER 301338.000000 0 FOR 301338.000000 FOR Arrowhead Pharmaceuticals, Inc. 04280A100 US04280A1007 03/12/2025 Election of Directors: Christopher Anzalone DIRECTOR ELECTIONS ISSUER 301338.000000 0 FOR 301338.000000 FOR Arrowhead Pharmaceuticals, Inc. 04280A100 US04280A1007 03/12/2025 Election of Directors: Mauro Ferrari DIRECTOR ELECTIONS ISSUER 301338.000000 0 FOR 301338.000000 FOR Arrowhead Pharmaceuticals, Inc. 04280A100 US04280A1007 03/12/2025 Election of Directors: Adeoye Olukotun DIRECTOR ELECTIONS ISSUER 301338.000000 0 FOR 301338.000000 FOR Arrowhead Pharmaceuticals, Inc. 04280A100 US04280A1007 03/12/2025 Election of Directors: William Waddill DIRECTOR ELECTIONS ISSUER 301338.000000 0 FOR 301338.000000 FOR Arrowhead Pharmaceuticals, Inc. 04280A100 US04280A1007 03/12/2025 Election of Directors: Victoria Vakiener DIRECTOR ELECTIONS ISSUER 301338.000000 0 FOR 301338.000000 FOR Arrowhead Pharmaceuticals, Inc. 04280A100 US04280A1007 03/12/2025 Election of Directors: Douglas Ingram DIRECTOR ELECTIONS ISSUER 301338.000000 0 FOR 301338.000000 FOR Arrowhead Pharmaceuticals, Inc. 04280A100 US04280A1007 03/12/2025 Advisory Vote to Approve Executive Compensation. SECTION 14A SAY-ON-PAY VOTES ISSUER 301338.000000 0 FOR 301338.000000 FOR Arrowhead Pharmaceuticals, Inc. 04280A100 US04280A1007 03/12/2025 Advisory Vote on Frequency of Executive Compensation Advisory Votes. SECTION 14A SAY-ON-PAY VOTES ISSUER 301338.000000 0 ONE YEAR 301338.000000 FOR Arrowhead Pharmaceuticals, Inc. 04280A100 US04280A1007 03/12/2025 To ratify the selection of KPMG LLP as independent auditors of the Company for the fiscal year ending September 30, 2025. AUDIT-RELATED ISSUER 301338.000000 0 FOR 301338.000000 FOR AstraZeneca PLC 046353108 US0463531089 04/11/2025 Accept Financial Statements and Statutory Reports CORPORATE GOVERNANCE ISSUER 229467.000000 0 FOR 229467.000000 FOR AstraZeneca PLC 046353108 US0463531089 04/11/2025 Approve Dividends CAPITAL STRUCTURE ISSUER 229467.000000 0 FOR 229467.000000 FOR AstraZeneca PLC 046353108 US0463531089 04/11/2025 Reappoint PricewaterhouseCoopers LLP as Auditors AUDIT-RELATED ISSUER 229467.000000 0 FOR 229467.000000 FOR AstraZeneca PLC 046353108 US0463531089 04/11/2025 Authorise Board to Fix Remuneration of Auditors AUDIT-RELATED ISSUER 229467.000000 0 FOR 229467.000000 FOR AstraZeneca PLC 046353108 US0463531089 04/11/2025 Re-elect Michel Demare as Director DIRECTOR ELECTIONS ISSUER 229467.000000 0 FOR 229467.000000 FOR AstraZeneca PLC 046353108 US0463531089 04/11/2025 Re-elect Pascal Soriot as Director DIRECTOR ELECTIONS ISSUER 229467.000000 0 FOR 229467.000000 FOR AstraZeneca PLC 046353108 US0463531089 04/11/2025 Re-elect Aradhana Sarin as Director DIRECTOR ELECTIONS ISSUER 229467.000000 0 FOR 229467.000000 FOR AstraZeneca PLC 046353108 US0463531089 04/11/2025 Re-elect Philip Broadley as Director DIRECTOR ELECTIONS ISSUER 229467.000000 0 FOR 229467.000000 FOR AstraZeneca PLC 046353108 US0463531089 04/11/2025 Re-elect Euan Ashley as Director DIRECTOR ELECTIONS ISSUER 229467.000000 0 FOR 229467.000000 FOR AstraZeneca PLC 046353108 US0463531089 04/11/2025 Elect Birgit Conix as Director DIRECTOR ELECTIONS ISSUER 229467.000000 0 FOR 229467.000000 FOR AstraZeneca PLC 046353108 US0463531089 04/11/2025 Elect Rene Haas as Director DIRECTOR ELECTIONS ISSUER 229467.000000 0 FOR 229467.000000 FOR AstraZeneca PLC 046353108 US0463531089 04/11/2025 Elect Karen Knudsen as Director DIRECTOR ELECTIONS ISSUER 229467.000000 0 FOR 229467.000000 FOR AstraZeneca PLC 046353108 US0463531089 04/11/2025 Re-elect Diana Layfield as Director DIRECTOR ELECTIONS ISSUER 229467.000000 0 FOR 229467.000000 FOR AstraZeneca PLC 046353108 US0463531089 04/11/2025 Re-elect Anna Manz as Director DIRECTOR ELECTIONS ISSUER 229467.000000 0 FOR 229467.000000 FOR AstraZeneca PLC 046353108 US0463531089 04/11/2025 Re-elect Sheri McCoy as Director DIRECTOR ELECTIONS ISSUER 229467.000000 0 FOR 229467.000000 FOR AstraZeneca PLC 046353108 US0463531089 04/11/2025 Re-elect Tony Mok as Director DIRECTOR ELECTIONS ISSUER 229467.000000 0 FOR 229467.000000 FOR AstraZeneca PLC 046353108 US0463531089 04/11/2025 Re-elect Nazneen Rahman as Director DIRECTOR ELECTIONS ISSUER 229467.000000 0 FOR 229467.000000 FOR AstraZeneca PLC 046353108 US0463531089 04/11/2025 Re-elect Marcus Wallenberg as Director DIRECTOR ELECTIONS ISSUER 229467.000000 0 FOR 229467.000000 FOR AstraZeneca PLC 046353108 US0463531089 04/11/2025 Approve Remuneration Report COMPENSATION ISSUER 229467.000000 0 FOR 229467.000000 FOR AstraZeneca PLC 046353108 US0463531089 04/11/2025 Authorise UK Political Donations and Expenditure OTHER SOCIAL ISSUES ISSUER 229467.000000 0 FOR 229467.000000 FOR AstraZeneca PLC 046353108 US0463531089 04/11/2025 Authorise Issue of Equity CAPITAL STRUCTURE ISSUER 229467.000000 0 FOR 229467.000000 FOR AstraZeneca PLC 046353108 US0463531089 04/11/2025 Authorise Issue of Equity without Pre-emptive Rights CAPITAL STRUCTURE ISSUER 229467.000000 0 FOR 229467.000000 FOR AstraZeneca PLC 046353108 US0463531089 04/11/2025 Authorise Issue of Equity without Pre-emptive Rights in Connection with an Acquisition or Other Capital Investment CAPITAL STRUCTURE ISSUER 229467.000000 0 FOR 229467.000000 FOR AstraZeneca PLC 046353108 US0463531089 04/11/2025 Authorise Market Purchase of Ordinary Shares CAPITAL STRUCTURE ISSUER 229467.000000 0 FOR 229467.000000 FOR AstraZeneca PLC 046353108 US0463531089 04/11/2025 Authorise the Company to Call General Meeting with Two Weeks' Notice CORPORATE GOVERNANCE ISSUER 229467.000000 0 FOR 229467.000000 FOR HCA Healthcare, Inc. 40412C101 US40412C1018 04/24/2025 Election of Directors: Thomas F. Frist III DIRECTOR ELECTIONS ISSUER 14452.000000 0 AGAINST 14452.000000 AGAINST HCA Healthcare, Inc. 40412C101 US40412C1018 04/24/2025 Election of Directors: Samuel N. Hazen DIRECTOR ELECTIONS ISSUER 14452.000000 0 FOR 14452.000000 FOR HCA Healthcare, Inc. 40412C101 US40412C1018 04/24/2025 Election of Directors: Robert J. Dennis DIRECTOR ELECTIONS ISSUER 14452.000000 0 FOR 14452.000000 FOR HCA Healthcare, Inc. 40412C101 US40412C1018 04/24/2025 Election of Directors: Nancy-Ann DeParle DIRECTOR ELECTIONS ISSUER 14452.000000 0 FOR 14452.000000 FOR HCA Healthcare, Inc. 40412C101 US40412C1018 04/24/2025 Election of Directors: William R. Frist DIRECTOR ELECTIONS ISSUER 14452.000000 0 AGAINST 14452.000000 AGAINST HCA Healthcare, Inc. 40412C101 US40412C1018 04/24/2025 Election of Directors: Hugh F. Johnston DIRECTOR ELECTIONS ISSUER 14452.000000 0 FOR 14452.000000 FOR HCA Healthcare, Inc. 40412C101 US40412C1018 04/24/2025 Election of Directors: Michael W. Michelson DIRECTOR ELECTIONS ISSUER 14452.000000 0 FOR 14452.000000 FOR HCA Healthcare, Inc. 40412C101 US40412C1018 04/24/2025 Election of Directors: Wayne J. Riley M.D. DIRECTOR ELECTIONS ISSUER 14452.000000 0 FOR 14452.000000 FOR HCA Healthcare, Inc. 40412C101 US40412C1018 04/24/2025 Election of Directors: Andrea B. Smith DIRECTOR ELECTIONS ISSUER 14452.000000 0 FOR 14452.000000 FOR HCA Healthcare, Inc. 40412C101 US40412C1018 04/24/2025 To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2025. AUDIT-RELATED ISSUER 14452.000000 0 AGAINST 14452.000000 AGAINST HCA Healthcare, Inc. 40412C101 US40412C1018 04/24/2025 Advisory vote to approve named executive officer compensation. SECTION 14A SAY-ON-PAY VOTES ISSUER 14452.000000 0 AGAINST 14452.000000 AGAINST HCA Healthcare, Inc. 40412C101 US40412C1018 04/24/2025 To approve the First Amendment to the 2020 Stock Incentive Plan for Key Employees of HCA Healthcare, Inc. and its Affiliates. COMPENSATION ISSUER 14452.000000 0 FOR 14452.000000 FOR HCA Healthcare, Inc. 40412C101 US40412C1018 04/24/2025 To approve an amendment to our amended and restated certificate of incorporation to provide for the exculpation of officers as permitted by Delaware law. CORPORATE GOVERNANCE ISSUER 14452.000000 0 FOR 14452.000000 FOR HCA Healthcare, Inc. 40412C101 US40412C1018 04/24/2025 Stockholder proposal, if properly presented at the meeting, regarding lavish golden parachutes. COMPENSATION SECURITY HOLDER 14452.000000 0 FOR 14452.000000 AGAINST HCA Healthcare, Inc. 40412C101 US40412C1018 04/24/2025 Stockholder proposal, if properly presented at the meeting, regarding an amendment to Patient Safety and Quality of Care Committee charter. OTHER SOCIAL ISSUES SECURITY HOLDER 14452.000000 0 AGAINST 14452.000000 FOR HCA Healthcare, Inc. 40412C101 US40412C1018 04/24/2025 Stockholder proposal, if properly presented at the meeting, regarding report on acquisition strategy. OTHER SOCIAL ISSUES SECURITY HOLDER 14452.000000 0 AGAINST 14452.000000 FOR Abbott Laboratories 002824100 US0028241000 04/25/2025 Election of 12 Directors: R. J. Alpern DIRECTOR ELECTIONS ISSUER 139100.000000 0 AGAINST 139100.000000 AGAINST Abbott Laboratories 002824100 US0028241000 04/25/2025 Election of 12 Directors: C. Babineaux-Fontenot DIRECTOR ELECTIONS ISSUER 139100.000000 0 FOR 139100.000000 FOR Abbott Laboratories 002824100 US0028241000 04/25/2025 Election of 12 Directors: S. E. Blount DIRECTOR ELECTIONS ISSUER 139100.000000 0 FOR 139100.000000 FOR Abbott Laboratories 002824100 US0028241000 04/25/2025 Election of 12 Directors: R. B. Ford DIRECTOR ELECTIONS ISSUER 139100.000000 0 FOR 139100.000000 FOR Abbott Laboratories 002824100 US0028241000 04/25/2025 Election of 12 Directors: P. Gonzalez DIRECTOR ELECTIONS ISSUER 139100.000000 0 FOR 139100.000000 FOR Abbott Laboratories 002824100 US0028241000 04/25/2025 Election of 12 Directors: M. A. Kumbier DIRECTOR ELECTIONS ISSUER 139100.000000 0 FOR 139100.000000 FOR Abbott Laboratories 002824100 US0028241000 04/25/2025 Election of 12 Directors: D. W. McDew DIRECTOR ELECTIONS ISSUER 139100.000000 0 FOR 139100.000000 FOR Abbott Laboratories 002824100 US0028241000 04/25/2025 Election of 12 Directors: N. McKinstry DIRECTOR ELECTIONS ISSUER 139100.000000 0 FOR 139100.000000 FOR Abbott Laboratories 002824100 US0028241000 04/25/2025 Election of 12 Directors: M. G. O'Grady DIRECTOR ELECTIONS ISSUER 139100.000000 0 FOR 139100.000000 FOR Abbott Laboratories 002824100 US0028241000 04/25/2025 Election of 12 Directors: M. F. Roman DIRECTOR ELECTIONS ISSUER 139100.000000 0 FOR 139100.000000 FOR Abbott Laboratories 002824100 US0028241000 04/25/2025 Election of 12 Directors: D. J. Starks DIRECTOR ELECTIONS ISSUER 139100.000000 0 FOR 139100.000000 FOR Abbott Laboratories 002824100 US0028241000 04/25/2025 Election of 12 Directors: J. G. Stratton DIRECTOR ELECTIONS ISSUER 139100.000000 0 FOR 139100.000000 FOR Abbott Laboratories 002824100 US0028241000 04/25/2025 Ratification of Ernst & Young LLP As Auditors AUDIT-RELATED ISSUER 139100.000000 0 FOR 139100.000000 FOR Abbott Laboratories 002824100 US0028241000 04/25/2025 Say on Pay - An Advisory Vote on the Approval of Executive Compensation SECTION 14A SAY-ON-PAY VOTES ISSUER 139100.000000 0 AGAINST 139100.000000 AGAINST Molina Healthcare, Inc. 60855R100 US60855R1005 04/30/2025 To elect nine directors to hold office until the 2026 Annual Meeting: Barbara L. Brasier DIRECTOR ELECTIONS ISSUER 14994.000000 0 FOR 14994.000000 FOR Molina Healthcare, Inc. 60855R100 US60855R1005 04/30/2025 To elect nine directors to hold office until the 2026 Annual Meeting: Leo P. Grohowski DIRECTOR ELECTIONS ISSUER 14994.000000 0 FOR 14994.000000 FOR Molina Healthcare, Inc. 60855R100 US60855R1005 04/30/2025 To elect nine directors to hold office until the 2026 Annual Meeting: Stephen H. Lockhart DIRECTOR ELECTIONS ISSUER 14994.000000 0 FOR 14994.000000 FOR Molina Healthcare, Inc. 60855R100 US60855R1005 04/30/2025 To elect nine directors to hold office until the 2026 Annual Meeting: Steven J. Orlando DIRECTOR ELECTIONS ISSUER 14994.000000 0 AGAINST 14994.000000 AGAINST Molina Healthcare, Inc. 60855R100 US60855R1005 04/30/2025 To elect nine directors to hold office until the 2026 Annual Meeting: Ronna E. Romney DIRECTOR ELECTIONS ISSUER 14994.000000 0 AGAINST 14994.000000 AGAINST Molina Healthcare, Inc. 60855R100 US60855R1005 04/30/2025 To elect nine directors to hold office until the 2026 Annual Meeting: Richard M. Schapiro DIRECTOR ELECTIONS ISSUER 14994.000000 0 FOR 14994.000000 FOR Molina Healthcare, Inc. 60855R100 US60855R1005 04/30/2025 To elect nine directors to hold office until the 2026 Annual Meeting: Dale B. Wolf DIRECTOR ELECTIONS ISSUER 14994.000000 0 FOR 14994.000000 FOR Molina Healthcare, Inc. 60855R100 US60855R1005 04/30/2025 To elect nine directors to hold office until the 2026 Annual Meeting: Richard C. Zoretic DIRECTOR ELECTIONS ISSUER 14994.000000 0 FOR 14994.000000 FOR Molina Healthcare, Inc. 60855R100 US60855R1005 04/30/2025 To elect nine directors to hold office until the 2026 Annual Meeting: Joseph M. Zubretsky DIRECTOR ELECTIONS ISSUER 14994.000000 0 FOR 14994.000000 FOR Molina Healthcare, Inc. 60855R100 US60855R1005 04/30/2025 To consider and approve, on a non-binding, advisory basis, the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 14994.000000 0 AGAINST 14994.000000 AGAINST Molina Healthcare, Inc. 60855R100 US60855R1005 04/30/2025 To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for 2025. AUDIT-RELATED ISSUER 14994.000000 0 AGAINST 14994.000000 AGAINST Molina Healthcare, Inc. 60855R100 US60855R1005 04/30/2025 To consider and approve the Company's 2025 Equity Incentive Plan. COMPENSATION ISSUER 14994.000000 0 FOR 14994.000000 FOR Molina Healthcare, Inc. 60855R100 US60855R1005 04/30/2025 Stockholder proposal regarding stockholders ability to call a special stockholders meeting, if properly presented. CORPORATE GOVERNANCE SECURITY HOLDER 14994.000000 0 FOR 14994.000000 AGAINST Boston Scientific Corporation 101137107 US1011371077 05/01/2025 Proposal to elect ten Directors: Yoshiaki Fujimori DIRECTOR ELECTIONS ISSUER 32613.000000 0 FOR 32613.000000 FOR Boston Scientific Corporation 101137107 US1011371077 05/01/2025 Proposal to elect ten Directors: David C. Habiger DIRECTOR ELECTIONS ISSUER 32613.000000 0 FOR 32613.000000 FOR Boston Scientific Corporation 101137107 US1011371077 05/01/2025 Proposal to elect ten Directors: Edward J. Ludwig DIRECTOR ELECTIONS ISSUER 32613.000000 0 FOR 32613.000000 FOR Boston Scientific Corporation 101137107 US1011371077 05/01/2025 Proposal to elect ten Directors: Michael F. Mahoney DIRECTOR ELECTIONS ISSUER 32613.000000 0 FOR 32613.000000 FOR Boston Scientific Corporation 101137107 US1011371077 05/01/2025 Proposal to elect ten Directors: Jessica L. Mega DIRECTOR ELECTIONS ISSUER 32613.000000 0 FOR 32613.000000 FOR Boston Scientific Corporation 101137107 US1011371077 05/01/2025 Proposal to elect ten Directors: Susan E. Morano DIRECTOR ELECTIONS ISSUER 32613.000000 0 FOR 32613.000000 FOR Boston Scientific Corporation 101137107 US1011371077 05/01/2025 Proposal to elect ten Directors: Cheryl Pegus DIRECTOR ELECTIONS ISSUER 32613.000000 0 FOR 32613.000000 FOR Boston Scientific Corporation 101137107 US1011371077 05/01/2025 Proposal to elect ten Directors: John E. Sununu DIRECTOR ELECTIONS ISSUER 32613.000000 0 FOR 32613.000000 FOR Boston Scientific Corporation 101137107 US1011371077 05/01/2025 Proposal to elect ten Directors: David S. Wichmann DIRECTOR ELECTIONS ISSUER 32613.000000 0 FOR 32613.000000 FOR Boston Scientific Corporation 101137107 US1011371077 05/01/2025 Proposal to elect ten Directors: Ellen M. Zane DIRECTOR ELECTIONS ISSUER 32613.000000 0 FOR 32613.000000 FOR Boston Scientific Corporation 101137107 US1011371077 05/01/2025 To approve, on a non-binding, advisory basis, the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 32613.000000 0 AGAINST 32613.000000 AGAINST Boston Scientific Corporation 101137107 US1011371077 05/01/2025 To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the 2025 fiscal year. AUDIT-RELATED ISSUER 32613.000000 0 AGAINST 32613.000000 AGAINST Boston Scientific Corporation 101137107 US1011371077 05/01/2025 Stockholder proposal titled "Support Simple Majority Vote." CORPORATE GOVERNANCE SECURITY HOLDER 32613.000000 0 FOR 32613.000000 NONE Halozyme Therapeutics, Inc. 40637H109 US40637H1095 05/01/2025 Election of Class III Directors: Jeffrey W. Henderson DIRECTOR ELECTIONS ISSUER 82576.000000 0 FOR 82576.000000 FOR Halozyme Therapeutics, Inc. 40637H109 US40637H1095 05/01/2025 Election of Class III Directors: Helen I. Torley DIRECTOR ELECTIONS ISSUER 82576.000000 0 FOR 82576.000000 FOR Halozyme Therapeutics, Inc. 40637H109 US40637H1095 05/01/2025 To approve, by a non-binding advisory vote, the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 82576.000000 0 AGAINST 82576.000000 AGAINST Halozyme Therapeutics, Inc. 40637H109 US40637H1095 05/01/2025 To ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025. AUDIT-RELATED ISSUER 82576.000000 0 FOR 82576.000000 FOR Inspire Medical Systems, Inc. 457730109 US4577301090 05/01/2025 Election of Class I Directors: Cynthia B. Burks DIRECTOR ELECTIONS ISSUER 45501.000000 0 WITHHOLD 45501.000000 AGAINST Inspire Medical Systems, Inc. 457730109 US4577301090 05/01/2025 Election of Class I Directors: Timothy P. Herbert DIRECTOR ELECTIONS ISSUER 45501.000000 0 FOR 45501.000000 FOR Inspire Medical Systems, Inc. 457730109 US4577301090 05/01/2025 Election of Class I Directors: Shawn T McCormick DIRECTOR ELECTIONS ISSUER 45501.000000 0 WITHHOLD 45501.000000 AGAINST Inspire Medical Systems, Inc. 457730109 US4577301090 05/01/2025 Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for 2025. AUDIT-RELATED ISSUER 45501.000000 0 FOR 45501.000000 FOR Inspire Medical Systems, Inc. 457730109 US4577301090 05/01/2025 Approval, on an advisory (non-binding) basis, of the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 45501.000000 0 AGAINST 45501.000000 AGAINST Intuitive Surgical, Inc. 46120E602 US46120E6023 05/01/2025 Election of Directors: Craig H. Barratt, Ph.D. DIRECTOR ELECTIONS ISSUER 21846.000000 0 FOR 21846.000000 FOR Intuitive Surgical, Inc. 46120E602 US46120E6023 05/01/2025 Election of Directors: Joseph C. Beery DIRECTOR ELECTIONS ISSUER 21846.000000 0 FOR 21846.000000 FOR Intuitive Surgical, Inc. 46120E602 US46120E6023 05/01/2025 Election of Directors: Lewis Chew DIRECTOR ELECTIONS ISSUER 21846.000000 0 FOR 21846.000000 FOR Intuitive Surgical, Inc. 46120E602 US46120E6023 05/01/2025 Election of Directors: Gary S. Guthart, Ph.D. DIRECTOR ELECTIONS ISSUER 21846.000000 0 FOR 21846.000000 FOR Intuitive Surgical, Inc. 46120E602 US46120E6023 05/01/2025 Election of Directors: Amal M. Johnson DIRECTOR ELECTIONS ISSUER 21846.000000 0 FOR 21846.000000 FOR Intuitive Surgical, Inc. 46120E602 US46120E6023 05/01/2025 Election of Directors: Sreelakshmi Kolli DIRECTOR ELECTIONS ISSUER 21846.000000 0 FOR 21846.000000 FOR Intuitive Surgical, Inc. 46120E602 US46120E6023 05/01/2025 Election of Directors: Amy L. Ladd, M.D. DIRECTOR ELECTIONS ISSUER 21846.000000 0 FOR 21846.000000 FOR Intuitive Surgical, Inc. 46120E602 US46120E6023 05/01/2025 Election of Directors: Keith R. Leonard, Jr. DIRECTOR ELECTIONS ISSUER 21846.000000 0 FOR 21846.000000 FOR Intuitive Surgical, Inc. 46120E602 US46120E6023 05/01/2025 Election of Directors: Jami Dover Nachtsheim DIRECTOR ELECTIONS ISSUER 21846.000000 0 FOR 21846.000000 FOR Intuitive Surgical, Inc. 46120E602 US46120E6023 05/01/2025 Election of Directors: Monica P. Reed, M.D. DIRECTOR ELECTIONS ISSUER 21846.000000 0 FOR 21846.000000 FOR Intuitive Surgical, Inc. 46120E602 US46120E6023 05/01/2025 Election of Directors: David J. Rosa DIRECTOR ELECTIONS ISSUER 21846.000000 0 FOR 21846.000000 FOR Intuitive Surgical, Inc. 46120E602 US46120E6023 05/01/2025 To approve, by advisory vote, the compensation of the Company's Named Executive Officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 21846.000000 0 AGAINST 21846.000000 AGAINST Intuitive Surgical, Inc. 46120E602 US46120E6023 05/01/2025 The ratification of appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025. AUDIT-RELATED ISSUER 21846.000000 0 FOR 21846.000000 FOR Intuitive Surgical, Inc. 46120E602 US46120E6023 05/01/2025 The amendment and restatement of the Amended and Restated 2010 Incentive Award Plan. COMPENSATION ISSUER 21846.000000 0 FOR 21846.000000 FOR Intuitive Surgical, Inc. 46120E602 US46120E6023 05/01/2025 The stockholder proposal purportedly "to improve the executive compensation program," if properly presented at the Annual Meeting. COMPENSATION SECURITY HOLDER 21846.000000 0 AGAINST 21846.000000 FOR Intuitive Surgical, Inc. 46120E602 US46120E6023 05/01/2025 The stockholder proposal that is titled "requesting a shareholder approval requirement for excessive golden parachutes," if properly presented at the Annual Meeting. COMPENSATION SECURITY HOLDER 21846.000000 0 FOR 21846.000000 AGAINST Eli Lilly and Company 532457108 US5324571083 05/05/2025 Election of the following directors, each to serve a three-year term: Ralph Alvarez DIRECTOR ELECTIONS ISSUER 41131.000000 0 AGAINST 41131.000000 AGAINST Eli Lilly and Company 532457108 US5324571083 05/05/2025 Election of the following directors, each to serve a three-year term: Mary Lynne Hedley DIRECTOR ELECTIONS ISSUER 41131.000000 0 FOR 41131.000000 FOR Eli Lilly and Company 532457108 US5324571083 05/05/2025 Election of the following directors, each to serve a three-year term: Kimberly Johnson DIRECTOR ELECTIONS ISSUER 41131.000000 0 FOR 41131.000000 FOR Eli Lilly and Company 532457108 US5324571083 05/05/2025 Election of the following directors, each to serve a three-year term: Juan Luciano DIRECTOR ELECTIONS ISSUER 41131.000000 0 FOR 41131.000000 FOR Eli Lilly and Company 532457108 US5324571083 05/05/2025 Approval, on an advisory basis, of the compensation paid to the company's named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 41131.000000 0 FOR 41131.000000 FOR Eli Lilly and Company 532457108 US5324571083 05/05/2025 Ratification of the appointment of Ernst & Young LLP as the independent auditor for 2025. AUDIT-RELATED ISSUER 41131.000000 0 AGAINST 41131.000000 AGAINST Eli Lilly and Company 532457108 US5324571083 05/05/2025 Approval of amendments to the company's Articles of Incorporation to eliminate the classified board structure. SHAREHOLDER RIGHTS AND DEFENSES ISSUER 41131.000000 0 FOR 41131.000000 FOR Eli Lilly and Company 532457108 US5324571083 05/05/2025 Approval of amendments to the company's Articles of Incorporation to eliminate supermajority voting provisions. CORPORATE GOVERNANCE ISSUER 41131.000000 0 FOR 41131.000000 FOR Bristol-Myers Squibb Company 110122108 US1101221083 05/06/2025 Election of Directors: Peter J. Arduini DIRECTOR ELECTIONS ISSUER 123666.000000 0 FOR 123666.000000 FOR Bristol-Myers Squibb Company 110122108 US1101221083 05/06/2025 Election of Directors: Deepak L. Bhatt, M.D., M.P.H., M.B.A. DIRECTOR ELECTIONS ISSUER 123666.000000 0 FOR 123666.000000 FOR Bristol-Myers Squibb Company 110122108 US1101221083 05/06/2025 Election of Directors: Christopher S. Boerner, Ph.D. DIRECTOR ELECTIONS ISSUER 123666.000000 0 FOR 123666.000000 FOR Bristol-Myers Squibb Company 110122108 US1101221083 05/06/2025 Election of Directors: Julia A. Haller, M.D. DIRECTOR ELECTIONS ISSUER 123666.000000 0 FOR 123666.000000 FOR Bristol-Myers Squibb Company 110122108 US1101221083 05/06/2025 Election of Directors: Manuel Hidalgo Medina, M.D., Ph.D. DIRECTOR ELECTIONS ISSUER 123666.000000 0 FOR 123666.000000 FOR Bristol-Myers Squibb Company 110122108 US1101221083 05/06/2025 Election of Directors: Michael R. McMullen DIRECTOR ELECTIONS ISSUER 123666.000000 0 FOR 123666.000000 FOR Bristol-Myers Squibb Company 110122108 US1101221083 05/06/2025 Election of Directors: Paula A. Price DIRECTOR ELECTIONS ISSUER 123666.000000 0 FOR 123666.000000 FOR Bristol-Myers Squibb Company 110122108 US1101221083 05/06/2025 Election of Directors: Derica W. Rice DIRECTOR ELECTIONS ISSUER 123666.000000 0 FOR 123666.000000 FOR Bristol-Myers Squibb Company 110122108 US1101221083 05/06/2025 Election of Directors: Theodore R. Samuels DIRECTOR ELECTIONS ISSUER 123666.000000 0 FOR 123666.000000 FOR Bristol-Myers Squibb Company 110122108 US1101221083 05/06/2025 Election of Directors: Karen H. Vousden, Ph.D. DIRECTOR ELECTIONS ISSUER 123666.000000 0 FOR 123666.000000 FOR Bristol-Myers Squibb Company 110122108 US1101221083 05/06/2025 Election of Directors: Phyllis R. Yale DIRECTOR ELECTIONS ISSUER 123666.000000 0 FOR 123666.000000 FOR Bristol-Myers Squibb Company 110122108 US1101221083 05/06/2025 Advisory Vote to Approve the Compensation of our Named Executive Officers SECTION 14A SAY-ON-PAY VOTES ISSUER 123666.000000 0 AGAINST 123666.000000 AGAINST Bristol-Myers Squibb Company 110122108 US1101221083 05/06/2025 Ratification of the Appointment of an Independent Registered Public Accounting Firm AUDIT-RELATED ISSUER 123666.000000 0 FOR 123666.000000 FOR Bristol-Myers Squibb Company 110122108 US1101221083 05/06/2025 Shareholder Proposal on Corporate Financial Sustainability ENVIRONMENT OR CLIMATE DIVERSITY, EQUITY, AND INCLUSION OTHER SOCIAL ISSUES SECURITY HOLDER 123666.000000 0 AGAINST 123666.000000 FOR Bristol-Myers Squibb Company 110122108 US1101221083 05/06/2025 Shareholder Proposal on a Request to Cease DEI Efforts ENVIRONMENT OR CLIMATE DIVERSITY, EQUITY, AND INCLUSION OTHER SOCIAL ISSUES SECURITY HOLDER 123666.000000 0 AGAINST 123666.000000 FOR Danaher Corporation 235851102 US2358511028 05/06/2025 To elect the thirteen directors named in the attached Proxy Statement to hold office until the 2026 Annual Meeting of Shareholders and until their successors are elected and qualified: Rainer M. Blair DIRECTOR ELECTIONS ISSUER 20650.000000 0 FOR 20650.000000 FOR Danaher Corporation 235851102 US2358511028 05/06/2025 To elect the thirteen directors named in the attached Proxy Statement to hold office until the 2026 Annual Meeting of Shareholders and until their successors are elected and qualified: Feroz Dewan DIRECTOR ELECTIONS ISSUER 20650.000000 0 FOR 20650.000000 FOR Danaher Corporation 235851102 US2358511028 05/06/2025 To elect the thirteen directors named in the attached Proxy Statement to hold office until the 2026 Annual Meeting of Shareholders and until their successors are elected and qualified: Linda Filler DIRECTOR ELECTIONS ISSUER 20650.000000 0 AGAINST 20650.000000 AGAINST Danaher Corporation 235851102 US2358511028 05/06/2025 To elect the thirteen directors named in the attached Proxy Statement to hold office until the 2026 Annual Meeting of Shareholders and until their successors are elected and qualified: Charles W. Lamanna DIRECTOR ELECTIONS ISSUER 20650.000000 0 FOR 20650.000000 FOR Danaher Corporation 235851102 US2358511028 05/06/2025 To elect the thirteen directors named in the attached Proxy Statement to hold office until the 2026 Annual Meeting of Shareholders and until their successors are elected and qualified: Teri List DIRECTOR ELECTIONS ISSUER 20650.000000 0 AGAINST 20650.000000 AGAINST Danaher Corporation 235851102 US2358511028 05/06/2025 To elect the thirteen directors named in the attached Proxy Statement to hold office until the 2026 Annual Meeting of Shareholders and until their successors are elected and qualified: Jessica L. Mega, MD, MPH DIRECTOR ELECTIONS ISSUER 20650.000000 0 FOR 20650.000000 FOR Danaher Corporation 235851102 US2358511028 05/06/2025 To elect the thirteen directors named in the attached Proxy Statement to hold office until the 2026 Annual Meeting of Shareholders and until their successors are elected and qualified: Mitchell P. Rales DIRECTOR ELECTIONS ISSUER 20650.000000 0 FOR 20650.000000 FOR Danaher Corporation 235851102 US2358511028 05/06/2025 To elect the thirteen directors named in the attached Proxy Statement to hold office until the 2026 Annual Meeting of Shareholders and until their successors are elected and qualified: Steven M. Rales DIRECTOR ELECTIONS ISSUER 20650.000000 0 FOR 20650.000000 FOR Danaher Corporation 235851102 US2358511028 05/06/2025 To elect the thirteen directors named in the attached Proxy Statement to hold office until the 2026 Annual Meeting of Shareholders and until their successors are elected and qualified: A. Shane Sanders DIRECTOR ELECTIONS ISSUER 20650.000000 0 AGAINST 20650.000000 AGAINST Danaher Corporation 235851102 US2358511028 05/06/2025 To elect the thirteen directors named in the attached Proxy Statement to hold office until the 2026 Annual Meeting of Shareholders and until their successors are elected and qualified: John T. Schwieters DIRECTOR ELECTIONS ISSUER 20650.000000 0 AGAINST 20650.000000 AGAINST Danaher Corporation 235851102 US2358511028 05/06/2025 To elect the thirteen directors named in the attached Proxy Statement to hold office until the 2026 Annual Meeting of Shareholders and until their successors are elected and qualified: Alan G. Spoon DIRECTOR ELECTIONS ISSUER 20650.000000 0 AGAINST 20650.000000 AGAINST Danaher Corporation 235851102 US2358511028 05/06/2025 To elect the thirteen directors named in the attached Proxy Statement to hold office until the 2026 Annual Meeting of Shareholders and until their successors are elected and qualified: Raymond C. Stevens, Ph.D. DIRECTOR ELECTIONS ISSUER 20650.000000 0 AGAINST 20650.000000 AGAINST Danaher Corporation 235851102 US2358511028 05/06/2025 To elect the thirteen directors named in the attached Proxy Statement to hold office until the 2026 Annual Meeting of Shareholders and until their successors are elected and qualified: Elias A. Zerhouni, MD DIRECTOR ELECTIONS ISSUER 20650.000000 0 AGAINST 20650.000000 AGAINST Danaher Corporation 235851102 US2358511028 05/06/2025 To ratify the selection of Ernst & Young LLP as Danaher's independent registered public accounting firm for the year ending December 31, 2025. AUDIT-RELATED ISSUER 20650.000000 0 FOR 20650.000000 FOR Danaher Corporation 235851102 US2358511028 05/06/2025 To approve on an advisory basis the Company's named executive officer compensation. SECTION 14A SAY-ON-PAY VOTES ISSUER 20650.000000 0 AGAINST 20650.000000 AGAINST Gilead Sciences, Inc. 375558103 US3755581036 05/07/2025 To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until their successors are elected and qualified: Jacqueline K. Barton, Ph.D. DIRECTOR ELECTIONS ISSUER 564556.000000 0 FOR 564556.000000 FOR Gilead Sciences, Inc. 375558103 US3755581036 05/07/2025 To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until their successors are elected and qualified: Jeffrey A. Bluestone, Ph.D. DIRECTOR ELECTIONS ISSUER 564556.000000 0 FOR 564556.000000 FOR Gilead Sciences, Inc. 375558103 US3755581036 05/07/2025 To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until their successors are elected and qualified: Sandra J. Horning, M.D. DIRECTOR ELECTIONS ISSUER 564556.000000 0 FOR 564556.000000 FOR Gilead Sciences, Inc. 375558103 US3755581036 05/07/2025 To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until their successors are elected and qualified: Kelly A. Kramer DIRECTOR ELECTIONS ISSUER 564556.000000 0 FOR 564556.000000 FOR Gilead Sciences, Inc. 375558103 US3755581036 05/07/2025 To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until their successors are elected and qualified: Ted W. Love, M.D. DIRECTOR ELECTIONS ISSUER 564556.000000 0 FOR 564556.000000 FOR Gilead Sciences, Inc. 375558103 US3755581036 05/07/2025 To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until their successors are elected and qualified: Harish Manwani DIRECTOR ELECTIONS ISSUER 564556.000000 0 FOR 564556.000000 FOR Gilead Sciences, Inc. 375558103 US3755581036 05/07/2025 To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until their successors are elected and qualified: Daniel P. O'Day DIRECTOR ELECTIONS ISSUER 564556.000000 0 FOR 564556.000000 FOR Gilead Sciences, Inc. 375558103 US3755581036 05/07/2025 To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until their successors are elected and qualified: Javier J. Rodriguez DIRECTOR ELECTIONS ISSUER 564556.000000 0 FOR 564556.000000 FOR Gilead Sciences, Inc. 375558103 US3755581036 05/07/2025 To elect the nine director nominees to be named in the Proxy Statement to serve for the next year and until their successors are elected and qualified: Anthony Welters DIRECTOR ELECTIONS ISSUER 564556.000000 0 FOR 564556.000000 FOR Gilead Sciences, Inc. 375558103 US3755581036 05/07/2025 To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025. AUDIT-RELATED ISSUER 564556.000000 0 AGAINST 564556.000000 AGAINST Gilead Sciences, Inc. 375558103 US3755581036 05/07/2025 To approve, on an advisory basis, the compensation of our Named Executive Officers as presented in the Proxy Statement. SECTION 14A SAY-ON-PAY VOTES ISSUER 564556.000000 0 AGAINST 564556.000000 AGAINST Gilead Sciences, Inc. 375558103 US3755581036 05/07/2025 To vote on a stockholder proposal requesting the CEO pay ratio factor be included in the Company's executive compensation programs, if properly presented at the Annual Meeting. DIVERSITY, EQUITY, AND INCLUSION SECURITY HOLDER 564556.000000 0 AGAINST 564556.000000 FOR Gilead Sciences, Inc. 375558103 US3755581036 05/07/2025 To vote on a stockholder proposal requesting an independent Board Chair policy, if properly presented at the Annual Meeting. CORPORATE GOVERNANCE SECURITY HOLDER 564556.000000 0 FOR 564556.000000 AGAINST Gilead Sciences, Inc. 375558103 US3755581036 05/07/2025 To vote on a stockholder proposal requesting a comprehensive human rights policy and human rights due diligence process, if properly presented at the Annual Meeting. HUMAN RIGHTS OR HUMAN CAPITAL/WORKFORCE SECURITY HOLDER 564556.000000 0 FOR 564556.000000 AGAINST Gilead Sciences, Inc. 375558103 US3755581036 05/07/2025 To vote on a stockholder proposal requesting a report on the risks of the Company's DEI practices for contractors, if properly presented at the Annual Meeting. ENVIRONMENT OR CLIMATE DIVERSITY, EQUITY, AND INCLUSION OTHER SOCIAL ISSUES SECURITY HOLDER 564556.000000 0 AGAINST 564556.000000 FOR Alnylam Pharmaceuticals, Inc. 02043Q107 US02043Q1076 05/08/2025 To elect the following nominees as Class III directors of Alnylam: Carolyn R. Bertozzi, Ph.D. DIRECTOR ELECTIONS ISSUER 104848.000000 0 FOR 104848.000000 FOR Alnylam Pharmaceuticals, Inc. 02043Q107 US02043Q1076 05/08/2025 To elect the following nominees as Class III directors of Alnylam: Margaret A. Hamburg, M.D. DIRECTOR ELECTIONS ISSUER 104848.000000 0 FOR 104848.000000 FOR Alnylam Pharmaceuticals, Inc. 02043Q107 US02043Q1076 05/08/2025 To elect the following nominees as Class III directors of Alnylam: Colleen F. Reitan DIRECTOR ELECTIONS ISSUER 104848.000000 0 FOR 104848.000000 FOR Alnylam Pharmaceuticals, Inc. 02043Q107 US02043Q1076 05/08/2025 To elect the following nominees as Class III directors of Alnylam: Amy W. Schulman DIRECTOR ELECTIONS ISSUER 104848.000000 0 FOR 104848.000000 FOR Alnylam Pharmaceuticals, Inc. 02043Q107 US02043Q1076 05/08/2025 To approve an Amendment to our Restated Certificate of Incorporation allowing for officer exculpation. CORPORATE GOVERNANCE ISSUER 104848.000000 0 FOR 104848.000000 FOR Alnylam Pharmaceuticals, Inc. 02043Q107 US02043Q1076 05/08/2025 To approve the second amended and restated 2018 Stock Incentive Plan. COMPENSATION ISSUER 104848.000000 0 FOR 104848.000000 FOR Alnylam Pharmaceuticals, Inc. 02043Q107 US02043Q1076 05/08/2025 To approve, in a non-binding advisory vote, the compensation of Alnylam's named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 104848.000000 0 AGAINST 104848.000000 AGAINST Alnylam Pharmaceuticals, Inc. 02043Q107 US02043Q1076 05/08/2025 To ratify the appointment of PricewaterhouseCoopers LLP, an independent registered public accounting firm, as Alnylam's independent auditors for the fiscal year ending December 31, 2025. AUDIT-RELATED ISSUER 104848.000000 0 AGAINST 104848.000000 AGAINST DexCom, Inc. 252131107 US2521311074 05/08/2025 To elect ten nominees for director, each to hold office until our 2026 annual meeting of stockholders: Kevin R. Sayer DIRECTOR ELECTIONS ISSUER 64933.000000 0 FOR 64933.000000 FOR DexCom, Inc. 252131107 US2521311074 05/08/2025 To elect ten nominees for director, each to hold office until our 2026 annual meeting of stockholders: Steven R. Altman DIRECTOR ELECTIONS ISSUER 64933.000000 0 FOR 64933.000000 FOR DexCom, Inc. 252131107 US2521311074 05/08/2025 To elect ten nominees for director, each to hold office until our 2026 annual meeting of stockholders: Nicholas Augustinos DIRECTOR ELECTIONS ISSUER 64933.000000 0 FOR 64933.000000 FOR DexCom, Inc. 252131107 US2521311074 05/08/2025 To elect ten nominees for director, each to hold office until our 2026 annual meeting of stockholders: Richard A. Collins DIRECTOR ELECTIONS ISSUER 64933.000000 0 FOR 64933.000000 FOR DexCom, Inc. 252131107 US2521311074 05/08/2025 To elect ten nominees for director, each to hold office until our 2026 annual meeting of stockholders: Rimma Driscoll DIRECTOR ELECTIONS ISSUER 64933.000000 0 FOR 64933.000000 FOR DexCom, Inc. 252131107 US2521311074 05/08/2025 To elect ten nominees for director, each to hold office until our 2026 annual meeting of stockholders: Mark G. Foletta DIRECTOR ELECTIONS ISSUER 64933.000000 0 FOR 64933.000000 FOR DexCom, Inc. 252131107 US2521311074 05/08/2025 To elect ten nominees for director, each to hold office until our 2026 annual meeting of stockholders: Renee Gala DIRECTOR ELECTIONS ISSUER 64933.000000 0 FOR 64933.000000 FOR DexCom, Inc. 252131107 US2521311074 05/08/2025 To elect ten nominees for director, each to hold office until our 2026 annual meeting of stockholders: Bridgette P. Heller DIRECTOR ELECTIONS ISSUER 64933.000000 0 FOR 64933.000000 FOR DexCom, Inc. 252131107 US2521311074 05/08/2025 To elect ten nominees for director, each to hold office until our 2026 annual meeting of stockholders: Kyle Malady DIRECTOR ELECTIONS ISSUER 64933.000000 0 FOR 64933.000000 FOR DexCom, Inc. 252131107 US2521311074 05/08/2025 To ratify the selection by the Audit Committee of our Board of Directors of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025. AUDIT-RELATED ISSUER 64933.000000 0 FOR 64933.000000 FOR DexCom, Inc. 252131107 US2521311074 05/08/2025 To provide a non-binding advisory vote on the compensation of our named executive officers for the fiscal year ended December 31, 2024. SECTION 14A SAY-ON-PAY VOTES ISSUER 64933.000000 0 AGAINST 64933.000000 AGAINST DexCom, Inc. 252131107 US2521311074 05/08/2025 To approve our Amended and Restated 2015 Equity Incentive Plan (as amended and restated) to, among other things, increase the number of shares reserved for issuance thereunder by 3,400,000 shares. COMPENSATION ISSUER 64933.000000 0 FOR 64933.000000 FOR DexCom, Inc. 252131107 US2521311074 05/08/2025 To approve our Amended and Restated 2015 Employee Stock Purchase Plan to, among other things, increase the number of shares reserved for issuance thereunder by 8,000,000 shares. COMPENSATION ISSUER 64933.000000 0 FOR 64933.000000 FOR Stryker Corporation 863667101 US8636671013 05/08/2025 Election of Ten Directors: Mary K. Brainerd DIRECTOR ELECTIONS ISSUER 5969.000000 0 FOR 5969.000000 FOR Stryker Corporation 863667101 US8636671013 05/08/2025 Election of Ten Directors: Giovanni Caforio, M.D. DIRECTOR ELECTIONS ISSUER 5969.000000 0 FOR 5969.000000 FOR Stryker Corporation 863667101 US8636671013 05/08/2025 Election of Ten Directors: Kevin A. Lobo DIRECTOR ELECTIONS ISSUER 5969.000000 0 FOR 5969.000000 FOR Stryker Corporation 863667101 US8636671013 05/08/2025 Election of Ten Directors: Emmanuel P. Maceda DIRECTOR ELECTIONS ISSUER 5969.000000 0 FOR 5969.000000 FOR Stryker Corporation 863667101 US8636671013 05/08/2025 Election of Ten Directors: Sherilyn S. McCoy DIRECTOR ELECTIONS ISSUER 5969.000000 0 FOR 5969.000000 FOR Stryker Corporation 863667101 US8636671013 05/08/2025 Election of Ten Directors: Rachel M. Ruggeri DIRECTOR ELECTIONS ISSUER 5969.000000 0 FOR 5969.000000 FOR Stryker Corporation 863667101 US8636671013 05/08/2025 Election of Ten Directors: Andrew K. Silvernail DIRECTOR ELECTIONS ISSUER 5969.000000 0 FOR 5969.000000 FOR Stryker Corporation 863667101 US8636671013 05/08/2025 Election of Ten Directors: Lisa M. Skeete Tatum DIRECTOR ELECTIONS ISSUER 5969.000000 0 FOR 5969.000000 FOR Stryker Corporation 863667101 US8636671013 05/08/2025 Election of Ten Directors: Ronda E. Stryker DIRECTOR ELECTIONS ISSUER 5969.000000 0 AGAINST 5969.000000 AGAINST Stryker Corporation 863667101 US8636671013 05/08/2025 Election of Ten Directors: Rajeev Suri DIRECTOR ELECTIONS ISSUER 5969.000000 0 FOR 5969.000000 FOR Stryker Corporation 863667101 US8636671013 05/08/2025 Ratification of Appointment of Ernst & Young LLP as Our Independent Registered Public Accounting Firm for 2025. AUDIT-RELATED ISSUER 5969.000000 0 AGAINST 5969.000000 AGAINST Stryker Corporation 863667101 US8636671013 05/08/2025 Approval of the 2011 Long-Term Incentive Plan, as Amended and Restated. COMPENSATION ISSUER 5969.000000 0 FOR 5969.000000 FOR Stryker Corporation 863667101 US8636671013 05/08/2025 Approval of the 2011 Performance Incentive Award Plan, as Amended and Restated. COMPENSATION ISSUER 5969.000000 0 FOR 5969.000000 FOR Stryker Corporation 863667101 US8636671013 05/08/2025 Approval of the 2008 Stock Purchase Plan, as Amended and Restated. COMPENSATION ISSUER 5969.000000 0 FOR 5969.000000 FOR Stryker Corporation 863667101 US8636671013 05/08/2025 Advisory Vote to Approve Named Executive Officer Compensation. SECTION 14A SAY-ON-PAY VOTES ISSUER 5969.000000 0 AGAINST 5969.000000 AGAINST Stryker Corporation 863667101 US8636671013 05/08/2025 Shareholder Proposal to Support Transparency in Political Spending. OTHER SOCIAL ISSUES SECURITY HOLDER 5969.000000 0 AGAINST 5969.000000 FOR AbbVie Inc. 00287Y109 US00287Y1091 05/09/2025 Election of Class I Directors: William H.L. Burnside DIRECTOR ELECTIONS ISSUER 86154.000000 0 FOR 86154.000000 FOR AbbVie Inc. 00287Y109 US00287Y1091 05/09/2025 Election of Class I Directors: Thomas C. Freyman DIRECTOR ELECTIONS ISSUER 86154.000000 0 FOR 86154.000000 FOR AbbVie Inc. 00287Y109 US00287Y1091 05/09/2025 Election of Class I Directors: Brett J. Hart DIRECTOR ELECTIONS ISSUER 86154.000000 0 FOR 86154.000000 FOR AbbVie Inc. 00287Y109 US00287Y1091 05/09/2025 Election of Class I Directors: Edward J. Rapp DIRECTOR ELECTIONS ISSUER 86154.000000 0 FOR 86154.000000 FOR AbbVie Inc. 00287Y109 US00287Y1091 05/09/2025 Ratification of Ernst & Young LLP as AbbVie's independent registered public accounting firm for 2025 AUDIT-RELATED ISSUER 86154.000000 0 FOR 86154.000000 FOR AbbVie Inc. 00287Y109 US00287Y1091 05/09/2025 Say on Pay - An advisory vote on the approval of executive compensation SECTION 14A SAY-ON-PAY VOTES ISSUER 86154.000000 0 AGAINST 86154.000000 AGAINST AbbVie Inc. 00287Y109 US00287Y1091 05/09/2025 Approval of a management proposal regarding amendment of the certificate of incorporation to eliminate supermajority voting CORPORATE GOVERNANCE ISSUER 86154.000000 0 FOR 86154.000000 FOR AbbVie Inc. 00287Y109 US00287Y1091 05/09/2025 Stockholder Proposal - to Implement Simple Majority Vote CORPORATE GOVERNANCE SECURITY HOLDER 86154.000000 0 FOR 86154.000000 AGAINST Rallybio Corporation 75120L100 US75120L1008 05/13/2025 Election of Class I Directors: Martin W. Mackay DIRECTOR ELECTIONS ISSUER 755076.000000 0 AGAINST 755076.000000 AGAINST Rallybio Corporation 75120L100 US75120L1008 05/13/2025 Election of Class I Directors: Paula Soteropoulos DIRECTOR ELECTIONS ISSUER 755076.000000 0 AGAINST 755076.000000 AGAINST Rallybio Corporation 75120L100 US75120L1008 05/13/2025 Ratification of the appointment of Deloitte & Touche LLP as the independent registered public accounting firm. AUDIT-RELATED ISSUER 755076.000000 0 FOR 755076.000000 FOR Cytokinetics, Incorporated 23282W605 US23282W6057 05/14/2025 To elect the three nominees listed below as Class III Directors, each to serve for a three-year term and until their successors are duly elected and qualified: John T. Henderson DIRECTOR ELECTIONS ISSUER 285648.000000 0 WITHHOLD 285648.000000 AGAINST Cytokinetics, Incorporated 23282W605 US23282W6057 05/14/2025 To elect the three nominees listed below as Class III Directors, each to serve for a three-year term and until their successors are duly elected and qualified: B. Lynne Parshall DIRECTOR ELECTIONS ISSUER 285648.000000 0 FOR 285648.000000 FOR Cytokinetics, Incorporated 23282W605 US23282W6057 05/14/2025 To elect the three nominees listed below as Class III Directors, each to serve for a three-year term and until their successors are duly elected and qualified: Muna Bhanji DIRECTOR ELECTIONS ISSUER 285648.000000 0 FOR 285648.000000 FOR Cytokinetics, Incorporated 23282W605 US23282W6057 05/14/2025 To approve the amendment and restatement of the Cytokinetics Amended and Restated 2004 Equity Incentive Plan to: (i) increase the number of authorized shares reserved for issuance under such plan by 5,000,000 shares of common stock and (ii) provide for limitations on the maximum grant value that non-executive directors may receive under such plan of $1,000,000 for annual grants to continuing directors and $1,250,000 for the initial grant to new directors. COMPENSATION ISSUER 285648.000000 0 FOR 285648.000000 FOR Cytokinetics, Incorporated 23282W605 US23282W6057 05/14/2025 To approve an amendment to Cytokinetics, Incorporated's Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common available for issuance by Cytokinetics, Incorporated from 163,000,000 to 326,000,000 shares of common stock. CAPITAL STRUCTURE ISSUER 285648.000000 0 FOR 285648.000000 FOR Cytokinetics, Incorporated 23282W605 US23282W6057 05/14/2025 To ratify the appointment by the Audit Committee of the Board of Directors of Ernst & Young LLP as the Cytokinetics, Incorporated's independent registered public accounting firm for the fiscal year ending December 31, 2025. AUDIT-RELATED ISSUER 285648.000000 0 FOR 285648.000000 FOR Cytokinetics, Incorporated 23282W605 US23282W6057 05/14/2025 To approve, on an advisory basis, the compensation of Cytokinetics, Incorporated's named executive officers, as disclosed in the Proxy Statement. SECTION 14A SAY-ON-PAY VOTES ISSUER 285648.000000 0 FOR 285648.000000 FOR Elevance Health, Inc. 036752103 US0367521038 05/14/2025 Election of Directors: Susan D. DeVore DIRECTOR ELECTIONS ISSUER 23071.000000 0 FOR 23071.000000 FOR Elevance Health, Inc. 036752103 US0367521038 05/14/2025 Election of Directors: Bahija Jallal DIRECTOR ELECTIONS ISSUER 23071.000000 0 FOR 23071.000000 FOR Elevance Health, Inc. 036752103 US0367521038 05/14/2025 Election of Directors: Ryan M. Schneider DIRECTOR ELECTIONS ISSUER 23071.000000 0 FOR 23071.000000 FOR Elevance Health, Inc. 036752103 US0367521038 05/14/2025 Advisory vote to approve the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 23071.000000 0 AGAINST 23071.000000 AGAINST Elevance Health, Inc. 036752103 US0367521038 05/14/2025 To ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm for 2025. AUDIT-RELATED ISSUER 23071.000000 0 AGAINST 23071.000000 AGAINST Elevance Health, Inc. 036752103 US0367521038 05/14/2025 Shareholder proposal requesting report on the effectiveness of Diversity, Equity and Inclusion efforts. DIVERSITY, EQUITY, AND INCLUSION SECURITY HOLDER 23071.000000 0 AGAINST 23071.000000 FOR Vertex Pharmaceuticals Incorporated 92532F100 US92532F1003 05/14/2025 Election of Directors: Sangeeta Bhatia DIRECTOR ELECTIONS ISSUER 84402.000000 0 FOR 84402.000000 FOR Vertex Pharmaceuticals Incorporated 92532F100 US92532F1003 05/14/2025 Election of Directors: Lloyd Carney DIRECTOR ELECTIONS ISSUER 84402.000000 0 FOR 84402.000000 FOR Vertex Pharmaceuticals Incorporated 92532F100 US92532F1003 05/14/2025 Election of Directors: Alan Garber DIRECTOR ELECTIONS ISSUER 84402.000000 0 FOR 84402.000000 FOR Vertex Pharmaceuticals Incorporated 92532F100 US92532F1003 05/14/2025 Election of Directors: Reshma Kewalramani DIRECTOR ELECTIONS ISSUER 84402.000000 0 FOR 84402.000000 FOR Vertex Pharmaceuticals Incorporated 92532F100 US92532F1003 05/14/2025 Election of Directors: Michel Lagarde DIRECTOR ELECTIONS ISSUER 84402.000000 0 FOR 84402.000000 FOR Vertex Pharmaceuticals Incorporated 92532F100 US92532F1003 05/14/2025 Election of Directors: Jeffrey Leiden DIRECTOR ELECTIONS ISSUER 84402.000000 0 FOR 84402.000000 FOR Vertex Pharmaceuticals Incorporated 92532F100 US92532F1003 05/14/2025 Election of Directors: Diana McKenzie DIRECTOR ELECTIONS ISSUER 84402.000000 0 FOR 84402.000000 FOR Vertex Pharmaceuticals Incorporated 92532F100 US92532F1003 05/14/2025 Election of Directors: Bruce Sachs DIRECTOR ELECTIONS ISSUER 84402.000000 0 AGAINST 84402.000000 AGAINST Vertex Pharmaceuticals Incorporated 92532F100 US92532F1003 05/14/2025 Election of Directors: Jennifer Schneider DIRECTOR ELECTIONS ISSUER 84402.000000 0 FOR 84402.000000 FOR Vertex Pharmaceuticals Incorporated 92532F100 US92532F1003 05/14/2025 Election of Directors: Nancy Thornberry DIRECTOR ELECTIONS ISSUER 84402.000000 0 FOR 84402.000000 FOR Vertex Pharmaceuticals Incorporated 92532F100 US92532F1003 05/14/2025 Election of Directors: Suketu Upadhyay DIRECTOR ELECTIONS ISSUER 84402.000000 0 FOR 84402.000000 FOR Vertex Pharmaceuticals Incorporated 92532F100 US92532F1003 05/14/2025 Ratification of Ernst & Young LLP as independent Registered Public Accounting firm for the year ending December 31, 2025. AUDIT-RELATED ISSUER 84402.000000 0 AGAINST 84402.000000 AGAINST Vertex Pharmaceuticals Incorporated 92532F100 US92532F1003 05/14/2025 Advisory vote to approve named executive officer compensation. SECTION 14A SAY-ON-PAY VOTES ISSUER 84402.000000 0 AGAINST 84402.000000 AGAINST Vertex Pharmaceuticals Incorporated 92532F100 US92532F1003 05/14/2025 Shareholder proposal, if properly presented at the meeting, regarding excessive golden parachutes. COMPENSATION SECURITY HOLDER 84402.000000 0 FOR 84402.000000 AGAINST Insmed Incorporated 457669307 US4576693075 05/15/2025 Election of two Class I directors, Leo Lee and William H. Lewis, to serve until the 2028 Annual Meeting of Shareholders: Leo Lee DIRECTOR ELECTIONS ISSUER 210996.000000 0 FOR 210996.000000 FOR Insmed Incorporated 457669307 US4576693075 05/15/2025 Election of two Class I directors, Leo Lee and William H. Lewis, to serve until the 2028 Annual Meeting of Shareholders: William H. Lewis DIRECTOR ELECTIONS ISSUER 210996.000000 0 FOR 210996.000000 FOR Insmed Incorporated 457669307 US4576693075 05/15/2025 An advisory vote on the 2024 compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 210996.000000 0 FOR 210996.000000 FOR Insmed Incorporated 457669307 US4576693075 05/15/2025 Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2025. AUDIT-RELATED ISSUER 210996.000000 0 FOR 210996.000000 FOR Insmed Incorporated 457669307 US4576693075 05/15/2025 Approval of Amendment No. 2 to the Insmed Incorporated Amended and Restated 2019 Incentive Plan. COMPENSATION ISSUER 210996.000000 0 FOR 210996.000000 FOR Travere Therapeutics, Inc. 89422G107 US89422G1076 05/15/2025 To elect each of the Board's ten nominees for director named in the accompanying proxy statement to serve for a term of one year: Roy Baynes DIRECTOR ELECTIONS ISSUER 276167.000000 0 FOR 276167.000000 FOR Travere Therapeutics, Inc. 89422G107 US89422G1076 05/15/2025 To elect each of the Board's ten nominees for director named in the accompanying proxy statement to serve for a term of one year: Suzanne Bruhn DIRECTOR ELECTIONS ISSUER 276167.000000 0 FOR 276167.000000 FOR Travere Therapeutics, Inc. 89422G107 US89422G1076 05/15/2025 To elect each of the Board's ten nominees for director named in the accompanying proxy statement to serve for a term of one year: Timothy Coughlin DIRECTOR ELECTIONS ISSUER 276167.000000 0 FOR 276167.000000 FOR Travere Therapeutics, Inc. 89422G107 US89422G1076 05/15/2025 To elect each of the Board's ten nominees for director named in the accompanying proxy statement to serve for a term of one year: Eric Dube DIRECTOR ELECTIONS ISSUER 276167.000000 0 FOR 276167.000000 FOR Travere Therapeutics, Inc. 89422G107 US89422G1076 05/15/2025 To elect each of the Board's ten nominees for director named in the accompanying proxy statement to serve for a term of one year: Gary Lyons DIRECTOR ELECTIONS ISSUER 276167.000000 0 FOR 276167.000000 FOR Travere Therapeutics, Inc. 89422G107 US89422G1076 05/15/2025 To elect each of the Board's ten nominees for director named in the accompanying proxy statement to serve for a term of one year: Jeffrey Meckler DIRECTOR ELECTIONS ISSUER 276167.000000 0 FOR 276167.000000 FOR Travere Therapeutics, Inc. 89422G107 US89422G1076 05/15/2025 To elect each of the Board's ten nominees for director named in the accompanying proxy statement to serve for a term of one year: John Orwin DIRECTOR ELECTIONS ISSUER 276167.000000 0 FOR 276167.000000 FOR Travere Therapeutics, Inc. 89422G107 US89422G1076 05/15/2025 To elect each of the Board's ten nominees for director named in the accompanying proxy statement to serve for a term of one year: Sandra Poole DIRECTOR ELECTIONS ISSUER 276167.000000 0 FOR 276167.000000 FOR Travere Therapeutics, Inc. 89422G107 US89422G1076 05/15/2025 To elect each of the Board's ten nominees for director named in the accompanying proxy statement to serve for a term of one year: Ron Squarer DIRECTOR ELECTIONS ISSUER 276167.000000 0 FOR 276167.000000 FOR Travere Therapeutics, Inc. 89422G107 US89422G1076 05/15/2025 To elect each of the Board's ten nominees for director named in the accompanying proxy statement to serve for a term of one year: Ruth Williams-Brinkley DIRECTOR ELECTIONS ISSUER 276167.000000 0 FOR 276167.000000 FOR Travere Therapeutics, Inc. 89422G107 US89422G1076 05/15/2025 To approve the Company's 2018 Equity Incentive Plan, as amended, to increase the number of shares of common stock authorized for issuance thereunder by 4,000,000 shares. COMPENSATION ISSUER 276167.000000 0 FOR 276167.000000 FOR Travere Therapeutics, Inc. 89422G107 US89422G1076 05/15/2025 To approve, on an advisory basis, the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 276167.000000 0 FOR 276167.000000 FOR Travere Therapeutics, Inc. 89422G107 US89422G1076 05/15/2025 To ratify the selection of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2025. AUDIT-RELATED ISSUER 276167.000000 0 FOR 276167.000000 FOR Ultragenyx Pharmaceutical Inc. 90400D108 US90400D1081 05/15/2025 Nominees: Matthew K. Fust DIRECTOR ELECTIONS ISSUER 297732.000000 0 FOR 297732.000000 FOR Ultragenyx Pharmaceutical Inc. 90400D108 US90400D1081 05/15/2025 Nominees: Amrit Ray, M.D. DIRECTOR ELECTIONS ISSUER 297732.000000 0 FOR 297732.000000 FOR Ultragenyx Pharmaceutical Inc. 90400D108 US90400D1081 05/15/2025 Approval of the Second Amended and Restated 2023 Incentive Plan. COMPENSATION ISSUER 297732.000000 0 AGAINST 297732.000000 AGAINST Ultragenyx Pharmaceutical Inc. 90400D108 US90400D1081 05/15/2025 Ratification of the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025. AUDIT-RELATED ISSUER 297732.000000 0 FOR 297732.000000 FOR Ultragenyx Pharmaceutical Inc. 90400D108 US90400D1081 05/15/2025 Advisory (non-binding) vote to approve the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 297732.000000 0 AGAINST 297732.000000 AGAINST BioNTech SE 09075V102 US09075V1026 05/16/2025 Approve Allocation of Income and Omission of Dividends CAPITAL STRUCTURE ISSUER 211403.000000 0 FOR 211403.000000 FOR BioNTech SE 09075V102 US09075V1026 05/16/2025 Approve Discharge of Management Board for Fiscal Year 2024 CORPORATE GOVERNANCE ISSUER 211403.000000 0 FOR 211403.000000 FOR BioNTech SE 09075V102 US09075V1026 05/16/2025 Approve Discharge of Supervisory Board for Fiscal Year 2024 CORPORATE GOVERNANCE ISSUER 211403.000000 0 FOR 211403.000000 FOR BioNTech SE 09075V102 US09075V1026 05/16/2025 Ratify EY GmbH & Co. KG as Auditors for Fiscal Year 2025 AUDIT-RELATED ISSUER 211403.000000 0 FOR 211403.000000 FOR BioNTech SE 09075V102 US09075V1026 05/16/2025 Appoint EY GmbH & Co. KG as Auditor for Sustainability Reporting for Fiscal Year 2025 AUDIT-RELATED ISSUER 211403.000000 0 FOR 211403.000000 FOR BioNTech SE 09075V102 US09075V1026 05/16/2025 Approve Remuneration Report COMPENSATION ISSUER 211403.000000 0 AGAINST 211403.000000 AGAINST BioNTech SE 09075V102 US09075V1026 05/16/2025 Approve Creation of EUR 124.3 Million Pool of Authorized Capital with or without Exclusion of Preemptive Rights CAPITAL STRUCTURE ISSUER 211403.000000 0 AGAINST 211403.000000 AGAINST Krystal Biotech, Inc. 501147102 US5011471027 05/16/2025 Election of Class II Directors: Daniel S. Janney DIRECTOR ELECTIONS ISSUER 38460.000000 0 WITHHOLD 38460.000000 AGAINST Krystal Biotech, Inc. 501147102 US5011471027 05/16/2025 Election of Class II Directors: Dino A. Rossi DIRECTOR ELECTIONS ISSUER 38460.000000 0 FOR 38460.000000 FOR Krystal Biotech, Inc. 501147102 US5011471027 05/16/2025 Election of Class II Directors: E. Rand Sutherland DIRECTOR ELECTIONS ISSUER 38460.000000 0 FOR 38460.000000 FOR Krystal Biotech, Inc. 501147102 US5011471027 05/16/2025 To ratify the appointment of KPMG LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2025. AUDIT-RELATED ISSUER 38460.000000 0 FOR 38460.000000 FOR Krystal Biotech, Inc. 501147102 US5011471027 05/16/2025 Approval of the compensation of the Company's named executive officers, on a non-binding, advisory basis. SECTION 14A SAY-ON-PAY VOTES ISSUER 38460.000000 0 FOR 38460.000000 FOR Medpace Holdings, Inc. 58506Q109 US58506Q1094 05/16/2025 Election of Directors: August J. Troendle DIRECTOR ELECTIONS ISSUER 15401.000000 0 FOR 15401.000000 FOR Medpace Holdings, Inc. 58506Q109 US58506Q1094 05/16/2025 Election of Directors: Dani S. Zander DIRECTOR ELECTIONS ISSUER 15401.000000 0 FOR 15401.000000 FOR Medpace Holdings, Inc. 58506Q109 US58506Q1094 05/16/2025 To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025. AUDIT-RELATED ISSUER 15401.000000 0 AGAINST 15401.000000 AGAINST Medpace Holdings, Inc. 58506Q109 US58506Q1094 05/16/2025 To approve, on an advisory basis, the compensation of our named executive officers as disclosed in the proxy statement for the 2025 Annual Meeting. SECTION 14A SAY-ON-PAY VOTES ISSUER 15401.000000 0 AGAINST 15401.000000 AGAINST Medpace Holdings, Inc. 58506Q109 US58506Q1094 05/16/2025 To approve the Medpace Holdings, Inc. 2016 Amended and Restated Incentive Award Plan. COMPENSATION ISSUER 15401.000000 0 FOR 15401.000000 FOR Medpace Holdings, Inc. 58506Q109 US58506Q1094 05/16/2025 Stockholder proposal regarding implementation of simple majority voting, if properly presented at the meeting. CORPORATE GOVERNANCE SECURITY HOLDER 15401.000000 0 FOR 15401.000000 AGAINST Personalis, Inc. 71535D106 US71535D1063 05/16/2025 Election of Directors: A. Blaine Bowman DIRECTOR ELECTIONS ISSUER 740839.000000 0 FOR 740839.000000 FOR Personalis, Inc. 71535D106 US71535D1063 05/16/2025 Election of Directors: Karin Eastham DIRECTOR ELECTIONS ISSUER 740839.000000 0 WITHHOLD 740839.000000 AGAINST Personalis, Inc. 71535D106 US71535D1063 05/16/2025 Ratification of the selection by the Audit Committee of the Board of Directors of BDO USA, P.C. as the Company's independent registered public accounting firm for the year ending December 31, 2025. AUDIT-RELATED ISSUER 740839.000000 0 FOR 740839.000000 FOR Personalis, Inc. 71535D106 US71535D1063 05/16/2025 Approval, on a non-binding, advisory basis, of the compensation of the Company's named executive officers, as disclosed in the proxy statement. SECTION 14A SAY-ON-PAY VOTES ISSUER 740839.000000 0 AGAINST 740839.000000 AGAINST BioMarin Pharmaceutical Inc. 09061G101 US09061G1013 05/20/2025 Election of Directors: Elizabeth M. Anderson DIRECTOR ELECTIONS ISSUER 393089.000000 0 FOR 393089.000000 FOR BioMarin Pharmaceutical Inc. 09061G101 US09061G1013 05/20/2025 Election of Directors: Barbara W. Bodem DIRECTOR ELECTIONS ISSUER 393089.000000 0 FOR 393089.000000 FOR BioMarin Pharmaceutical Inc. 09061G101 US09061G1013 05/20/2025 Election of Directors: Athena Countouriotis DIRECTOR ELECTIONS ISSUER 393089.000000 0 FOR 393089.000000 FOR BioMarin Pharmaceutical Inc. 09061G101 US09061G1013 05/20/2025 Election of Directors: Willard Dere DIRECTOR ELECTIONS ISSUER 393089.000000 0 FOR 393089.000000 FOR BioMarin Pharmaceutical Inc. 09061G101 US09061G1013 05/20/2025 Election of Directors: Mark J. Enyedy DIRECTOR ELECTIONS ISSUER 393089.000000 0 FOR 393089.000000 FOR BioMarin Pharmaceutical Inc. 09061G101 US09061G1013 05/20/2025 Election of Directors: Alexander Hardy DIRECTOR ELECTIONS ISSUER 393089.000000 0 FOR 393089.000000 FOR BioMarin Pharmaceutical Inc. 09061G101 US09061G1013 05/20/2025 Election of Directors: Maykin Ho DIRECTOR ELECTIONS ISSUER 393089.000000 0 FOR 393089.000000 FOR BioMarin Pharmaceutical Inc. 09061G101 US09061G1013 05/20/2025 Election of Directors: Robert J. Hombach DIRECTOR ELECTIONS ISSUER 393089.000000 0 FOR 393089.000000 FOR BioMarin Pharmaceutical Inc. 09061G101 US09061G1013 05/20/2025 Election of Directors: Richard A. Meier DIRECTOR ELECTIONS ISSUER 393089.000000 0 FOR 393089.000000 FOR BioMarin Pharmaceutical Inc. 09061G101 US09061G1013 05/20/2025 Election of Directors: Timothy P. Walbert DIRECTOR ELECTIONS ISSUER 393089.000000 0 FOR 393089.000000 FOR BioMarin Pharmaceutical Inc. 09061G101 US09061G1013 05/20/2025 To ratify the selection of KPMG LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2025. AUDIT-RELATED ISSUER 393089.000000 0 FOR 393089.000000 FOR BioMarin Pharmaceutical Inc. 09061G101 US09061G1013 05/20/2025 To approve, on an advisory basis, the compensation of the Company's Named Executive Officers as disclosed in the Proxy Statement. SECTION 14A SAY-ON-PAY VOTES ISSUER 393089.000000 0 FOR 393089.000000 FOR BioMarin Pharmaceutical Inc. 09061G101 US09061G1013 05/20/2025 To approve an amendment to the Company's 2017 Equity Incentive Plan, as amended. COMPENSATION ISSUER 393089.000000 0 FOR 393089.000000 FOR Tempus AI, Inc. 88023B103 US88023B1035 05/20/2025 To elect nine directors to serve until the next annual meeting and their successors are duly elected and qualified, or until their earlier death, resignation or removal: Eric Lefkofsky DIRECTOR ELECTIONS ISSUER 193691.000000 0 FOR 193691.000000 FOR Tempus AI, Inc. 88023B103 US88023B1035 05/20/2025 To elect nine directors to serve until the next annual meeting and their successors are duly elected and qualified, or until their earlier death, resignation or removal: Peter J. Barris DIRECTOR ELECTIONS ISSUER 193691.000000 0 WITHHOLD 193691.000000 AGAINST Tempus AI, Inc. 88023B103 US88023B1035 05/20/2025 To elect nine directors to serve until the next annual meeting and their successors are duly elected and qualified, or until their earlier death, resignation or removal: Eric D. Belcher DIRECTOR ELECTIONS ISSUER 193691.000000 0 FOR 193691.000000 FOR Tempus AI, Inc. 88023B103 US88023B1035 05/20/2025 To elect nine directors to serve until the next annual meeting and their successors are duly elected and qualified, or until their earlier death, resignation or removal: Jennifer A. Doudna DIRECTOR ELECTIONS ISSUER 193691.000000 0 WITHHOLD 193691.000000 AGAINST Tempus AI, Inc. 88023B103 US88023B1035 05/20/2025 To elect nine directors to serve until the next annual meeting and their successors are duly elected and qualified, or until their earlier death, resignation or removal: David R. Epstein DIRECTOR ELECTIONS ISSUER 193691.000000 0 WITHHOLD 193691.000000 AGAINST Tempus AI, Inc. 88023B103 US88023B1035 05/20/2025 To elect nine directors to serve until the next annual meeting and their successors are duly elected and qualified, or until their earlier death, resignation or removal: Wayne A.I. Frederick, M.D. DIRECTOR ELECTIONS ISSUER 193691.000000 0 FOR 193691.000000 FOR Tempus AI, Inc. 88023B103 US88023B1035 05/20/2025 To elect nine directors to serve until the next annual meeting and their successors are duly elected and qualified, or until their earlier death, resignation or removal: Scott Gottlieb, M.D. DIRECTOR ELECTIONS ISSUER 193691.000000 0 WITHHOLD 193691.000000 AGAINST Tempus AI, Inc. 88023B103 US88023B1035 05/20/2025 To elect nine directors to serve until the next annual meeting and their successors are duly elected and qualified, or until their earlier death, resignation or removal: Theodore J. Leonsis DIRECTOR ELECTIONS ISSUER 193691.000000 0 WITHHOLD 193691.000000 AGAINST Tempus AI, Inc. 88023B103 US88023B1035 05/20/2025 To elect nine directors to serve until the next annual meeting and their successors are duly elected and qualified, or until their earlier death, resignation or removal: Nadja West, M.D. DIRECTOR ELECTIONS ISSUER 193691.000000 0 WITHHOLD 193691.000000 AGAINST Tempus AI, Inc. 88023B103 US88023B1035 05/20/2025 To ratify the appointment by the Audit Committee of the Board of Directors of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025. AUDIT-RELATED ISSUER 193691.000000 0 FOR 193691.000000 FOR Tempus AI, Inc. 88023B103 US88023B1035 05/20/2025 To approve the reincorporation of the Company from the State of Delaware to the State of Nevada by conversion. EXTRAORDINARY TRANSACTIONS CORPORATE GOVERNANCE ISSUER 193691.000000 0 AGAINST 193691.000000 AGAINST Alkermes plc G01767105 IE00B56GVS15 05/21/2025 To elect as directors to serve a one-year term until the Company's 2026 annual general meeting of shareholders: Shane M. Cooke DIRECTOR ELECTIONS ISSUER 89235.000000 0 FOR 89235.000000 FOR Alkermes plc G01767105 IE00B56GVS15 05/21/2025 To elect as directors to serve a one-year term until the Company's 2026 annual general meeting of shareholders: Richard B. Gaynor, M.D. DIRECTOR ELECTIONS ISSUER 89235.000000 0 FOR 89235.000000 FOR Alkermes plc G01767105 IE00B56GVS15 05/21/2025 To elect as directors to serve a one-year term until the Company's 2026 annual general meeting of shareholders: Cato T. Laurencin, M.D., Ph.D. DIRECTOR ELECTIONS ISSUER 89235.000000 0 FOR 89235.000000 FOR Alkermes plc G01767105 IE00B56GVS15 05/21/2025 To elect as directors to serve a one-year term until the Company's 2026 annual general meeting of shareholders: Nancy S. Lurker DIRECTOR ELECTIONS ISSUER 89235.000000 0 FOR 89235.000000 FOR Alkermes plc G01767105 IE00B56GVS15 05/21/2025 To elect as directors to serve a one-year term until the Company's 2026 annual general meeting of shareholders: Brian P. McKeon DIRECTOR ELECTIONS ISSUER 89235.000000 0 FOR 89235.000000 FOR Alkermes plc G01767105 IE00B56GVS15 05/21/2025 To elect as directors to serve a one-year term until the Company's 2026 annual general meeting of shareholders: Richard F. Pops DIRECTOR ELECTIONS ISSUER 89235.000000 0 FOR 89235.000000 FOR Alkermes plc G01767105 IE00B56GVS15 05/21/2025 To elect as directors to serve a one-year term until the Company's 2026 annual general meeting of shareholders: Nancy L. Snyderman, M.D. DIRECTOR ELECTIONS ISSUER 89235.000000 0 FOR 89235.000000 FOR Alkermes plc G01767105 IE00B56GVS15 05/21/2025 To elect as directors to serve a one-year term until the Company's 2026 annual general meeting of shareholders: Frank Anders Wilson DIRECTOR ELECTIONS ISSUER 89235.000000 0 FOR 89235.000000 FOR Alkermes plc G01767105 IE00B56GVS15 05/21/2025 To elect as directors to serve a one-year term until the Company's 2026 annual general meeting of shareholders: Christopher I. Wright, M.D., Ph.D. DIRECTOR ELECTIONS ISSUER 89235.000000 0 FOR 89235.000000 FOR Alkermes plc G01767105 IE00B56GVS15 05/21/2025 To approve, in a non-binding, advisory vote, the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 89235.000000 0 FOR 89235.000000 FOR Alkermes plc G01767105 IE00B56GVS15 05/21/2025 To ratify, in a non-binding vote, the appointment of PricewaterhouseCoopers LLP as the independent auditor and accounting firm of the Company and to authorize, in a binding vote, the Audit and Risk Committee of the Board to set the independent auditor and accounting firm's remuneration. AUDIT-RELATED ISSUER 89235.000000 0 FOR 89235.000000 FOR Alkermes plc G01767105 IE00B56GVS15 05/21/2025 To approve the Alkermes plc 2018 Stock Option and Incentive Plan, as amended. COMPENSATION ISSUER 89235.000000 0 FOR 89235.000000 FOR Alkermes plc G01767105 IE00B56GVS15 05/21/2025 To renew Board authority to allot and issue shares under Irish law. CAPITAL STRUCTURE ISSUER 89235.000000 0 FOR 89235.000000 FOR Alkermes plc G01767105 IE00B56GVS15 05/21/2025 To renew Board authority to disapply the statutory pre-emption rights that would otherwise apply under Irish law. CAPITAL STRUCTURE ISSUER 89235.000000 0 AGAINST 89235.000000 AGAINST Geron Corporation 374163103 US3741631036 05/21/2025 To elect the two nominees for director named below to hold office as Class II members of the Board of Directors until the 2028 annual meeting of stockholders: Dawn C. Bir DIRECTOR ELECTIONS ISSUER 2332131.000000 0 FOR 2332131.000000 FOR Geron Corporation 374163103 US3741631036 05/21/2025 To elect the two nominees for director named below to hold office as Class II members of the Board of Directors until the 2028 annual meeting of stockholders: Elizabeth G. O'Farrell DIRECTOR ELECTIONS ISSUER 2332131.000000 0 FOR 2332131.000000 FOR Geron Corporation 374163103 US3741631036 05/21/2025 To approve an amendment to our 2018 Equity Incentive Plan to, among other items, increase the total number of shares of our common stock issuable thereunder by 20,000,000 shares. COMPENSATION ISSUER 2332131.000000 0 FOR 2332131.000000 FOR Geron Corporation 374163103 US3741631036 05/21/2025 To approve an amendment to our 2014 Employee Stock Purchase Plan to increase the number of shares of our common stock issuable thereunder by 6,000,000 shares. COMPENSATION ISSUER 2332131.000000 0 FOR 2332131.000000 FOR Geron Corporation 374163103 US3741631036 05/21/2025 To approve, on an advisory basis, the compensation of our Named Executive Officers, as disclosed in our Proxy Statement. SECTION 14A SAY-ON-PAY VOTES ISSUER 2332131.000000 0 AGAINST 2332131.000000 AGAINST Geron Corporation 374163103 US3741631036 05/21/2025 To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025. AUDIT-RELATED ISSUER 2332131.000000 0 AGAINST 2332131.000000 AGAINST Illumina, Inc. 452327109 US4523271090 05/21/2025 Election of Directors: Frances Arnold, Ph.D. DIRECTOR ELECTIONS ISSUER 143240.000000 0 FOR 143240.000000 FOR Illumina, Inc. 452327109 US4523271090 05/21/2025 Election of Directors: Caroline D. Dorsa DIRECTOR ELECTIONS ISSUER 143240.000000 0 FOR 143240.000000 FOR Illumina, Inc. 452327109 US4523271090 05/21/2025 Election of Directors: Robert S. Epstein, M.D. DIRECTOR ELECTIONS ISSUER 143240.000000 0 FOR 143240.000000 FOR Illumina, Inc. 452327109 US4523271090 05/21/2025 Election of Directors: Scott Gottlieb, M.D. DIRECTOR ELECTIONS ISSUER 143240.000000 0 FOR 143240.000000 FOR Illumina, Inc. 452327109 US4523271090 05/21/2025 Election of Directors: Gary S. Guthart, Ph.D. DIRECTOR ELECTIONS ISSUER 143240.000000 0 FOR 143240.000000 FOR Illumina, Inc. 452327109 US4523271090 05/21/2025 Election of Directors: Keith A. Meister DIRECTOR ELECTIONS ISSUER 143240.000000 0 FOR 143240.000000 FOR Illumina, Inc. 452327109 US4523271090 05/21/2025 Election of Directors: Anna Richo DIRECTOR ELECTIONS ISSUER 143240.000000 0 FOR 143240.000000 FOR Illumina, Inc. 452327109 US4523271090 05/21/2025 Election of Directors: Philip W. Schiller DIRECTOR ELECTIONS ISSUER 143240.000000 0 FOR 143240.000000 FOR Illumina, Inc. 452327109 US4523271090 05/21/2025 Election of Directors: Susan E. Siegel DIRECTOR ELECTIONS ISSUER 143240.000000 0 FOR 143240.000000 FOR Illumina, Inc. 452327109 US4523271090 05/21/2025 Election of Directors: Jacob Thaysen, Ph.D. DIRECTOR ELECTIONS ISSUER 143240.000000 0 FOR 143240.000000 FOR Illumina, Inc. 452327109 US4523271090 05/21/2025 Election of Directors: Scott B. Ullem DIRECTOR ELECTIONS ISSUER 143240.000000 0 FOR 143240.000000 FOR Illumina, Inc. 452327109 US4523271090 05/21/2025 To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 28, 2025. AUDIT-RELATED ISSUER 143240.000000 0 AGAINST 143240.000000 AGAINST Illumina, Inc. 452327109 US4523271090 05/21/2025 To approve, on an advisory basis, the compensation of the named executive officers as disclosed in the Proxy Statement. SECTION 14A SAY-ON-PAY VOTES ISSUER 143240.000000 0 AGAINST 143240.000000 AGAINST Illumina, Inc. 452327109 US4523271090 05/21/2025 To approve the Second Amended and Restated 2015 Stock and Incentive Plan of Illumina, Inc. COMPENSATION ISSUER 143240.000000 0 FOR 143240.000000 FOR Merus N.V. N5749R100 NL0011606264 05/21/2025 Adoption of Merus N.V.'s Dutch statutory annual accounts for the financial year 2024. CORPORATE GOVERNANCE ISSUER 79427.000000 0 FOR 79427.000000 FOR Merus N.V. N5749R100 NL0011606264 05/21/2025 Appointment of KPMG Accountants N.V. as Merus N.V.'s external auditor for the financial year 2025 for purposes of Dutch law. AUDIT-RELATED ISSUER 79427.000000 0 FOR 79427.000000 FOR Merus N.V. N5749R100 NL0011606264 05/21/2025 Release of each member of Merus N.V.'s board of directors from liability for the exercise of their duties during the financial year 2024. CORPORATE GOVERNANCE ISSUER 79427.000000 0 FOR 79427.000000 FOR Merus N.V. N5749R100 NL0011606264 05/21/2025 Opportunity to make recommendations for nomination by Merus N.V.'s group of non-executive directors. CORPORATE GOVERNANCE ISSUER 79427.000000 0 FOR 79427.000000 FOR Merus N.V. N5749R100 NL0011606264 05/21/2025 Re-appointment of Anand Mehra, M.D. as non-executive director. DIRECTOR ELECTIONS ISSUER 79427.000000 0 FOR 79427.000000 FOR Merus N.V. N5749R100 NL0011606264 05/21/2025 Opportunity to make recommendations for nomination by Merus N.V.'s group of non-executive directors. CORPORATE GOVERNANCE ISSUER 79427.000000 0 FOR 79427.000000 FOR Merus N.V. N5749R100 NL0011606264 05/21/2025 Re-appointment of Maxine Gowen, Ph.D. as non-executive director. DIRECTOR ELECTIONS ISSUER 79427.000000 0 FOR 79427.000000 FOR Merus N.V. N5749R100 NL0011606264 05/21/2025 Granting authorization to Merus N.V.'s board of directors to acquire shares (or depository receipts for such shares) in Merus N.V.'s capital. CAPITAL STRUCTURE ISSUER 79427.000000 0 FOR 79427.000000 FOR Merus N.V. N5749R100 NL0011606264 05/21/2025 Approval, on an advisory (non-binding) basis, of the compensation of Merus N.V.'s named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 79427.000000 0 AGAINST 79427.000000 AGAINST Neurocrine Biosciences, Inc. 64125C109 US64125C1099 05/21/2025 The election of the four nominees for Class II directors named below to the Board of Directors to serve for a term of three years: Kyle W. Gano, Ph.D. DIRECTOR ELECTIONS ISSUER 114326.000000 0 FOR 114326.000000 FOR Neurocrine Biosciences, Inc. 64125C109 US64125C1099 05/21/2025 The election of the four nominees for Class II directors named below to the Board of Directors to serve for a term of three years: Richard F. Pops DIRECTOR ELECTIONS ISSUER 114326.000000 0 FOR 114326.000000 FOR Neurocrine Biosciences, Inc. 64125C109 US64125C1099 05/21/2025 The election of the four nominees for Class II directors named below to the Board of Directors to serve for a term of three years: Shalini Sharp DIRECTOR ELECTIONS ISSUER 114326.000000 0 FOR 114326.000000 FOR Neurocrine Biosciences, Inc. 64125C109 US64125C1099 05/21/2025 The election of the four nominees for Class II directors named below to the Board of Directors to serve for a term of three years: Stephen A. Sherwin, M.D. DIRECTOR ELECTIONS ISSUER 114326.000000 0 FOR 114326.000000 FOR Neurocrine Biosciences, Inc. 64125C109 US64125C1099 05/21/2025 Advisory vote on the compensation paid to the Company's named executive officers; SECTION 14A SAY-ON-PAY VOTES ISSUER 114326.000000 0 FOR 114326.000000 FOR Neurocrine Biosciences, Inc. 64125C109 US64125C1099 05/21/2025 To approve the Company's 2025 Equity Incentive Plan; COMPENSATION ISSUER 114326.000000 0 FOR 114326.000000 FOR Neurocrine Biosciences, Inc. 64125C109 US64125C1099 05/21/2025 To approve an amendment and restatement of the Company's 2018 Employee Stock Purchase Plan; and COMPENSATION ISSUER 114326.000000 0 FOR 114326.000000 FOR Neurocrine Biosciences, Inc. 64125C109 US64125C1099 05/21/2025 To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025. AUDIT-RELATED ISSUER 114326.000000 0 FOR 114326.000000 FOR Tandem Diabetes Care, Inc. 875372203 US8753722037 05/21/2025 To elect eight directors for a one-year term expiring at the 2026 annual meeting of stockholders: Rebecca Robertson DIRECTOR ELECTIONS ISSUER 170194.000000 0 FOR 170194.000000 FOR Tandem Diabetes Care, Inc. 875372203 US8753722037 05/21/2025 To elect eight directors for a one-year term expiring at the 2026 annual meeting of stockholders: Myoungil Cha DIRECTOR ELECTIONS ISSUER 170194.000000 0 FOR 170194.000000 FOR Tandem Diabetes Care, Inc. 875372203 US8753722037 05/21/2025 To elect eight directors for a one-year term expiring at the 2026 annual meeting of stockholders: Peyton Howell DIRECTOR ELECTIONS ISSUER 170194.000000 0 FOR 170194.000000 FOR Tandem Diabetes Care, Inc. 875372203 US8753722037 05/21/2025 To elect eight directors for a one-year term expiring at the 2026 annual meeting of stockholders: Joao Malagueira DIRECTOR ELECTIONS ISSUER 170194.000000 0 FOR 170194.000000 FOR Tandem Diabetes Care, Inc. 875372203 US8753722037 05/21/2025 To elect eight directors for a one-year term expiring at the 2026 annual meeting of stockholders: Kathleen McGroddy-Goetz DIRECTOR ELECTIONS ISSUER 170194.000000 0 FOR 170194.000000 FOR Tandem Diabetes Care, Inc. 875372203 US8753722037 05/21/2025 To elect eight directors for a one-year term expiring at the 2026 annual meeting of stockholders: John Sheridan DIRECTOR ELECTIONS ISSUER 170194.000000 0 FOR 170194.000000 FOR Tandem Diabetes Care, Inc. 875372203 US8753722037 05/21/2025 To elect eight directors for a one-year term expiring at the 2026 annual meeting of stockholders: Rajwant Sodhi DIRECTOR ELECTIONS ISSUER 170194.000000 0 FOR 170194.000000 FOR Tandem Diabetes Care, Inc. 875372203 US8753722037 05/21/2025 To elect eight directors for a one-year term expiring at the 2026 annual meeting of stockholders: Christopher Twomey DIRECTOR ELECTIONS ISSUER 170194.000000 0 FOR 170194.000000 FOR Tandem Diabetes Care, Inc. 875372203 US8753722037 05/21/2025 To approve, on a non-binding, advisory basis, the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 170194.000000 0 AGAINST 170194.000000 AGAINST Tandem Diabetes Care, Inc. 875372203 US8753722037 05/21/2025 To approve, on a non-binding, advisory basis, the frequency of future stockholder advisory votes to approve the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 170194.000000 0 ONE YEAR 170194.000000 FOR Tandem Diabetes Care, Inc. 875372203 US8753722037 05/21/2025 To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025. AUDIT-RELATED ISSUER 170194.000000 0 FOR 170194.000000 FOR Thermo Fisher Scientific Inc. 883556102 US8835561023 05/21/2025 Election of Directors: Marc N. Casper DIRECTOR ELECTIONS ISSUER 26994.000000 0 FOR 26994.000000 FOR Thermo Fisher Scientific Inc. 883556102 US8835561023 05/21/2025 Election of Directors: Nelson J. Chai DIRECTOR ELECTIONS ISSUER 26994.000000 0 FOR 26994.000000 FOR Thermo Fisher Scientific Inc. 883556102 US8835561023 05/21/2025 Election of Directors: Ruby R. Chandy DIRECTOR ELECTIONS ISSUER 26994.000000 0 FOR 26994.000000 FOR Thermo Fisher Scientific Inc. 883556102 US8835561023 05/21/2025 Election of Directors: C. Martin Harris DIRECTOR ELECTIONS ISSUER 26994.000000 0 FOR 26994.000000 FOR Thermo Fisher Scientific Inc. 883556102 US8835561023 05/21/2025 Election of Directors: Tyler Jacks DIRECTOR ELECTIONS ISSUER 26994.000000 0 AGAINST 26994.000000 AGAINST Thermo Fisher Scientific Inc. 883556102 US8835561023 05/21/2025 Election of Directors: Jennifer M. Johnson DIRECTOR ELECTIONS ISSUER 26994.000000 0 FOR 26994.000000 FOR Thermo Fisher Scientific Inc. 883556102 US8835561023 05/21/2025 Election of Directors: R. Alexandra Keith DIRECTOR ELECTIONS ISSUER 26994.000000 0 FOR 26994.000000 FOR Thermo Fisher Scientific Inc. 883556102 US8835561023 05/21/2025 Election of Directors: Karen S. Lynch DIRECTOR ELECTIONS ISSUER 26994.000000 0 FOR 26994.000000 FOR Thermo Fisher Scientific Inc. 883556102 US8835561023 05/21/2025 Election of Directors: James C. Mullen DIRECTOR ELECTIONS ISSUER 26994.000000 0 FOR 26994.000000 FOR Thermo Fisher Scientific Inc. 883556102 US8835561023 05/21/2025 Election of Directors: Debora L. Spar DIRECTOR ELECTIONS ISSUER 26994.000000 0 FOR 26994.000000 FOR Thermo Fisher Scientific Inc. 883556102 US8835561023 05/21/2025 Election of Directors: Scott M. Sperling DIRECTOR ELECTIONS ISSUER 26994.000000 0 AGAINST 26994.000000 AGAINST Thermo Fisher Scientific Inc. 883556102 US8835561023 05/21/2025 Election of Directors: Dion J. Weisler DIRECTOR ELECTIONS ISSUER 26994.000000 0 FOR 26994.000000 FOR Thermo Fisher Scientific Inc. 883556102 US8835561023 05/21/2025 An advisory vote to approve named executive officer compensation. SECTION 14A SAY-ON-PAY VOTES ISSUER 26994.000000 0 AGAINST 26994.000000 AGAINST Thermo Fisher Scientific Inc. 883556102 US8835561023 05/21/2025 Ratification of the Audit Committee's selection of PricewaterhouseCoopers LLP as the Company's independent auditors for 2025. AUDIT-RELATED ISSUER 26994.000000 0 FOR 26994.000000 FOR Thermo Fisher Scientific Inc. 883556102 US8835561023 05/21/2025 Shareholder proposal. CORPORATE GOVERNANCE SECURITY HOLDER 26994.000000 0 AGAINST 26994.000000 FOR Zoetis Inc. 98978V103 US98978V1035 05/21/2025 Election of Directors: Paul M. Bisaro DIRECTOR ELECTIONS ISSUER 45408.000000 0 FOR 45408.000000 FOR Zoetis Inc. 98978V103 US98978V1035 05/21/2025 Election of Directors: Vanessa Broadhurst DIRECTOR ELECTIONS ISSUER 45408.000000 0 FOR 45408.000000 FOR Zoetis Inc. 98978V103 US98978V1035 05/21/2025 Election of Directors: Frank A. D'Amelio DIRECTOR ELECTIONS ISSUER 45408.000000 0 FOR 45408.000000 FOR Zoetis Inc. 98978V103 US98978V1035 05/21/2025 Election of Directors: Gavin D.K. Hattersley DIRECTOR ELECTIONS ISSUER 45408.000000 0 FOR 45408.000000 FOR Zoetis Inc. 98978V103 US98978V1035 05/21/2025 Election of Directors: Sanjay Khosla DIRECTOR ELECTIONS ISSUER 45408.000000 0 FOR 45408.000000 FOR Zoetis Inc. 98978V103 US98978V1035 05/21/2025 Election of Directors: Antoinette R. Leatherberry DIRECTOR ELECTIONS ISSUER 45408.000000 0 FOR 45408.000000 FOR Zoetis Inc. 98978V103 US98978V1035 05/21/2025 Election of Directors: Michael B. McCallister DIRECTOR ELECTIONS ISSUER 45408.000000 0 FOR 45408.000000 FOR Zoetis Inc. 98978V103 US98978V1035 05/21/2025 Election of Directors: Gregory Norden DIRECTOR ELECTIONS ISSUER 45408.000000 0 FOR 45408.000000 FOR Zoetis Inc. 98978V103 US98978V1035 05/21/2025 Election of Directors: Louise M. Parent DIRECTOR ELECTIONS ISSUER 45408.000000 0 FOR 45408.000000 FOR Zoetis Inc. 98978V103 US98978V1035 05/21/2025 Election of Directors: Kristin C. Peck DIRECTOR ELECTIONS ISSUER 45408.000000 0 FOR 45408.000000 FOR Zoetis Inc. 98978V103 US98978V1035 05/21/2025 Election of Directors: Willie M. Reed DIRECTOR ELECTIONS ISSUER 45408.000000 0 FOR 45408.000000 FOR Zoetis Inc. 98978V103 US98978V1035 05/21/2025 Election of Directors: Mark Stetter DIRECTOR ELECTIONS ISSUER 45408.000000 0 FOR 45408.000000 FOR Zoetis Inc. 98978V103 US98978V1035 05/21/2025 Advisory vote to approve our executive compensation. SECTION 14A SAY-ON-PAY VOTES ISSUER 45408.000000 0 AGAINST 45408.000000 AGAINST Zoetis Inc. 98978V103 US98978V1035 05/21/2025 Ratification of appointment of KPMG LLP as our independent registered public accounting firm for 2025. AUDIT-RELATED ISSUER 45408.000000 0 FOR 45408.000000 FOR Zoetis Inc. 98978V103 US98978V1035 05/21/2025 Shareholder proposal regarding a special shareholder meeting improvement. CORPORATE GOVERNANCE SECURITY HOLDER 45408.000000 0 AGAINST 45408.000000 FOR Insulet Corporation 45784P101 US45784P1012 05/22/2025 Election of Directors: Jessica Hopfield DIRECTOR ELECTIONS ISSUER 4770.000000 0 FOR 4770.000000 FOR Insulet Corporation 45784P101 US45784P1012 05/22/2025 Election of Directors: Ashley A. McEvoy DIRECTOR ELECTIONS ISSUER 4770.000000 0 FOR 4770.000000 FOR Insulet Corporation 45784P101 US45784P1012 05/22/2025 Election of Directors: Elizabeth H. Weatherman DIRECTOR ELECTIONS ISSUER 4770.000000 0 FOR 4770.000000 FOR Insulet Corporation 45784P101 US45784P1012 05/22/2025 To approve, on a non-binding, advisory basis, the compensation of certain executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 4770.000000 0 AGAINST 4770.000000 AGAINST Insulet Corporation 45784P101 US45784P1012 05/22/2025 To approve the Insulet Corporation 2025 Stock Option and Incentive Plan. COMPENSATION ISSUER 4770.000000 0 FOR 4770.000000 FOR Insulet Corporation 45784P101 US45784P1012 05/22/2025 To ratify the appointment of Grant Thornton LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025. AUDIT-RELATED ISSUER 4770.000000 0 FOR 4770.000000 FOR SCHOLAR ROCK HOLDING CORPORATION 80706P103 US80706P1030 05/22/2025 To elect three Class I directors to our Board of Directors, each to serve until the 2028 Annual Meeting of stockholders and until his successor has been duly elected and qualified, or until his earlier death, resignation, or removal: Srinivas Akkaraju, M.D., Ph.D. DIRECTOR ELECTIONS ISSUER 58722.000000 0 WITHHOLD 58722.000000 AGAINST SCHOLAR ROCK HOLDING CORPORATION 80706P103 US80706P1030 05/22/2025 To elect three Class I directors to our Board of Directors, each to serve until the 2028 Annual Meeting of stockholders and until his successor has been duly elected and qualified, or until his earlier death, resignation, or removal: Joshua Reed DIRECTOR ELECTIONS ISSUER 58722.000000 0 WITHHOLD 58722.000000 AGAINST SCHOLAR ROCK HOLDING CORPORATION 80706P103 US80706P1030 05/22/2025 To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 58722.000000 0 AGAINST 58722.000000 AGAINST Tenet Healthcare Corporation 88033G407 US88033G4073 05/22/2025 Election of Directors: Saumya Sutaria DIRECTOR ELECTIONS ISSUER 35984.000000 0 FOR 35984.000000 FOR Tenet Healthcare Corporation 88033G407 US88033G4073 05/22/2025 Election of Directors: J. Robert Kerrey DIRECTOR ELECTIONS ISSUER 35984.000000 0 AGAINST 35984.000000 AGAINST Tenet Healthcare Corporation 88033G407 US88033G4073 05/22/2025 Election of Directors: Vineeta Agarwala DIRECTOR ELECTIONS ISSUER 35984.000000 0 FOR 35984.000000 FOR Tenet Healthcare Corporation 88033G407 US88033G4073 05/22/2025 Election of Directors: James L. Bierman DIRECTOR ELECTIONS ISSUER 35984.000000 0 FOR 35984.000000 FOR Tenet Healthcare Corporation 88033G407 US88033G4073 05/22/2025 Election of Directors: Roy Blunt DIRECTOR ELECTIONS ISSUER 35984.000000 0 FOR 35984.000000 FOR Tenet Healthcare Corporation 88033G407 US88033G4073 05/22/2025 Election of Directors: Richard W. Fisher DIRECTOR ELECTIONS ISSUER 35984.000000 0 FOR 35984.000000 FOR Tenet Healthcare Corporation 88033G407 US88033G4073 05/22/2025 Election of Directors: Meghan M. FitzGerald DIRECTOR ELECTIONS ISSUER 35984.000000 0 FOR 35984.000000 FOR Tenet Healthcare Corporation 88033G407 US88033G4073 05/22/2025 Election of Directors: Cecil D. Haney DIRECTOR ELECTIONS ISSUER 35984.000000 0 FOR 35984.000000 FOR Tenet Healthcare Corporation 88033G407 US88033G4073 05/22/2025 Election of Directors: Christopher S. Lynch DIRECTOR ELECTIONS ISSUER 35984.000000 0 FOR 35984.000000 FOR Tenet Healthcare Corporation 88033G407 US88033G4073 05/22/2025 Election of Directors: Richard J. Mark DIRECTOR ELECTIONS ISSUER 35984.000000 0 FOR 35984.000000 FOR Tenet Healthcare Corporation 88033G407 US88033G4073 05/22/2025 Election of Directors: Tammy Romo DIRECTOR ELECTIONS ISSUER 35984.000000 0 FOR 35984.000000 FOR Tenet Healthcare Corporation 88033G407 US88033G4073 05/22/2025 Election of Directors: Stephen H. Rusckowski DIRECTOR ELECTIONS ISSUER 35984.000000 0 FOR 35984.000000 FOR Tenet Healthcare Corporation 88033G407 US88033G4073 05/22/2025 Election of Directors: Nadja Y. West DIRECTOR ELECTIONS ISSUER 35984.000000 0 FOR 35984.000000 FOR Tenet Healthcare Corporation 88033G407 US88033G4073 05/22/2025 To approve, on an advisory basis, the Company's executive compensation. SECTION 14A SAY-ON-PAY VOTES ISSUER 35984.000000 0 AGAINST 35984.000000 AGAINST Tenet Healthcare Corporation 88033G407 US88033G4073 05/22/2025 To ratify the selection of Deloitte & Touche LLP as the Company's independent registered public accountants for the year ending December 31, 2025. AUDIT-RELATED ISSUER 35984.000000 0 FOR 35984.000000 FOR Tenet Healthcare Corporation 88033G407 US88033G4073 05/22/2025 To report on strategies and programs for improving maternal health outcomes. OTHER SOCIAL ISSUES SECURITY HOLDER 35984.000000 0 AGAINST 35984.000000 FOR Amgen Inc. 031162100 US0311621009 05/23/2025 To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2026 annual meeting of stockholders. The nominees for election to the Board of Directors are: Dr. Wanda M. Austin DIRECTOR ELECTIONS ISSUER 201529.000000 0 FOR 201529.000000 FOR Amgen Inc. 031162100 US0311621009 05/23/2025 To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2026 annual meeting of stockholders. The nominees for election to the Board of Directors are: Mr. Robert A. Bradway DIRECTOR ELECTIONS ISSUER 201529.000000 0 FOR 201529.000000 FOR Amgen Inc. 031162100 US0311621009 05/23/2025 To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2026 annual meeting of stockholders. The nominees for election to the Board of Directors are: Dr. Michael V. Drake DIRECTOR ELECTIONS ISSUER 201529.000000 0 FOR 201529.000000 FOR Amgen Inc. 031162100 US0311621009 05/23/2025 To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2026 annual meeting of stockholders. The nominees for election to the Board of Directors are: Dr. Brian J. Druker DIRECTOR ELECTIONS ISSUER 201529.000000 0 FOR 201529.000000 FOR Amgen Inc. 031162100 US0311621009 05/23/2025 To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2026 annual meeting of stockholders. The nominees for election to the Board of Directors are: Mr. Robert A. Eckert DIRECTOR ELECTIONS ISSUER 201529.000000 0 FOR 201529.000000 FOR Amgen Inc. 031162100 US0311621009 05/23/2025 To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2026 annual meeting of stockholders. The nominees for election to the Board of Directors are: Mr. Greg C. Garland DIRECTOR ELECTIONS ISSUER 201529.000000 0 FOR 201529.000000 FOR Amgen Inc. 031162100 US0311621009 05/23/2025 To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2026 annual meeting of stockholders. The nominees for election to the Board of Directors are: Mr. Charles M. Holley, Jr. DIRECTOR ELECTIONS ISSUER 201529.000000 0 FOR 201529.000000 FOR Amgen Inc. 031162100 US0311621009 05/23/2025 To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2026 annual meeting of stockholders. The nominees for election to the Board of Directors are: Dr. S. Omar Ishrak DIRECTOR ELECTIONS ISSUER 201529.000000 0 FOR 201529.000000 FOR Amgen Inc. 031162100 US0311621009 05/23/2025 To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2026 annual meeting of stockholders. The nominees for election to the Board of Directors are: Dr. Tyler Jacks DIRECTOR ELECTIONS ISSUER 201529.000000 0 FOR 201529.000000 FOR Amgen Inc. 031162100 US0311621009 05/23/2025 To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2026 annual meeting of stockholders. The nominees for election to the Board of Directors are: Dr. Mary E. Klotman DIRECTOR ELECTIONS ISSUER 201529.000000 0 FOR 201529.000000 FOR Amgen Inc. 031162100 US0311621009 05/23/2025 To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2026 annual meeting of stockholders. The nominees for election to the Board of Directors are: Ms. Ellen J. Kullman DIRECTOR ELECTIONS ISSUER 201529.000000 0 FOR 201529.000000 FOR Amgen Inc. 031162100 US0311621009 05/23/2025 To elect twelve directors to the Board of Directors of Amgen Inc. for a term of office expiring at the 2026 annual meeting of stockholders. The nominees for election to the Board of Directors are: Ms. Amy E. Miles DIRECTOR ELECTIONS ISSUER 201529.000000 0 FOR 201529.000000 FOR Amgen Inc. 031162100 US0311621009 05/23/2025 Advisory vote to approve our executive compensation. SECTION 14A SAY-ON-PAY VOTES ISSUER 201529.000000 0 AGAINST 201529.000000 AGAINST Amgen Inc. 031162100 US0311621009 05/23/2025 To ratify the selection of Ernst & Young LLP as our independent registered public accountants for the fiscal year ending December 31, 2025. AUDIT-RELATED ISSUER 201529.000000 0 AGAINST 201529.000000 AGAINST argenx SE 04016X101 US04016X1019 05/27/2025 Approve Remuneration Report COMPENSATION ISSUER 29509.000000 0 AGAINST 29509.000000 AGAINST argenx SE 04016X101 US04016X1019 05/27/2025 Adopt Financial Statements and Statutory Reports CORPORATE GOVERNANCE ISSUER 29509.000000 0 FOR 29509.000000 FOR argenx SE 04016X101 US04016X1019 05/27/2025 Approve Allocation of Income to the Retained Earnings of the Company CAPITAL STRUCTURE ISSUER 29509.000000 0 FOR 29509.000000 FOR argenx SE 04016X101 US04016X1019 05/27/2025 Approve Discharge of Directors CORPORATE GOVERNANCE ISSUER 29509.000000 0 FOR 29509.000000 FOR argenx SE 04016X101 US04016X1019 05/27/2025 Approve Remuneration Policy COMPENSATION ISSUER 29509.000000 0 AGAINST 29509.000000 AGAINST argenx SE 04016X101 US04016X1019 05/27/2025 Reelect Anthony Rosenberg as Non-Executive Director DIRECTOR ELECTIONS ISSUER 29509.000000 0 FOR 29509.000000 FOR argenx SE 04016X101 US04016X1019 05/27/2025 Grant Board Authority to Issue Shares and Exclude Pre-emptive Rights CAPITAL STRUCTURE ISSUER 29509.000000 0 FOR 29509.000000 FOR Ascendis Pharma A/S 04351P101 US04351P1012 05/27/2025 Elect Lars Luthjohan as Chair of Meeting CORPORATE GOVERNANCE ISSUER 96830.000000 0 FOR 96830.000000 FOR Ascendis Pharma A/S 04351P101 US04351P1012 05/27/2025 Accept Financial Statements and Statutory Reports; Approve Discharge of Management and Board CAPITAL STRUCTURE CORPORATE GOVERNANCE ISSUER 96830.000000 0 FOR 96830.000000 FOR Ascendis Pharma A/S 04351P101 US04351P1012 05/27/2025 Approve Treatment of Net Loss CAPITAL STRUCTURE ISSUER 96830.000000 0 FOR 96830.000000 FOR Ascendis Pharma A/S 04351P101 US04351P1012 05/27/2025 Reelect Albert Cha as Director DIRECTOR ELECTIONS ISSUER 96830.000000 0 FOR 96830.000000 FOR Ascendis Pharma A/S 04351P101 US04351P1012 05/27/2025 Reelect Lars Holtug as Director DIRECTOR ELECTIONS ISSUER 96830.000000 0 FOR 96830.000000 FOR Ascendis Pharma A/S 04351P101 US04351P1012 05/27/2025 Reelect Jan Moller Mikkelsen as Director DIRECTOR ELECTIONS ISSUER 96830.000000 0 FOR 96830.000000 FOR Ascendis Pharma A/S 04351P101 US04351P1012 05/27/2025 Reelect Lisa Jane Morrison as Director DIRECTOR ELECTIONS ISSUER 96830.000000 0 FOR 96830.000000 FOR Ascendis Pharma A/S 04351P101 US04351P1012 05/27/2025 Reelect William Carl Fairey Jr as Director DIRECTOR ELECTIONS ISSUER 96830.000000 0 FOR 96830.000000 FOR Ascendis Pharma A/S 04351P101 US04351P1012 05/27/2025 Reelect Siham Imani as Director DIRECTOR ELECTIONS ISSUER 96830.000000 0 FOR 96830.000000 FOR Ascendis Pharma A/S 04351P101 US04351P1012 05/27/2025 Ratify Deloitte as Auditor AUDIT-RELATED ISSUER 96830.000000 0 FOR 96830.000000 FOR Ascendis Pharma A/S 04351P101 US04351P1012 05/27/2025 Approve Creation of DKK 3.8 Million Pool of Capital without Preemptive Rights CAPITAL STRUCTURE ISSUER 96830.000000 0 FOR 96830.000000 FOR Ascendis Pharma A/S 04351P101 US04351P1012 05/27/2025 Approve Issuance of Warrants to Board Members COMPENSATION ISSUER 96830.000000 0 AGAINST 96830.000000 AGAINST Ascendis Pharma A/S 04351P101 US04351P1012 05/27/2025 Amend Articles Re: Board-Related CORPORATE GOVERNANCE ISSUER 96830.000000 0 FOR 96830.000000 FOR Merck & Co., Inc. 58933Y105 US58933Y1055 05/27/2025 Election of Directors: Douglas M. Baker, Jr. DIRECTOR ELECTIONS ISSUER 127564.000000 0 FOR 127564.000000 FOR Merck & Co., Inc. 58933Y105 US58933Y1055 05/27/2025 Election of Directors: Mary Ellen Coe DIRECTOR ELECTIONS ISSUER 127564.000000 0 FOR 127564.000000 FOR Merck & Co., Inc. 58933Y105 US58933Y1055 05/27/2025 Election of Directors: Pamela J. Craig DIRECTOR ELECTIONS ISSUER 127564.000000 0 FOR 127564.000000 FOR Merck & Co., Inc. 58933Y105 US58933Y1055 05/27/2025 Election of Directors: Robert M. Davis DIRECTOR ELECTIONS ISSUER 127564.000000 0 FOR 127564.000000 FOR Merck & Co., Inc. 58933Y105 US58933Y1055 05/27/2025 Election of Directors: Thomas H. Glocer DIRECTOR ELECTIONS ISSUER 127564.000000 0 AGAINST 127564.000000 AGAINST Merck & Co., Inc. 58933Y105 US58933Y1055 05/27/2025 Election of Directors: Surendralal L. Karsanbhai DIRECTOR ELECTIONS ISSUER 127564.000000 0 FOR 127564.000000 FOR Merck & Co., Inc. 58933Y105 US58933Y1055 05/27/2025 Election of Directors: Risa J. Lavizzo-Mourey, M.D. DIRECTOR ELECTIONS ISSUER 127564.000000 0 FOR 127564.000000 FOR Merck & Co., Inc. 58933Y105 US58933Y1055 05/27/2025 Election of Directors: Stephen L. Mayo, Ph.D. DIRECTOR ELECTIONS ISSUER 127564.000000 0 FOR 127564.000000 FOR Merck & Co., Inc. 58933Y105 US58933Y1055 05/27/2025 Election of Directors: Paul B. Rothman, M.D. DIRECTOR ELECTIONS ISSUER 127564.000000 0 FOR 127564.000000 FOR Merck & Co., Inc. 58933Y105 US58933Y1055 05/27/2025 Election of Directors: Patricia F. Russo DIRECTOR ELECTIONS ISSUER 127564.000000 0 AGAINST 127564.000000 AGAINST Merck & Co., Inc. 58933Y105 US58933Y1055 05/27/2025 Election of Directors: Christine E. Seidman, M.D. DIRECTOR ELECTIONS ISSUER 127564.000000 0 FOR 127564.000000 FOR Merck & Co., Inc. 58933Y105 US58933Y1055 05/27/2025 Election of Directors: Inge G. Thulin DIRECTOR ELECTIONS ISSUER 127564.000000 0 FOR 127564.000000 FOR Merck & Co., Inc. 58933Y105 US58933Y1055 05/27/2025 Election of Directors: Kathy J. Warden DIRECTOR ELECTIONS ISSUER 127564.000000 0 FOR 127564.000000 FOR Merck & Co., Inc. 58933Y105 US58933Y1055 05/27/2025 Non-binding advisory vote to approve the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 127564.000000 0 AGAINST 127564.000000 AGAINST Merck & Co., Inc. 58933Y105 US58933Y1055 05/27/2025 Ratification of the appointment of the Company's independent registered public accounting firm for 2025. AUDIT-RELATED ISSUER 127564.000000 0 AGAINST 127564.000000 AGAINST Merck & Co., Inc. 58933Y105 US58933Y1055 05/27/2025 Shareholder proposal regarding a human rights impact assessment. HUMAN RIGHTS OR HUMAN CAPITAL/WORKFORCE SECURITY HOLDER 127564.000000 0 AGAINST 127564.000000 FOR Merck & Co., Inc. 58933Y105 US58933Y1055 05/27/2025 Shareholder proposal regarding a tax transparency report. OTHER SOCIAL ISSUES SECURITY HOLDER 127564.000000 0 AGAINST 127564.000000 FOR Merck & Co., Inc. 58933Y105 US58933Y1055 05/27/2025 Shareholder proposal to revisit DEl goals in executive pay incentives. ENVIRONMENT OR CLIMATE DIVERSITY, EQUITY, AND INCLUSION OTHER SOCIAL ISSUES SECURITY HOLDER 127564.000000 0 AGAINST 127564.000000 FOR Merck & Co., Inc. 58933Y105 US58933Y1055 05/27/2025 Shareholder proposal regarding a report on civil liberties in advertising services. ENVIRONMENT OR CLIMATE DIVERSITY, EQUITY, AND INCLUSION OTHER SOCIAL ISSUES SECURITY HOLDER 127564.000000 0 AGAINST 127564.000000 FOR GRAIL, Inc. 384747101 US3847471014 05/29/2025 Election of Class I Director to serve until the 2028 Annual Meeting of Stockholders, and until their respective successor has been duly elected and qualified: William (Bill) Chase DIRECTOR ELECTIONS ISSUER 198327.000000 0 FOR 198327.000000 FOR GRAIL, Inc. 384747101 US3847471014 05/29/2025 The ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025. AUDIT-RELATED ISSUER 198327.000000 0 FOR 198327.000000 FOR Vir Biotechnology, Inc. 92764N102 US92764N1028 05/29/2025 To elect the following two nominees for director to hold office until the 2028 Annual Meeting of Stockholders, and until their successor is duly elected and qualified, or until their earlier death, resignation or removal: Jeffrey S. Hatfield DIRECTOR ELECTIONS ISSUER 477038.000000 0 WITHHOLD 477038.000000 AGAINST Vir Biotechnology, Inc. 92764N102 US92764N1028 05/29/2025 To elect the following two nominees for director to hold office until the 2028 Annual Meeting of Stockholders, and until their successor is duly elected and qualified, or until their earlier death, resignation or removal: Saira Ramasastry DIRECTOR ELECTIONS ISSUER 477038.000000 0 FOR 477038.000000 FOR Vir Biotechnology, Inc. 92764N102 US92764N1028 05/29/2025 To approve, on an advisory basis, the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 477038.000000 0 AGAINST 477038.000000 AGAINST Vir Biotechnology, Inc. 92764N102 US92764N1028 05/29/2025 To ratify the appointment by the Audit Committee of the Board of Directors of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025. AUDIT-RELATED ISSUER 477038.000000 0 FOR 477038.000000 FOR UnitedHealth Group Incorporated 91324P102 US91324P1021 06/02/2025 Election of Directors: Charles Baker DIRECTOR ELECTIONS ISSUER 46775.000000 0 FOR 46775.000000 FOR UnitedHealth Group Incorporated 91324P102 US91324P1021 06/02/2025 Election of Directors: Timothy Flynn DIRECTOR ELECTIONS ISSUER 46775.000000 0 FOR 46775.000000 FOR UnitedHealth Group Incorporated 91324P102 US91324P1021 06/02/2025 Election of Directors: Paul Garcia DIRECTOR ELECTIONS ISSUER 46775.000000 0 FOR 46775.000000 FOR UnitedHealth Group Incorporated 91324P102 US91324P1021 06/02/2025 Election of Directors: Kristen Gil DIRECTOR ELECTIONS ISSUER 46775.000000 0 FOR 46775.000000 FOR UnitedHealth Group Incorporated 91324P102 US91324P1021 06/02/2025 Election of Directors: Stephen Hemsley DIRECTOR ELECTIONS ISSUER 46775.000000 0 FOR 46775.000000 FOR UnitedHealth Group Incorporated 91324P102 US91324P1021 06/02/2025 Election of Directors: Michele Hooper DIRECTOR ELECTIONS ISSUER 46775.000000 0 AGAINST 46775.000000 AGAINST UnitedHealth Group Incorporated 91324P102 US91324P1021 06/02/2025 Election of Directors: F. William McNabb III DIRECTOR ELECTIONS ISSUER 46775.000000 0 FOR 46775.000000 FOR UnitedHealth Group Incorporated 91324P102 US91324P1021 06/02/2025 Election of Directors: Valerie Montgomery Rice, M.D. DIRECTOR ELECTIONS ISSUER 46775.000000 0 FOR 46775.000000 FOR UnitedHealth Group Incorporated 91324P102 US91324P1021 06/02/2025 Election of Directors: John Noseworthy, M.D. DIRECTOR ELECTIONS ISSUER 46775.000000 0 FOR 46775.000000 FOR UnitedHealth Group Incorporated 91324P102 US91324P1021 06/02/2025 Advisory approval of the Company's executive compensation. SECTION 14A SAY-ON-PAY VOTES ISSUER 46775.000000 0 AGAINST 46775.000000 AGAINST UnitedHealth Group Incorporated 91324P102 US91324P1021 06/02/2025 Ratification of the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the Company for the year ending December 31, 2025. AUDIT-RELATED ISSUER 46775.000000 0 AGAINST 46775.000000 AGAINST UnitedHealth Group Incorporated 91324P102 US91324P1021 06/02/2025 If properly presented at the 2025 Annual Meeting of Shareholders, the shareholder proposal requesting a shareholder vote regarding excessive golden parachutes. COMPENSATION SECURITY HOLDER 46775.000000 0 AGAINST 46775.000000 FOR Akero Therapeutics, Inc. 00973Y108 US00973Y1082 06/03/2025 To elect two class III directors, Judy Chou, Ph.D. and Tomas Heyman, to our board of directors, to serve until the 2028 Annual Meeting of stockholders and until her or his successor has been duly elected and qualified, or until her or his earlier death, resignation or removal: Judy Chou, Ph.D. DIRECTOR ELECTIONS ISSUER 242032.000000 0 WITHHOLD 242032.000000 AGAINST Akero Therapeutics, Inc. 00973Y108 US00973Y1082 06/03/2025 To elect two class III directors, Judy Chou, Ph.D. and Tomas Heyman, to our board of directors, to serve until the 2028 Annual Meeting of stockholders and until her or his successor has been duly elected and qualified, or until her or his earlier death, resignation or removal: Tomas Heyman DIRECTOR ELECTIONS ISSUER 242032.000000 0 WITHHOLD 242032.000000 AGAINST Akero Therapeutics, Inc. 00973Y108 US00973Y1082 06/03/2025 To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025. AUDIT-RELATED ISSUER 242032.000000 0 FOR 242032.000000 FOR Akero Therapeutics, Inc. 00973Y108 US00973Y1082 06/03/2025 To consider and act upon a non-binding, advisory vote to approve the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 242032.000000 0 FOR 242032.000000 FOR Denali Therapeutics Inc. 24823R105 US24823R1059 06/03/2025 ELECTION OF DIRECTORS: Julian Baker DIRECTOR ELECTIONS ISSUER 422310.000000 0 FOR 422310.000000 FOR Denali Therapeutics Inc. 24823R105 US24823R1059 06/03/2025 ELECTION OF DIRECTORS: Peter Klein DIRECTOR ELECTIONS ISSUER 422310.000000 0 FOR 422310.000000 FOR Denali Therapeutics Inc. 24823R105 US24823R1059 06/03/2025 ELECTION OF DIRECTORS: Steve Krognes DIRECTOR ELECTIONS ISSUER 422310.000000 0 WITHHOLD 422310.000000 AGAINST Denali Therapeutics Inc. 24823R105 US24823R1059 06/03/2025 Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2025 AUDIT-RELATED ISSUER 422310.000000 0 FOR 422310.000000 FOR Denali Therapeutics Inc. 24823R105 US24823R1059 06/03/2025 Advisory vote on executive compensation SECTION 14A SAY-ON-PAY VOTES ISSUER 422310.000000 0 FOR 422310.000000 FOR Immunic, Inc. 4525EP101 US4525EP1011 06/04/2025 Election of Directors for a term expiring at the 2028 Annual Meeting of Stockholders: Dr. Jorg Neermann DIRECTOR ELECTIONS ISSUER 3935222.000000 0 WITHHOLD 3935222.000000 AGAINST Immunic, Inc. 4525EP101 US4525EP1011 06/04/2025 Election of Directors for a term expiring at the 2028 Annual Meeting of Stockholders: Ms. Tamar Howson DIRECTOR ELECTIONS ISSUER 3935222.000000 0 FOR 3935222.000000 FOR Immunic, Inc. 4525EP101 US4525EP1011 06/04/2025 Election of Directors for a term expiring at the 2028 Annual Meeting of Stockholders: Mr. Barclay Phillips DIRECTOR ELECTIONS ISSUER 3935222.000000 0 FOR 3935222.000000 FOR Immunic, Inc. 4525EP101 US4525EP1011 06/04/2025 Amendment to the Immunic, Inc. 2019 Omnibus Equity Incentive Plan, as Amended, to increase the number of shares of common stock authorized for issuance by 7,000,000 shares to a total of 26,448,871 shares. COMPENSATION ISSUER 3935222.000000 0 AGAINST 3935222.000000 AGAINST Immunic, Inc. 4525EP101 US4525EP1011 06/04/2025 Ratification of appointment of Baker Tilly US, LLP as our independent registered public accounting firm for fiscal year ending December 31, 2025 AUDIT-RELATED ISSUER 3935222.000000 0 FOR 3935222.000000 FOR NewAmsterdam Pharma Company N.V. N62509109 NL00150012L7 06/04/2025 Adoption of the Dutch statutory annual accounts for the fiscal year ended December 31, 2024. CORPORATE GOVERNANCE ISSUER 256886.000000 0 FOR 256886.000000 FOR NewAmsterdam Pharma Company N.V. N62509109 NL00150012L7 06/04/2025 Discharge from liability for the Company's directors with respect to the performance of their duties during the fiscal year ended December 31, 2024. CORPORATE GOVERNANCE ISSUER 256886.000000 0 FOR 256886.000000 FOR NewAmsterdam Pharma Company N.V. N62509109 NL00150012L7 06/04/2025 Instruction to Deloitte Accountants B.V. as the Company's external auditor of the Company's Dutch statutory annual accounts and Dutch statutory board report for the fiscal year ending December 31, 2025. AUDIT-RELATED ISSUER 256886.000000 0 FOR 256886.000000 FOR NewAmsterdam Pharma Company N.V. N62509109 NL00150012L7 06/04/2025 Ratification of the selection of Deloitte Accountants B.V. as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2025 by the audit committee of the Company's Board of Directors. AUDIT-RELATED ISSUER 256886.000000 0 FOR 256886.000000 FOR NewAmsterdam Pharma Company N.V. N62509109 NL00150012L7 06/04/2025 Appointment of the following individuals as non-executive directors of the Company until the annual general meeting set forth next to their name: Wouter Joustra DIRECTOR ELECTIONS ISSUER 256886.000000 0 FOR 256886.000000 FOR NewAmsterdam Pharma Company N.V. N62509109 NL00150012L7 06/04/2025 Appointment of the following individuals as non-executive directors of the Company until the annual general meeting set forth next to their name: Mark McKenna DIRECTOR ELECTIONS ISSUER 256886.000000 0 FOR 256886.000000 FOR NewAmsterdam Pharma Company N.V. N62509109 NL00150012L7 06/04/2025 Appointment of the following individuals as non-executive directors of the Company until the annual general meeting set forth next to their name: Adele Gulfo DIRECTOR ELECTIONS ISSUER 256886.000000 0 FOR 256886.000000 FOR NewAmsterdam Pharma Company N.V. N62509109 NL00150012L7 06/04/2025 Reappointment of Michael Davidson M.D. as executive director and Dr. James N. Topper as non-executive director of the Company until the 2029 annual general meeting: Michael Davidson DIRECTOR ELECTIONS ISSUER 256886.000000 0 AGAINST 256886.000000 AGAINST NewAmsterdam Pharma Company N.V. N62509109 NL00150012L7 06/04/2025 Reappointment of Michael Davidson M.D. as executive director and Dr. James N. Topper as non-executive director of the Company until the 2029 annual general meeting: James N. Topper DIRECTOR ELECTIONS ISSUER 256886.000000 0 AGAINST 256886.000000 AGAINST NewAmsterdam Pharma Company N.V. N62509109 NL00150012L7 06/04/2025 Extension of authorization for the Board of Directors to acquire ordinary shares and depository receipts for ordinary shares in the Company's capital. CAPITAL STRUCTURE ISSUER 256886.000000 0 FOR 256886.000000 FOR NewAmsterdam Pharma Company N.V. N62509109 NL00150012L7 06/04/2025 Non-binding, advisory vote to approve the 2024 compensation of named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 256886.000000 0 FOR 256886.000000 FOR NewAmsterdam Pharma Company N.V. N62509109 NL00150012L7 06/04/2025 Non-binding, advisory vote regarding frequency of future shareholders' advisory votes on the compensation of named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 256886.000000 0 ONE YEAR 256886.000000 FOR Oculis Holding AG H5870P102 CH1242303498 06/04/2025 Accept Financial Statements and Statutory Reports CORPORATE GOVERNANCE ISSUER 0.000000 0 Oculis Holding AG H5870P102 CH1242303498 06/04/2025 Approve Treatment of Net Loss CAPITAL STRUCTURE ISSUER 0.000000 0 Oculis Holding AG H5870P102 CH1242303498 06/04/2025 Approve Discharge of Board and Senior Management CORPORATE GOVERNANCE ISSUER 0.000000 0 Oculis Holding AG H5870P102 CH1242303498 06/04/2025 Reelect Anthony Rosenberg as Director and Board Chair DIRECTOR ELECTIONS ISSUER 0.000000 0 Oculis Holding AG H5870P102 CH1242303498 06/04/2025 Reelect Christina Ackermann as Director DIRECTOR ELECTIONS ISSUER 0.000000 0 Oculis Holding AG H5870P102 CH1242303498 06/04/2025 Reelect Lionel Carnot as Director DIRECTOR ELECTIONS ISSUER 0.000000 0 Oculis Holding AG H5870P102 CH1242303498 06/04/2025 Reelect Arshad Khanani as Director DIRECTOR ELECTIONS ISSUER 0.000000 0 Oculis Holding AG H5870P102 CH1242303498 06/04/2025 Reelect Martijn Kleijwegt as Director DIRECTOR ELECTIONS ISSUER 0.000000 0 Oculis Holding AG H5870P102 CH1242303498 06/04/2025 Reelect Geraldine O'Keeffe as Director DIRECTOR ELECTIONS ISSUER 0.000000 0 Oculis Holding AG H5870P102 CH1242303498 06/04/2025 Reelect Riad Sherif as Director DIRECTOR ELECTIONS ISSUER 0.000000 0 Oculis Holding AG H5870P102 CH1242303498 06/04/2025 Reelect Robert Warner as Director DIRECTOR ELECTIONS ISSUER 0.000000 0 Oculis Holding AG H5870P102 CH1242303498 06/04/2025 Reappoint Christina Ackermann as Member of the Compensation Committee DIRECTOR ELECTIONS CORPORATE GOVERNANCE ISSUER 0.000000 0 Oculis Holding AG H5870P102 CH1242303498 06/04/2025 Reappoint Lionel Carnot as Member of the Compensation Committee DIRECTOR ELECTIONS CORPORATE GOVERNANCE ISSUER 0.000000 0 Oculis Holding AG H5870P102 CH1242303498 06/04/2025 Appoint Robert Warner as Member of the Compensation Committee DIRECTOR ELECTIONS CORPORATE GOVERNANCE ISSUER 0.000000 0 Oculis Holding AG H5870P102 CH1242303498 06/04/2025 Ratify PricewaterhouseCoopers SA as Statutory Auditors AUDIT-RELATED ISSUER 0.000000 0 Oculis Holding AG H5870P102 CH1242303498 06/04/2025 Designate PST Legal AG as Independent Proxy CORPORATE GOVERNANCE ISSUER 0.000000 0 Oculis Holding AG H5870P102 CH1242303498 06/04/2025 Approve Fixed Remuneration of Directors in the Amount of USD 572,000 COMPENSATION ISSUER 0.000000 0 Oculis Holding AG H5870P102 CH1242303498 06/04/2025 Approve Equity-Based Remuneration of Directors in the Amount of USD 2.2 Million COMPENSATION ISSUER 0.000000 0 Oculis Holding AG H5870P102 CH1242303498 06/04/2025 Approve Fixed Remuneration of Executive Committee in the Amount of USD 2.5 Million COMPENSATION ISSUER 0.000000 0 Oculis Holding AG H5870P102 CH1242303498 06/04/2025 Approve Variable Remuneration of Executive Committee in the Amount of USD 1.8 Million COMPENSATION ISSUER 0.000000 0 Oculis Holding AG H5870P102 CH1242303498 06/04/2025 Approve Equity-Based Remuneration of Executive Committee in the Amount of USD 15.5 Million COMPENSATION ISSUER 0.000000 0 Oculis Holding AG H5870P102 CH1242303498 06/04/2025 Approve Remuneration Report (Non-Binding) COMPENSATION ISSUER 0.000000 0 Oculis Holding AG H5870P102 CH1242303498 06/04/2025 Approve Creation of Capital Band within the Upper Limit of CHF 818,005 and the Lower Limit of CHF 545,337 with or without Exclusion of Preemptive Rights CAPITAL STRUCTURE ISSUER 0.000000 0 Oculis Holding AG H5870P102 CH1242303498 06/04/2025 Approve Creation of CHF 124,800 Pool of Conditional Capital for Employee Equity Plans COMPENSATION ISSUER 0.000000 0 Oculis Holding AG H5870P102 CH1242303498 06/04/2025 Transact Other Business (Voting) CORPORATE GOVERNANCE ISSUER 0.000000 0 Xenon Pharmaceuticals Inc. 98420N105 CA98420N1050 06/04/2025 To elect as directors of the Corporation the eight nominees named in the accompanying Proxy Statement and Management Information Circular to hold office until the next annual meeting of the Corporation or until their successors are duly elected: Dawn Svoronos DIRECTOR ELECTIONS ISSUER 269103.000000 0 FOR 269103.000000 FOR Xenon Pharmaceuticals Inc. 98420N105 CA98420N1050 06/04/2025 To elect as directors of the Corporation the eight nominees named in the accompanying Proxy Statement and Management Information Circular to hold office until the next annual meeting of the Corporation or until their successors are duly elected: Gillian Cannon DIRECTOR ELECTIONS ISSUER 269103.000000 0 FOR 269103.000000 FOR Xenon Pharmaceuticals Inc. 98420N105 CA98420N1050 06/04/2025 To elect as directors of the Corporation the eight nominees named in the accompanying Proxy Statement and Management Information Circular to hold office until the next annual meeting of the Corporation or until their successors are duly elected: Steven Gannon DIRECTOR ELECTIONS ISSUER 269103.000000 0 FOR 269103.000000 FOR Xenon Pharmaceuticals Inc. 98420N105 CA98420N1050 06/04/2025 To elect as directors of the Corporation the eight nominees named in the accompanying Proxy Statement and Management Information Circular to hold office until the next annual meeting of the Corporation or until their successors are duly elected: Elizabeth Garofalo DIRECTOR ELECTIONS ISSUER 269103.000000 0 FOR 269103.000000 FOR Xenon Pharmaceuticals Inc. 98420N105 CA98420N1050 06/04/2025 To elect as directors of the Corporation the eight nominees named in the accompanying Proxy Statement and Management Information Circular to hold office until the next annual meeting of the Corporation or until their successors are duly elected: Justin Gover DIRECTOR ELECTIONS ISSUER 269103.000000 0 FOR 269103.000000 FOR Xenon Pharmaceuticals Inc. 98420N105 CA98420N1050 06/04/2025 To elect as directors of the Corporation the eight nominees named in the accompanying Proxy Statement and Management Information Circular to hold office until the next annual meeting of the Corporation or until their successors are duly elected: Patrick Machado DIRECTOR ELECTIONS ISSUER 269103.000000 0 FOR 269103.000000 FOR Xenon Pharmaceuticals Inc. 98420N105 CA98420N1050 06/04/2025 To elect as directors of the Corporation the eight nominees named in the accompanying Proxy Statement and Management Information Circular to hold office until the next annual meeting of the Corporation or until their successors are duly elected: Ian Mortimer DIRECTOR ELECTIONS ISSUER 269103.000000 0 FOR 269103.000000 FOR Xenon Pharmaceuticals Inc. 98420N105 CA98420N1050 06/04/2025 To elect as directors of the Corporation the eight nominees named in the accompanying Proxy Statement and Management Information Circular to hold office until the next annual meeting of the Corporation or until their successors are duly elected: Gary Patou DIRECTOR ELECTIONS ISSUER 269103.000000 0 FOR 269103.000000 FOR Xenon Pharmaceuticals Inc. 98420N105 CA98420N1050 06/04/2025 To approve, on an advisory basis, the compensation of the Corporation's named executive officers; SECTION 14A SAY-ON-PAY VOTES ISSUER 269103.000000 0 FOR 269103.000000 FOR Xenon Pharmaceuticals Inc. 98420N105 CA98420N1050 06/04/2025 To appoint PricewaterhouseCoopers LLP ("PwC") as the Corporation's auditor to hold office until the next annual meeting of the Corporation; AUDIT-RELATED ISSUER 269103.000000 0 FOR 269103.000000 FOR Xenon Pharmaceuticals Inc. 98420N105 CA98420N1050 06/04/2025 To authorize the Audit Committee of the board of directors of the Corporation to fix the remuneration to be paid to the auditors of the Corporation; AUDIT-RELATED ISSUER 269103.000000 0 FOR 269103.000000 FOR Amylyx Pharmaceuticals, Inc. 03237H101 US03237H1014 06/05/2025 Election of Directors: To elect the following persons to our board of directors, each to serve as a Class I director until the 2028 Annual Meeting of Stockholders and until their successor has been duly elected and qualified, or until such director's earlier death, resignation or removal: Karen Firestone DIRECTOR ELECTIONS ISSUER 1731822.000000 0 WITHHOLD 1731822.000000 AGAINST Amylyx Pharmaceuticals, Inc. 03237H101 US03237H1014 06/05/2025 Election of Directors: To elect the following persons to our board of directors, each to serve as a Class I director until the 2028 Annual Meeting of Stockholders and until their successor has been duly elected and qualified, or until such director's earlier death, resignation or removal: Justin Klee DIRECTOR ELECTIONS ISSUER 1731822.000000 0 FOR 1731822.000000 FOR Amylyx Pharmaceuticals, Inc. 03237H101 US03237H1014 06/05/2025 Election of Directors: To elect the following persons to our board of directors, each to serve as a Class I director until the 2028 Annual Meeting of Stockholders and until their successor has been duly elected and qualified, or until such director's earlier death, resignation or removal: Bernhardt Zeiher, M.D. DIRECTOR ELECTIONS ISSUER 1731822.000000 0 WITHHOLD 1731822.000000 AGAINST Amylyx Pharmaceuticals, Inc. 03237H101 US03237H1014 06/05/2025 To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025. AUDIT-RELATED ISSUER 1731822.000000 0 FOR 1731822.000000 FOR Amylyx Pharmaceuticals, Inc. 03237H101 US03237H1014 06/05/2025 To approve, on a non-binding, advisory basis, the compensation of our named executives officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 1731822.000000 0 AGAINST 1731822.000000 AGAINST Ionis Pharmaceuticals, Inc. 462222100 US4622221004 06/05/2025 Election of Directors: Allene M. Diaz DIRECTOR ELECTIONS ISSUER 264178.000000 0 FOR 264178.000000 FOR Ionis Pharmaceuticals, Inc. 462222100 US4622221004 06/05/2025 Election of Directors: Michael Hayden DIRECTOR ELECTIONS ISSUER 264178.000000 0 FOR 264178.000000 FOR Ionis Pharmaceuticals, Inc. 462222100 US4622221004 06/05/2025 Election of Directors: Joseph Klein, III DIRECTOR ELECTIONS ISSUER 264178.000000 0 AGAINST 264178.000000 AGAINST Ionis Pharmaceuticals, Inc. 462222100 US4622221004 06/05/2025 Election of Directors: Joseph Loscalzo DIRECTOR ELECTIONS ISSUER 264178.000000 0 FOR 264178.000000 FOR Ionis Pharmaceuticals, Inc. 462222100 US4622221004 06/05/2025 To make an advisory vote on executive compensation. SECTION 14A SAY-ON-PAY VOTES ISSUER 264178.000000 0 FOR 264178.000000 FOR Ionis Pharmaceuticals, Inc. 462222100 US4622221004 06/05/2025 To approve an amendment of the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan to increase the aggregate number of shares of common stock authorized for issuance under such plan by 4,000,000 shares to an aggregate of 42,500,000 shares. COMPENSATION ISSUER 264178.000000 0 FOR 264178.000000 FOR Ionis Pharmaceuticals, Inc. 462222100 US4622221004 06/05/2025 To ratify the Audit Committee's selection of Ernst & Young LLP as independent auditors for the 2025 fiscal year. AUDIT-RELATED ISSUER 264178.000000 0 AGAINST 264178.000000 AGAINST Sarepta Therapeutics, Inc. 803607100 US8036071004 06/05/2025 TO ELECT, AS CLASS II DIRECTORS TO HOLD OFFICE UNTIL THE 2027 ANNUAL MEETING OF STOCKHOLDERS, OR UNTIL THEIR SUCCESSORS ARE EARLIER ELECTED, THE FOLLOWING DIRECTOR NOMINEES: RICHARD J. BARRY DIRECTOR ELECTIONS ISSUER 284179.000000 0 FOR 284179.000000 FOR Sarepta Therapeutics, Inc. 803607100 US8036071004 06/05/2025 TO ELECT, AS CLASS II DIRECTORS TO HOLD OFFICE UNTIL THE 2027 ANNUAL MEETING OF STOCKHOLDERS, OR UNTIL THEIR SUCCESSORS ARE EARLIER ELECTED, THE FOLLOWING DIRECTOR NOMINEES: M. KATHLEEN BEHRENS, PH.D. DIRECTOR ELECTIONS ISSUER 284179.000000 0 FOR 284179.000000 FOR Sarepta Therapeutics, Inc. 803607100 US8036071004 06/05/2025 TO ELECT, AS CLASS II DIRECTORS TO HOLD OFFICE UNTIL THE 2027 ANNUAL MEETING OF STOCKHOLDERS, OR UNTIL THEIR SUCCESSORS ARE EARLIER ELECTED, THE FOLLOWING DIRECTOR NOMINEES: STEPHEN L. MAYO, PH.D. DIRECTOR ELECTIONS ISSUER 284179.000000 0 FOR 284179.000000 FOR Sarepta Therapeutics, Inc. 803607100 US8036071004 06/05/2025 TO ELECT, AS CLASS II DIRECTORS TO HOLD OFFICE UNTIL THE 2027 ANNUAL MEETING OF STOCKHOLDERS, OR UNTIL THEIR SUCCESSORS ARE EARLIER ELECTED, THE FOLLOWING DIRECTOR NOMINEES: CLAUDE NICAISE, M.D. DIRECTOR ELECTIONS ISSUER 284179.000000 0 FOR 284179.000000 FOR Sarepta Therapeutics, Inc. 803607100 US8036071004 06/05/2025 ADVISORY VOTE TO APPROVE, ON A NON-BINDING BASIS, NAMED EXECUTIVE OFFICER COMPENSATION SECTION 14A SAY-ON-PAY VOTES ISSUER 284179.000000 0 FOR 284179.000000 FOR Sarepta Therapeutics, Inc. 803607100 US8036071004 06/05/2025 APPROVE AN AMENDMENT TO THE COMPANY'S 2018 EQUITY INCENTIVE PLAN (THE "2018 PLAN") TO INCREASE THE MAXIMUM AGGREGATE NUMBER OF SHARES OF COMMON STOCK THAT MAY BE ISSUED PURSUANT TO AWARDS GRANTED UNDER THE 2018 PLAN BY 4,300,000 SHARES TO 17,487,596 SHARES COMPENSATION ISSUER 284179.000000 0 FOR 284179.000000 FOR Sarepta Therapeutics, Inc. 803607100 US8036071004 06/05/2025 APPROVE AN AMENDMENT TO THE AMENDED AND RESTATED 2013 EMPLOYEE STOCK PURCHASE PLAN (AS AMENDED AND RESTATED ON JUNE 27, 2016, AND AMENDED ON JUNE 6, 2019 AND ON JUNE 8, 2023) (THE "2016 ESPP") TO INCREASE THE NUMBER OF SHARES OF THE COMPANY'S COMMON STOCK AUTHORIZED FOR ISSUANCE UNDER THE 2016 ESPP BY 300,000 SHARES TO 1,700,000 SHARES COMPENSATION ISSUER 284179.000000 0 FOR 284179.000000 FOR Sarepta Therapeutics, Inc. 803607100 US8036071004 06/05/2025 RATIFY THE SELECTION OF KPMG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE CURRENT YEAR ENDING DECEMBER 31, 2025 AUDIT-RELATED ISSUER 284179.000000 0 FOR 284179.000000 FOR Sera Prognostics, Inc. 81749D107 US81749D1072 06/05/2025 Election of Directors: Jane F. Barlow, M.D. DIRECTOR ELECTIONS ISSUER 600000.000000 0 WITHHOLD 600000.000000 AGAINST Sera Prognostics, Inc. 81749D107 US81749D1072 06/05/2025 Election of Directors: Mansoor Raza Mirza, M.D. DIRECTOR ELECTIONS ISSUER 600000.000000 0 WITHHOLD 600000.000000 AGAINST Sera Prognostics, Inc. 81749D107 US81749D1072 06/05/2025 Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2025. AUDIT-RELATED ISSUER 600000.000000 0 FOR 600000.000000 FOR Teva Pharmaceutical Industries Limited 881624209 US8816242098 06/05/2025 ELECTION OF DIRECTORS: Chen Lichtenstein - to serve until Teva's 2027 Annual Meeting DIRECTOR ELECTIONS ISSUER 235815.000000 0 FOR 235815.000000 FOR Teva Pharmaceutical Industries Limited 881624209 US8816242098 06/05/2025 ELECTION OF DIRECTORS: Amir Elstein - to serve until Teva's 2028 Annual Meeting DIRECTOR ELECTIONS ISSUER 235815.000000 0 FOR 235815.000000 FOR Teva Pharmaceutical Industries Limited 881624209 US8816242098 06/05/2025 ELECTION OF DIRECTORS: Roberto A. Mignone to serve until Teva's 2028 Annual Meeting] DIRECTOR ELECTIONS ISSUER 235815.000000 0 FOR 235815.000000 FOR Teva Pharmaceutical Industries Limited 881624209 US8816242098 06/05/2025 ELECTION OF DIRECTORS: Dr. Perry D. Nisen to serve until Teva's 2028 Annual Meeting DIRECTOR ELECTIONS ISSUER 235815.000000 0 FOR 235815.000000 FOR Teva Pharmaceutical Industries Limited 881624209 US8816242098 06/05/2025 ELECTION OF DIRECTORS: Dr. Tal Zaks to serve until Teva's 2028 Annual Meeting DIRECTOR ELECTIONS ISSUER 235815.000000 0 FOR 235815.000000 FOR Teva Pharmaceutical Industries Limited 881624209 US8816242098 06/05/2025 TO APPROVE, ON A NON-BINDING ADVISORY BASIS, THE COMPENSATION FOR TEVA'S NAMED EXECUTIVE OFFICERS SECTION 14A SAY-ON-PAY VOTES ISSUER 235815.000000 0 FOR 235815.000000 FOR Teva Pharmaceutical Industries Limited 881624209 US8816242098 06/05/2025 TO APPROVE AN AMENDED COMPENSATION POLICY WITH RESPECT TO THE TERMS OF OFFICE AND EMPLOYMENT OF TEVA'S EXECUTIVE OFFICERS AND DIRECTORS* COMPENSATION ISSUER 235815.000000 0 FOR 235815.000000 FOR Teva Pharmaceutical Industries Limited 881624209 US8816242098 06/05/2025 TO APPROVE AN AMENDMENT TO THE TERMS OF OFFICE AND EMPLOYMENT OF TEVA'S PRESIDENT AND CHIEF EXECUTIVE OFFICER COMPENSATION ISSUER 235815.000000 0 FOR 235815.000000 FOR Teva Pharmaceutical Industries Limited 881624209 US8816242098 06/05/2025 TO APPROVE THE COMPENSATION TO BE PROVIDED TO TEVA'S NON-EMPLOYEE DIRECTORS COMPENSATION ISSUER 235815.000000 0 FOR 235815.000000 FOR Teva Pharmaceutical Industries Limited 881624209 US8816242098 06/05/2025 TO APPROVE THE COMPENSATION TO BE PROVIDED TO TEVA'S NON-EXECUTIVE CHAIRMAN OF THE BOARD COMPENSATION ISSUER 235815.000000 0 FOR 235815.000000 FOR Teva Pharmaceutical Industries Limited 881624209 US8816242098 06/05/2025 TO APPOINT KESSELMAN & KESSELMAN, A MEMBER OF PRICEWATERHOUSECOOPERS INTERNATIONAL LTD., AS TEVA'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM UNTIL TEVA'S 2026 ANNUAL MEETING OF SHAREHOLDERS AUDIT-RELATED ISSUER 235815.000000 0 FOR 235815.000000 FOR Axsome Therapeutics, Inc. 05464T104 US05464T1043 06/06/2025 Election of Director: Roger Jeffs, Ph.D. DIRECTOR ELECTIONS ISSUER 46864.000000 0 WITHHOLD 46864.000000 AGAINST Axsome Therapeutics, Inc. 05464T104 US05464T1043 06/06/2025 To approve the Company's 2025 Long-Term Incentive Plan. COMPENSATION ISSUER 46864.000000 0 AGAINST 46864.000000 AGAINST Axsome Therapeutics, Inc. 05464T104 US05464T1043 06/06/2025 To ratify the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the year ending December 31, 2025. AUDIT-RELATED ISSUER 46864.000000 0 FOR 46864.000000 FOR Axsome Therapeutics, Inc. 05464T104 US05464T1043 06/06/2025 To approve, by non-binding advisory vote, the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 46864.000000 0 FOR 46864.000000 FOR Sutro Biopharma, Inc. 869367102 US8693671021 06/06/2025 Election of Class I Directors: Heidi Hunter DIRECTOR ELECTIONS ISSUER 69389.000000 0 WITHHOLD 69389.000000 AGAINST Sutro Biopharma, Inc. 869367102 US8693671021 06/06/2025 Election of Class I Directors: Jon Wigginton, M.D. DIRECTOR ELECTIONS ISSUER 69389.000000 0 WITHHOLD 69389.000000 AGAINST Sutro Biopharma, Inc. 869367102 US8693671021 06/06/2025 Election of Class I Directors: Michael Dybbs, Ph.D. DIRECTOR ELECTIONS ISSUER 69389.000000 0 WITHHOLD 69389.000000 AGAINST Sutro Biopharma, Inc. 869367102 US8693671021 06/06/2025 To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025. AUDIT-RELATED ISSUER 69389.000000 0 FOR 69389.000000 FOR Sutro Biopharma, Inc. 869367102 US8693671021 06/06/2025 To approve, on a non-binding, advisory basis, the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 69389.000000 0 FOR 69389.000000 FOR Sutro Biopharma, Inc. 869367102 US8693671021 06/06/2025 To approve an amendment to our Restated Certificate of Incorporation to effect a reverse stock split of our outstanding shares of common stock at a ratio of any whole number between 1-for-5 and 1-for-25, with the exact ratio determined by the board of directors in its discretion, subject to the board of directors authority to abandon such amendment. CAPITAL STRUCTURE ISSUER 69389.000000 0 FOR 69389.000000 FOR Adaptive Biotechnologies Corporation 00650F109 US00650F1093 06/10/2025 To elect one Class III director nominee to serve on the board of directors of Adaptive Biotechnologies Corporation for a three-year term expiring at the 2028 annual meeting of shareholders: Chad Robins DIRECTOR ELECTIONS ISSUER 885180.000000 0 WITHHOLD 885180.000000 AGAINST Adaptive Biotechnologies Corporation 00650F109 US00650F1093 06/10/2025 To approve, on a non-binding advisory basis, the compensation of our named executive officers as described in the proxy statement; SECTION 14A SAY-ON-PAY VOTES ISSUER 885180.000000 0 FOR 885180.000000 FOR Adaptive Biotechnologies Corporation 00650F109 US00650F1093 06/10/2025 To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2025; and AUDIT-RELATED ISSUER 885180.000000 0 FOR 885180.000000 FOR Avidity Biosciences, Inc. 05370A108 US05370A1088 06/10/2025 To elect Class II directors for a three-year term that expires at the 2028 Annual Meeting of Stockholders and until their respective successors shall have been duly elected and qualified: Arthur Levin, Ph.D. DIRECTOR ELECTIONS ISSUER 141554.000000 0 FOR 141554.000000 FOR Avidity Biosciences, Inc. 05370A108 US05370A1088 06/10/2025 To elect Class II directors for a three-year term that expires at the 2028 Annual Meeting of Stockholders and until their respective successors shall have been duly elected and qualified: Simona Skerjanec DIRECTOR ELECTIONS ISSUER 141554.000000 0 FOR 141554.000000 FOR Avidity Biosciences, Inc. 05370A108 US05370A1088 06/10/2025 To elect Class II directors for a three-year term that expires at the 2028 Annual Meeting of Stockholders and until their respective successors shall have been duly elected and qualified: Tamar Thompson DIRECTOR ELECTIONS ISSUER 141554.000000 0 WITHHOLD 141554.000000 AGAINST Avidity Biosciences, Inc. 05370A108 US05370A1088 06/10/2025 To ratify the appointment of Deloitte & Touche LLP as our independent public accounting firm for the fiscal year ending December 31, 2025; AUDIT-RELATED ISSUER 141554.000000 0 FOR 141554.000000 FOR Avidity Biosciences, Inc. 05370A108 US05370A1088 06/10/2025 To consider and vote upon, on an advisory basis, the compensation of our named executive officers as disclosed in this proxy statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission; and SECTION 14A SAY-ON-PAY VOTES ISSUER 141554.000000 0 AGAINST 141554.000000 AGAINST LENZ Therapeutics, Inc. 52635N103 US52635N1037 06/10/2025 To elect two Class III directors to hold office until our 2027 annual meeting of stockholders and two Class I directors to hold office until our 2028 annual meeting of stockholders, each until their respective successors are elected and qualified: Class III: Kimberlee C. Drapkin DIRECTOR ELECTIONS ISSUER 36518.000000 0 WITHHOLD 36518.000000 AGAINST LENZ Therapeutics, Inc. 52635N103 US52635N1037 06/10/2025 To elect two Class III directors to hold office until our 2027 annual meeting of stockholders and two Class I directors to hold office until our 2028 annual meeting of stockholders, each until their respective successors are elected and qualified: Class III: Zach Scheiner DIRECTOR ELECTIONS ISSUER 36518.000000 0 WITHHOLD 36518.000000 AGAINST LENZ Therapeutics, Inc. 52635N103 US52635N1037 06/10/2025 To elect two Class III directors to hold office until our 2027 annual meeting of stockholders and two Class I directors to hold office until our 2028 annual meeting of stockholders, each until their respective successors are elected and qualified: Class I: Frederic Guerard DIRECTOR ELECTIONS ISSUER 36518.000000 0 FOR 36518.000000 FOR LENZ Therapeutics, Inc. 52635N103 US52635N1037 06/10/2025 To elect two Class III directors to hold office until our 2027 annual meeting of stockholders and two Class I directors to hold office until our 2028 annual meeting of stockholders, each until their respective successors are elected and qualified: Class I: James McCollum DIRECTOR ELECTIONS ISSUER 36518.000000 0 FOR 36518.000000 FOR LENZ Therapeutics, Inc. 52635N103 US52635N1037 06/10/2025 To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2025. AUDIT-RELATED ISSUER 36518.000000 0 FOR 36518.000000 FOR Crinetics Pharmaceuticals, Inc. 22663K107 US22663K1079 06/11/2025 To elect three directors to serve as Class I directors for a three-year term to expire at the 2028 annual meeting of stockholders: Matthew K. Fust DIRECTOR ELECTIONS ISSUER 167939.000000 0 WITHHOLD 167939.000000 AGAINST Crinetics Pharmaceuticals, Inc. 22663K107 US22663K1079 06/11/2025 To elect three directors to serve as Class I directors for a three-year term to expire at the 2028 annual meeting of stockholders: R. Scott Struthers, Ph.D. DIRECTOR ELECTIONS ISSUER 167939.000000 0 WITHHOLD 167939.000000 AGAINST Crinetics Pharmaceuticals, Inc. 22663K107 US22663K1079 06/11/2025 To elect three directors to serve as Class I directors for a three-year term to expire at the 2028 annual meeting of stockholders: Rogerio Vivaldi Coelho, M.D. DIRECTOR ELECTIONS ISSUER 167939.000000 0 WITHHOLD 167939.000000 AGAINST Crinetics Pharmaceuticals, Inc. 22663K107 US22663K1079 06/11/2025 To consider and vote upon the ratification of the selection of BDO USA, P.C. as our independent registered public accounting firm for the fiscal year ending December 31, 2025; AUDIT-RELATED ISSUER 167939.000000 0 FOR 167939.000000 FOR Crinetics Pharmaceuticals, Inc. 22663K107 US22663K1079 06/11/2025 To consider and vote upon, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the proxy statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission; SECTION 14A SAY-ON-PAY VOTES ISSUER 167939.000000 0 FOR 167939.000000 FOR Janux Therapeutics, Inc. 47103J105 US47103J1051 06/11/2025 To elect the three nominees for Class I director named in the accompanying proxy statement to serve for three-year terms until the 2028 Annual Meeting of Stockholders: Ronald Barrett, Ph.D. DIRECTOR ELECTIONS ISSUER 153551.000000 0 WITHHOLD 153551.000000 AGAINST Janux Therapeutics, Inc. 47103J105 US47103J1051 06/11/2025 To elect the three nominees for Class I director named in the accompanying proxy statement to serve for three-year terms until the 2028 Annual Meeting of Stockholders: David Campbell, Ph.D. DIRECTOR ELECTIONS ISSUER 153551.000000 0 FOR 153551.000000 FOR Janux Therapeutics, Inc. 47103J105 US47103J1051 06/11/2025 To elect the three nominees for Class I director named in the accompanying proxy statement to serve for three-year terms until the 2028 Annual Meeting of Stockholders: Winston Kung DIRECTOR ELECTIONS ISSUER 153551.000000 0 WITHHOLD 153551.000000 AGAINST Janux Therapeutics, Inc. 47103J105 US47103J1051 06/11/2025 To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2025. AUDIT-RELATED ISSUER 153551.000000 0 FOR 153551.000000 FOR Janux Therapeutics, Inc. 47103J105 US47103J1051 06/11/2025 Approval, on an advisory basis, of the compensation of our named executive officers ("Say-On-Pay"), as disclosed in the accompanying Proxy Statement. SECTION 14A SAY-ON-PAY VOTES ISSUER 153551.000000 0 AGAINST 153551.000000 AGAINST Janux Therapeutics, Inc. 47103J105 US47103J1051 06/11/2025 Indication, on an advisory basis, of the preferred frequency of holding future Say-On-Pay votes on the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 153551.000000 0 ONE YEAR 153551.000000 FOR Mural Oncology plc G63365103 IE000LK2BOB4 06/11/2025 To elect, by separate resolutions, the following six director nominees named in this proxy statement to the board of directors, to serve until the Company's 2026 annual general meeting: Francis Cuss DIRECTOR ELECTIONS ISSUER 17390.000000 0 FOR 17390.000000 FOR Mural Oncology plc G63365103 IE000LK2BOB4 06/11/2025 To elect, by separate resolutions, the following six director nominees named in this proxy statement to the board of directors, to serve until the Company's 2026 annual general meeting: George Golumbeski DIRECTOR ELECTIONS ISSUER 17390.000000 0 FOR 17390.000000 FOR Mural Oncology plc G63365103 IE000LK2BOB4 06/11/2025 To elect, by separate resolutions, the following six director nominees named in this proxy statement to the board of directors, to serve until the Company's 2026 annual general meeting: Benjamin Hickey DIRECTOR ELECTIONS ISSUER 17390.000000 0 FOR 17390.000000 FOR Mural Oncology plc G63365103 IE000LK2BOB4 06/11/2025 To elect, by separate resolutions, the following six director nominees named in this proxy statement to the board of directors, to serve until the Company's 2026 annual general meeting: Scott Jackson DIRECTOR ELECTIONS ISSUER 17390.000000 0 FOR 17390.000000 FOR Mural Oncology plc G63365103 IE000LK2BOB4 06/11/2025 To elect, by separate resolutions, the following six director nominees named in this proxy statement to the board of directors, to serve until the Company's 2026 annual general meeting: Caroline Loew DIRECTOR ELECTIONS ISSUER 17390.000000 0 FOR 17390.000000 FOR Mural Oncology plc G63365103 IE000LK2BOB4 06/11/2025 To elect, by separate resolutions, the following six director nominees named in this proxy statement to the board of directors, to serve until the Company's 2026 annual general meeting: Sachiyo Minegishi DIRECTOR ELECTIONS ISSUER 17390.000000 0 FOR 17390.000000 FOR Mural Oncology plc G63365103 IE000LK2BOB4 06/11/2025 To ratify, in a non-binding advisory vote, the selection of PricewaterhouseCoopers LLP as the Company's independent auditor for the fiscal year ending December 31, 2025 and to authorize, in a binding vote, the board of directors, acting through the audit committee, to set the independent auditor's remuneration; AUDIT-RELATED ISSUER 17390.000000 0 FOR 17390.000000 FOR uniQure N.V. N90064101 NL0010696654 06/11/2025 Adoption of the 2024 Dutch statutory annual accounts for the fiscal year ended December 31, 2024. CORPORATE GOVERNANCE ISSUER 1461717.000000 0 FOR 1461717.000000 FOR uniQure N.V. N90064101 NL0010696654 06/11/2025 Discharge of liability of the members of the Board for their management during the fiscal year ended December 31, 2024. CORPORATE GOVERNANCE ISSUER 1461717.000000 0 FOR 1461717.000000 FOR uniQure N.V. N90064101 NL0010696654 06/11/2025 Reappointment of Robert Gut, M.D., Ph.D. as non-executive director. DIRECTOR ELECTIONS ISSUER 1461717.000000 0 FOR 1461717.000000 FOR uniQure N.V. N90064101 NL0010696654 06/11/2025 Reappointment of Matthew Kapusta as executive director. DIRECTOR ELECTIONS ISSUER 1461717.000000 0 FOR 1461717.000000 FOR uniQure N.V. N90064101 NL0010696654 06/11/2025 Reappointment of Jeremy Springhorn, Ph.D. as non-executive director. DIRECTOR ELECTIONS ISSUER 1461717.000000 0 FOR 1461717.000000 FOR uniQure N.V. N90064101 NL0010696654 06/11/2025 Authorization of the Board to issue Ordinary Shares and grant rights to subscribe for Ordinary Shares. CAPITAL STRUCTURE ISSUER 1461717.000000 0 FOR 1461717.000000 FOR uniQure N.V. N90064101 NL0010696654 06/11/2025 Authorization of the Board to exclude or limit preemptive rights upon the issuance of Ordinary Shares. CAPITAL STRUCTURE ISSUER 1461717.000000 0 FOR 1461717.000000 FOR uniQure N.V. N90064101 NL0010696654 06/11/2025 Authorization of the Board to repurchase Ordinary Shares. CAPITAL STRUCTURE ISSUER 1461717.000000 0 FOR 1461717.000000 FOR uniQure N.V. N90064101 NL0010696654 06/11/2025 Appointment of KPMG as external auditor of the Company for the financial year 2025. AUDIT-RELATED ISSUER 1461717.000000 0 FOR 1461717.000000 FOR uniQure N.V. N90064101 NL0010696654 06/11/2025 Approval, on an advisory basis, of the compensation of the named executive officers of the Company. SECTION 14A SAY-ON-PAY VOTES ISSUER 1461717.000000 0 FOR 1461717.000000 FOR uniQure N.V. N90064101 NL0010696654 06/11/2025 Resolution to adopt the Amendment and Restatement of the 2014 Share Incentive Plan. COMPENSATION ISSUER 1461717.000000 0 FOR 1461717.000000 FOR Arcutis Biotherapeutics, Inc. 03969K108 US03969K1088 06/12/2025 Election of Class II directors to hold office until the 2028 Annual Meeting of Stockholders or until their successors are elected: Bhaskar Chaudhuri, Ph.D. DIRECTOR ELECTIONS ISSUER 456927.000000 0 WITHHOLD 456927.000000 AGAINST Arcutis Biotherapeutics, Inc. 03969K108 US03969K1088 06/12/2025 Election of Class II directors to hold office until the 2028 Annual Meeting of Stockholders or until their successors are elected: Sue-Jean Lin DIRECTOR ELECTIONS ISSUER 456927.000000 0 WITHHOLD 456927.000000 AGAINST Arcutis Biotherapeutics, Inc. 03969K108 US03969K1088 06/12/2025 Election of Class II directors to hold office until the 2028 Annual Meeting of Stockholders or until their successors are elected: Howard G. Welgus, M.D. DIRECTOR ELECTIONS ISSUER 456927.000000 0 WITHHOLD 456927.000000 AGAINST Arcutis Biotherapeutics, Inc. 03969K108 US03969K1088 06/12/2025 To ratify the selection, by the Audit Committee of the Company's Board of Directors, of Ernst & Young LLP, as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2025. AUDIT-RELATED ISSUER 456927.000000 0 FOR 456927.000000 FOR Arcutis Biotherapeutics, Inc. 03969K108 US03969K1088 06/12/2025 To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 456927.000000 0 AGAINST 456927.000000 AGAINST Sionna Therapeutics, Inc. 829401108 US8294011080 06/12/2025 To elect three class I directors to serve until our 2028 annual meeting of stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal: Joshua Resnick, M.D., M.B.A. DIRECTOR ELECTIONS ISSUER 571000.000000 0 FOR 571000.000000 FOR Sionna Therapeutics, Inc. 829401108 US8294011080 06/12/2025 To elect three class I directors to serve until our 2028 annual meeting of stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal: Bruce Booth, D.Phil. DIRECTOR ELECTIONS ISSUER 571000.000000 0 FOR 571000.000000 FOR Sionna Therapeutics, Inc. 829401108 US8294011080 06/12/2025 To elect three class I directors to serve until our 2028 annual meeting of stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal: Lucian Iancovici, M.D. DIRECTOR ELECTIONS ISSUER 571000.000000 0 FOR 571000.000000 FOR Sionna Therapeutics, Inc. 829401108 US8294011080 06/12/2025 To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025. AUDIT-RELATED ISSUER 571000.000000 0 FOR 571000.000000 FOR Summit Therapeutics Inc. 86627T108 US86627T1088 06/12/2025 ELECTION OF DIRECTORS: Robert W. Duggan DIRECTOR ELECTIONS ISSUER 788556.000000 0 FOR 788556.000000 FOR Summit Therapeutics Inc. 86627T108 US86627T1088 06/12/2025 ELECTION OF DIRECTORS: Mahkam Zanganeh DIRECTOR ELECTIONS ISSUER 788556.000000 0 FOR 788556.000000 FOR Summit Therapeutics Inc. 86627T108 US86627T1088 06/12/2025 ELECTION OF DIRECTORS: Manmeet S. Soni DIRECTOR ELECTIONS ISSUER 788556.000000 0 FOR 788556.000000 FOR Summit Therapeutics Inc. 86627T108 US86627T1088 06/12/2025 ELECTION OF DIRECTORS: Kenneth A. Clark DIRECTOR ELECTIONS ISSUER 788556.000000 0 AGAINST 788556.000000 AGAINST Summit Therapeutics Inc. 86627T108 US86627T1088 06/12/2025 ELECTION OF DIRECTORS: Robert Booth DIRECTOR ELECTIONS ISSUER 788556.000000 0 FOR 788556.000000 FOR Summit Therapeutics Inc. 86627T108 US86627T1088 06/12/2025 ELECTION OF DIRECTORS: Alessandra Cesano DIRECTOR ELECTIONS ISSUER 788556.000000 0 FOR 788556.000000 FOR Summit Therapeutics Inc. 86627T108 US86627T1088 06/12/2025 ELECTION OF DIRECTORS: Yu (Michelle) Xia DIRECTOR ELECTIONS ISSUER 788556.000000 0 AGAINST 788556.000000 AGAINST Summit Therapeutics Inc. 86627T108 US86627T1088 06/12/2025 ELECTION OF DIRECTORS: Mostafa Ronaghi DIRECTOR ELECTIONS ISSUER 788556.000000 0 FOR 788556.000000 FOR Summit Therapeutics Inc. 86627T108 US86627T1088 06/12/2025 ELECTION OF DIRECTORS: Jeff Huber DIRECTOR ELECTIONS ISSUER 788556.000000 0 FOR 788556.000000 FOR Summit Therapeutics Inc. 86627T108 US86627T1088 06/12/2025 Ratification of the appointment of PricewaterhouseCoopers LLP as Independent Registered Public Accounting Firm for the fiscal year ending December 31, 2025. AUDIT-RELATED ISSUER 788556.000000 0 FOR 788556.000000 FOR Summit Therapeutics Inc. 86627T108 US86627T1088 06/12/2025 Approval, by a non-binding advisory vote, of the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 788556.000000 0 AGAINST 788556.000000 AGAINST Vaxcyte, Inc. 92243G108 US92243G1085 06/12/2025 Election of Class II Directors Nominees would serve until the 2028 Annual Meeting of Stockholders and until their successors have been duly elected and qualified, or, if sooner, until the director's death, resignation or removal: John Furey DIRECTOR ELECTIONS ISSUER 204490.000000 0 FOR 204490.000000 FOR Vaxcyte, Inc. 92243G108 US92243G1085 06/12/2025 Election of Class II Directors Nominees would serve until the 2028 Annual Meeting of Stockholders and until their successors have been duly elected and qualified, or, if sooner, until the director's death, resignation or removal: Jacks Lee DIRECTOR ELECTIONS ISSUER 204490.000000 0 WITHHOLD 204490.000000 AGAINST Vaxcyte, Inc. 92243G108 US92243G1085 06/12/2025 Election of Class II Directors Nominees would serve until the 2028 Annual Meeting of Stockholders and until their successors have been duly elected and qualified, or, if sooner, until the director's death, resignation or removal: Heath Lukatch, Ph.D. DIRECTOR ELECTIONS ISSUER 204490.000000 0 WITHHOLD 204490.000000 AGAINST Vaxcyte, Inc. 92243G108 US92243G1085 06/12/2025 Ratification of the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025. AUDIT-RELATED ISSUER 204490.000000 0 FOR 204490.000000 FOR Vaxcyte, Inc. 92243G108 US92243G1085 06/12/2025 Approval, on a non-binding, advisory basis, of the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 204490.000000 0 AGAINST 204490.000000 AGAINST Vaxcyte, Inc. 92243G108 US92243G1085 06/12/2025 Approval of the amendment and restatement of the Company's Amended and Restated Certificate of Incorporation to provide for officer exculpation as permitted by recent amendments to the Delaware General Corporation Law. CORPORATE GOVERNANCE ISSUER 204490.000000 0 FOR 204490.000000 FOR Xencor, Inc. 98401F105 US98401F1057 06/12/2025 To elect the eight nominees to the Board of Directors named in the accompanying Proxy Statement to serve until the next annual meeting and until their successors are duly elected and qualified: Dr. Bassil I. Dahiyat DIRECTOR ELECTIONS ISSUER 191603.000000 0 FOR 191603.000000 FOR Xencor, Inc. 98401F105 US98401F1057 06/12/2025 To elect the eight nominees to the Board of Directors named in the accompanying Proxy Statement to serve until the next annual meeting and until their successors are duly elected and qualified: Dr. Ellen G. Feigal DIRECTOR ELECTIONS ISSUER 191603.000000 0 FOR 191603.000000 FOR Xencor, Inc. 98401F105 US98401F1057 06/12/2025 To elect the eight nominees to the Board of Directors named in the accompanying Proxy Statement to serve until the next annual meeting and until their successors are duly elected and qualified: Dr. Kevin C. Gorman DIRECTOR ELECTIONS ISSUER 191603.000000 0 FOR 191603.000000 FOR Xencor, Inc. 98401F105 US98401F1057 06/12/2025 To elect the eight nominees to the Board of Directors named in the accompanying Proxy Statement to serve until the next annual meeting and until their successors are duly elected and qualified: Mr. Kurt A. Gustafson DIRECTOR ELECTIONS ISSUER 191603.000000 0 FOR 191603.000000 FOR Xencor, Inc. 98401F105 US98401F1057 06/12/2025 To elect the eight nominees to the Board of Directors named in the accompanying Proxy Statement to serve until the next annual meeting and until their successors are duly elected and qualified: Dr. Barbara Klencke DIRECTOR ELECTIONS ISSUER 191603.000000 0 FOR 191603.000000 FOR Xencor, Inc. 98401F105 US98401F1057 06/12/2025 To elect the eight nominees to the Board of Directors named in the accompanying Proxy Statement to serve until the next annual meeting and until their successors are duly elected and qualified: Dr. A. Bruce Montgomery DIRECTOR ELECTIONS ISSUER 191603.000000 0 FOR 191603.000000 FOR Xencor, Inc. 98401F105 US98401F1057 06/12/2025 To elect the eight nominees to the Board of Directors named in the accompanying Proxy Statement to serve until the next annual meeting and until their successors are duly elected and qualified: Mr. Richard J. Ranieri DIRECTOR ELECTIONS ISSUER 191603.000000 0 FOR 191603.000000 FOR Xencor, Inc. 98401F105 US98401F1057 06/12/2025 To elect the eight nominees to the Board of Directors named in the accompanying Proxy Statement to serve until the next annual meeting and until their successors are duly elected and qualified: Mr. Todd E. Simpson DIRECTOR ELECTIONS ISSUER 191603.000000 0 FOR 191603.000000 FOR Xencor, Inc. 98401F105 US98401F1057 06/12/2025 To ratify the selection by the Audit Committee of the Board of Directors of KPMG LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2025; AUDIT-RELATED ISSUER 191603.000000 0 FOR 191603.000000 FOR Xencor, Inc. 98401F105 US98401F1057 06/12/2025 To approve the proposed amendment and restatement of the Company's 2023 Equity Incentive Plan to increase the number of authorized shares reserved for issuance thereunder by 3,000,000 shares; COMPENSATION ISSUER 191603.000000 0 AGAINST 191603.000000 AGAINST Xencor, Inc. 98401F105 US98401F1057 06/12/2025 To approve, on an advisory (non-binding) basis, the compensation of the Company's named executive officers, as disclosed in the accompanying Proxy Statement; SECTION 14A SAY-ON-PAY VOTES ISSUER 191603.000000 0 FOR 191603.000000 FOR Edgewise Therapeutics, Inc. 28036F105 US28036F1057 06/13/2025 Elect the directors named in the attached Proxy Statement to serve until the 2028 Annual Meeting of Stockholders: Alan Russell, Ph.D. DIRECTOR ELECTIONS ISSUER 290270.000000 0 FOR 290270.000000 FOR Edgewise Therapeutics, Inc. 28036F105 US28036F1057 06/13/2025 Elect the directors named in the attached Proxy Statement to serve until the 2028 Annual Meeting of Stockholders: Arlene Morris DIRECTOR ELECTIONS ISSUER 290270.000000 0 WITHHOLD 290270.000000 AGAINST Edgewise Therapeutics, Inc. 28036F105 US28036F1057 06/13/2025 Ratify the selection of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025. AUDIT-RELATED ISSUER 290270.000000 0 FOR 290270.000000 FOR Edgewise Therapeutics, Inc. 28036F105 US28036F1057 06/13/2025 Conduct an advisory vote on the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 290270.000000 0 FOR 290270.000000 FOR Edgewise Therapeutics, Inc. 28036F105 US28036F1057 06/13/2025 Conduct an advisory vote on the frequency of future advisory votes on the compensation of our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 290270.000000 0 ONE YEAR 290270.000000 FOR Regeneron Pharmaceuticals, Inc. 75886F107 US75886F1075 06/13/2025 Election of Directors: Bonnie L. Bassler, Ph.D. DIRECTOR ELECTIONS ISSUER 84008.000000 0 AGAINST 84008.000000 AGAINST Regeneron Pharmaceuticals, Inc. 75886F107 US75886F1075 06/13/2025 Election of Directors: Michael S. Brown, M.D. DIRECTOR ELECTIONS ISSUER 84008.000000 0 AGAINST 84008.000000 AGAINST Regeneron Pharmaceuticals, Inc. 75886F107 US75886F1075 06/13/2025 Election of Directors: Leonard S. Schleifer, M.D., Ph.D. DIRECTOR ELECTIONS ISSUER 84008.000000 0 FOR 84008.000000 FOR Regeneron Pharmaceuticals, Inc. 75886F107 US75886F1075 06/13/2025 Election of Directors: George D. Yancopoulos, M.D., Ph.D. DIRECTOR ELECTIONS ISSUER 84008.000000 0 FOR 84008.000000 FOR Regeneron Pharmaceuticals, Inc. 75886F107 US75886F1075 06/13/2025 Ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025. AUDIT-RELATED ISSUER 84008.000000 0 FOR 84008.000000 FOR Regeneron Pharmaceuticals, Inc. 75886F107 US75886F1075 06/13/2025 Proposal to approve, on an advisory basis, executive compensation. SECTION 14A SAY-ON-PAY VOTES ISSUER 84008.000000 0 FOR 84008.000000 FOR Regeneron Pharmaceuticals, Inc. 75886F107 US75886F1075 06/13/2025 Proposal to approve an amendment to the Company's Certificate of Incorporation to declassify the board of directors. SHAREHOLDER RIGHTS AND DEFENSES ISSUER 84008.000000 0 FOR 84008.000000 FOR Regeneron Pharmaceuticals, Inc. 75886F107 US75886F1075 06/13/2025 Amendments to the Company's Certificate of Incorporation to Eliminate Supermajority Vote Requirements Proposal to approve an amendment to Article IV, Section 2(e)(8) of the Certificate of Incorporation CORPORATE GOVERNANCE ISSUER 84008.000000 0 FOR 84008.000000 FOR Regeneron Pharmaceuticals, Inc. 75886F107 US75886F1075 06/13/2025 Amendments to the Company's Certificate of Incorporation to Eliminate Supermajority Vote Requirements Proposal to approve an amendment to Article VI of the Certificate of Incorporation. CORPORATE GOVERNANCE ISSUER 84008.000000 0 FOR 84008.000000 FOR Cidara Therapeutics, Inc. 171757206 US1717572069 06/18/2025 Election of Class I Directors: Jeffrey Stein, Ph.D. DIRECTOR ELECTIONS ISSUER 84117.000000 0 FOR 84117.000000 FOR Cidara Therapeutics, Inc. 171757206 US1717572069 06/18/2025 Election of Class I Directors: Bonnie Bassler, Ph.D. DIRECTOR ELECTIONS ISSUER 84117.000000 0 WITHHOLD 84117.000000 AGAINST Cidara Therapeutics, Inc. 171757206 US1717572069 06/18/2025 Election of Class I Directors: Ryan Spencer DIRECTOR ELECTIONS ISSUER 84117.000000 0 FOR 84117.000000 FOR Cidara Therapeutics, Inc. 171757206 US1717572069 06/18/2025 Amendment to the Company's Amended and Restated Certificate of Incorporation, as amended, to increase the total number of authorized shares of Common Stock from 50,000,000 shares to 100,000,000 shares. CAPITAL STRUCTURE ISSUER 84117.000000 0 FOR 84117.000000 FOR Cidara Therapeutics, Inc. 171757206 US1717572069 06/18/2025 Approval of an amendment to the Company's 2024 Equity Incentive Plan. COMPENSATION ISSUER 84117.000000 0 AGAINST 84117.000000 AGAINST Cidara Therapeutics, Inc. 171757206 US1717572069 06/18/2025 Ratification of the appointment of Ernst & Young LLP by the Audit Committee of the Board to serve as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2025. AUDIT-RELATED ISSUER 84117.000000 0 FOR 84117.000000 FOR Cidara Therapeutics, Inc. 171757206 US1717572069 06/18/2025 Approval, on an advisory basis, of the compensation of the Company's named executive officers, as disclosed in: the proxy statement. SECTION 14A SAY-ON-PAY VOTES ISSUER 84117.000000 0 AGAINST 84117.000000 AGAINST EyePoint Pharmaceuticals, Inc. 30233G209 US30233G2093 06/18/2025 Election of Directors: Goran Ando, M.D. DIRECTOR ELECTIONS ISSUER 519831.000000 0 FOR 519831.000000 FOR EyePoint Pharmaceuticals, Inc. 30233G209 US30233G2093 06/18/2025 Election of Directors: Jay S. Duker, M.D. DIRECTOR ELECTIONS ISSUER 519831.000000 0 FOR 519831.000000 FOR EyePoint Pharmaceuticals, Inc. 30233G209 US30233G2093 06/18/2025 Election of Directors: Nancy Lurker DIRECTOR ELECTIONS ISSUER 519831.000000 0 FOR 519831.000000 FOR EyePoint Pharmaceuticals, Inc. 30233G209 US30233G2093 06/18/2025 Election of Directors: John B. Landis, Ph.D. DIRECTOR ELECTIONS ISSUER 519831.000000 0 FOR 519831.000000 FOR EyePoint Pharmaceuticals, Inc. 30233G209 US30233G2093 06/18/2025 Election of Directors: Wendy DiCicco DIRECTOR ELECTIONS ISSUER 519831.000000 0 FOR 519831.000000 FOR EyePoint Pharmaceuticals, Inc. 30233G209 US30233G2093 06/18/2025 Election of Directors: Karen Zaderej DIRECTOR ELECTIONS ISSUER 519831.000000 0 FOR 519831.000000 FOR EyePoint Pharmaceuticals, Inc. 30233G209 US30233G2093 06/18/2025 Election of Directors: Stuart Duty DIRECTOR ELECTIONS ISSUER 519831.000000 0 FOR 519831.000000 FOR EyePoint Pharmaceuticals, Inc. 30233G209 US30233G2093 06/18/2025 Election of Directors: Fred Hassan DIRECTOR ELECTIONS ISSUER 519831.000000 0 FOR 519831.000000 FOR EyePoint Pharmaceuticals, Inc. 30233G209 US30233G2093 06/18/2025 Election of Directors: Reginald Sanders, M.D. DIRECTOR ELECTIONS ISSUER 519831.000000 0 FOR 519831.000000 FOR EyePoint Pharmaceuticals, Inc. 30233G209 US30233G2093 06/18/2025 To approve Amendment No. 2 to the EyePoint Pharmaceuticals, Inc. 2023 Long-Term Incentive Plan to increase the number of shares of common stock authorized for issuance thereunder by 2,900,000 shares. COMPENSATION ISSUER 519831.000000 0 AGAINST 519831.000000 AGAINST EyePoint Pharmaceuticals, Inc. 30233G209 US30233G2093 06/18/2025 To approve, on an advisory basis, the compensation paid to the Company's named executive officers as disclosed in the accompanying proxy statement. SECTION 14A SAY-ON-PAY VOTES ISSUER 519831.000000 0 AGAINST 519831.000000 AGAINST EyePoint Pharmaceuticals, Inc. 30233G209 US30233G2093 06/18/2025 To vote, on an advisory basis, on the frequency of advisory stockholder votes on the compensation paid to our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 519831.000000 0 ONE YEAR 519831.000000 FOR EyePoint Pharmaceuticals, Inc. 30233G209 US30233G2093 06/18/2025 To ratify the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025. AUDIT-RELATED ISSUER 519831.000000 0 FOR 519831.000000 FOR Guardant Health, Inc. 40131M109 US40131M1099 06/18/2025 Election of Class I Directors: Vijaya Gadde DIRECTOR ELECTIONS ISSUER 60643.000000 0 FOR 60643.000000 FOR Guardant Health, Inc. 40131M109 US40131M1099 06/18/2025 Election of Class I Directors: Roberto Mignone DIRECTOR ELECTIONS ISSUER 60643.000000 0 FOR 60643.000000 FOR Guardant Health, Inc. 40131M109 US40131M1099 06/18/2025 Election of Class I Directors: Myrtle Potter DIRECTOR ELECTIONS ISSUER 60643.000000 0 FOR 60643.000000 FOR Guardant Health, Inc. 40131M109 US40131M1099 06/18/2025 Election of Class I Directors: Musa Tariq DIRECTOR ELECTIONS ISSUER 60643.000000 0 WITHHOLD 60643.000000 AGAINST Guardant Health, Inc. 40131M109 US40131M1099 06/18/2025 Ratification of the appointment of Deloitte & Touche LLP as Guardant Health, Inc.'s independent registered public accounting firm for the year ending December 31, 2025. AUDIT-RELATED ISSUER 60643.000000 0 FOR 60643.000000 FOR Guardant Health, Inc. 40131M109 US40131M1099 06/18/2025 Non-binding advisory vote to approve Guardant Health, Inc.'s named executive officer compensation. SECTION 14A SAY-ON-PAY VOTES ISSUER 60643.000000 0 FOR 60643.000000 FOR Nuvalent, Inc. 670703107 US6707031075 06/18/2025 Election of the following nominees as Class I directors: Grant Bogle DIRECTOR ELECTIONS ISSUER 42867.000000 0 FOR 42867.000000 FOR Nuvalent, Inc. 670703107 US6707031075 06/18/2025 Election of the following nominees as Class I directors: James R. Porter, Ph.D. DIRECTOR ELECTIONS ISSUER 42867.000000 0 FOR 42867.000000 FOR Nuvalent, Inc. 670703107 US6707031075 06/18/2025 Election of the following nominees as Class I directors: Anna Protopapas DIRECTOR ELECTIONS ISSUER 42867.000000 0 WITHHOLD 42867.000000 AGAINST Nuvalent, Inc. 670703107 US6707031075 06/18/2025 To approve, on an advisory basis, the compensation paid to our named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 42867.000000 0 AGAINST 42867.000000 AGAINST Nuvalent, Inc. 670703107 US6707031075 06/18/2025 To ratify the appointment of KPMG LLP as Nuvalent, Inc.'s independent registered public accounting firm for the fiscal year ending December 31, 2025. AUDIT-RELATED ISSUER 42867.000000 0 FOR 42867.000000 FOR Pyxis Oncology, Inc. 747324101 US7473241013 06/18/2025 The election of Class I directors named in the proxy statement: Santhosh Palani, Ph.D., CFA DIRECTOR ELECTIONS ISSUER 626637.000000 0 WITHHOLD 626637.000000 AGAINST Pyxis Oncology, Inc. 747324101 US7473241013 06/18/2025 The election of Class I directors named in the proxy statement: Darren Cline DIRECTOR ELECTIONS ISSUER 626637.000000 0 WITHHOLD 626637.000000 AGAINST Pyxis Oncology, Inc. 747324101 US7473241013 06/18/2025 The election of Class I directors named in the proxy statement: Rachel Humphrey, M.D. DIRECTOR ELECTIONS ISSUER 626637.000000 0 WITHHOLD 626637.000000 AGAINST Pyxis Oncology, Inc. 747324101 US7473241013 06/18/2025 The ratification of the appointment of Ernst & Young LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2025; AUDIT-RELATED ISSUER 626637.000000 0 FOR 626637.000000 FOR Novavax, Inc. 670002401 US6700024010 06/20/2025 Election of three Class III directors to serve on the board of directors, each for a three-year term expiring at the 2028 Annual Meeting of Stockholders: Rachel K. King DIRECTOR ELECTIONS ISSUER 37188.000000 0 FOR 37188.000000 FOR Novavax, Inc. 670002401 US6700024010 06/20/2025 Election of three Class III directors to serve on the board of directors, each for a three-year term expiring at the 2028 Annual Meeting of Stockholders: John W. Shiver, Ph.D. DIRECTOR ELECTIONS ISSUER 37188.000000 0 FOR 37188.000000 FOR Novavax, Inc. 670002401 US6700024010 06/20/2025 Election of three Class III directors to serve on the board of directors, each for a three-year term expiring at the 2028 Annual Meeting of Stockholders: Charles W. Newton DIRECTOR ELECTIONS ISSUER 37188.000000 0 FOR 37188.000000 FOR Novavax, Inc. 670002401 US6700024010 06/20/2025 The approval, on an advisory basis, of the compensation paid of our Named Executive Officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 37188.000000 0 FOR 37188.000000 FOR Novavax, Inc. 670002401 US6700024010 06/20/2025 Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025. AUDIT-RELATED ISSUER 37188.000000 0 FOR 37188.000000 FOR Structure Therapeutics Inc. 86366E106 US86366E1064 06/23/2025 Election of the nominees for Class II director named below to hold office until the 2028 annual general meeting of shareholders and their successors are duly elected and qualified, or until their earlier death, resignation or removal: Eric Dobmeier DIRECTOR ELECTIONS ISSUER 169939.000000 0 FOR 169939.000000 FOR Structure Therapeutics Inc. 86366E106 US86366E1064 06/23/2025 Election of the nominees for Class II director named below to hold office until the 2028 annual general meeting of shareholders and their successors are duly elected and qualified, or until their earlier death, resignation or removal: Joanne Waldstreicher, M.D. DIRECTOR ELECTIONS ISSUER 169939.000000 0 FOR 169939.000000 FOR Structure Therapeutics Inc. 86366E106 US86366E1064 06/23/2025 To ratify the appointment by the Audit Committee of the Board of Directors of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025. AUDIT-RELATED ISSUER 169939.000000 0 FOR 169939.000000 FOR Structure Therapeutics Inc. 86366E106 US86366E1064 06/23/2025 To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement. SECTION 14A SAY-ON-PAY VOTES ISSUER 169939.000000 0 FOR 169939.000000 FOR Structure Therapeutics Inc. 86366E106 US86366E1064 06/23/2025 To indicate, on an advisory basis, the preferred frequency of shareholder advisory votes on the compensation of the Company's named executive officers. SECTION 14A SAY-ON-PAY VOTES ISSUER 169939.000000 0 ONE YEAR 169939.000000 FOR IDEAYA Biosciences, Inc. 45166A102 US45166A1025 06/24/2025 To elect two Class III directors to hold office until the 2028 annual meeting of stockholders or until their successors are elected: Jeffery L. Stein. Ph.D. DIRECTOR ELECTIONS ISSUER 286579.000000 0 FOR 286579.000000 FOR IDEAYA Biosciences, Inc. 45166A102 US45166A1025 06/24/2025 To elect two Class III directors to hold office until the 2028 annual meeting of stockholders or until their successors are elected: Scott W. Morrison DIRECTOR ELECTIONS ISSUER 286579.000000 0 WITHHOLD 286579.000000 AGAINST IDEAYA Biosciences, Inc. 45166A102 US45166A1025 06/24/2025 To ratify the selection, by the Audit Committee of the Company's Board of Directors, of PricewaterhouseCoopers LLP, as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2025; AUDIT-RELATED ISSUER 286579.000000 0 FOR 286579.000000 FOR IDEAYA Biosciences, Inc. 45166A102 US45166A1025 06/24/2025 To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement accompanying this Notice of Annual Meeting of Stockholders. SECTION 14A SAY-ON-PAY VOTES ISSUER 286579.000000 0 FOR 286579.000000 FOR Rhythm Pharmaceuticals, Inc. 76243J105 US76243J1051 06/24/2025 Election of the Class II directors, each to serve for a three year term until the 2028 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified: Jennifer Good DIRECTOR ELECTIONS ISSUER 52675.000000 0 FOR 52675.000000 FOR Rhythm Pharmaceuticals, Inc. 76243J105 US76243J1051 06/24/2025 Election of the Class II directors, each to serve for a three year term until the 2028 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified: Edward T. Mathers DIRECTOR ELECTIONS ISSUER 52675.000000 0 WITHHOLD 52675.000000 AGAINST Rhythm Pharmaceuticals, Inc. 76243J105 US76243J1051 06/24/2025 Ratification of the appointment of Ernst & Young LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2025. AUDIT-RELATED ISSUER 52675.000000 0 FOR 52675.000000 FOR Rhythm Pharmaceuticals, Inc. 76243J105 US76243J1051 06/24/2025 Approval, on an advisory (non-binding) basis, of the compensation of the named executive officers of the Company. SECTION 14A SAY-ON-PAY VOTES ISSUER 52675.000000 0 FOR 52675.000000 FOR Rhythm Pharmaceuticals, Inc. 76243J105 US76243J1051 06/24/2025 Approval of an amendment to our Amended and Restated Certificate of Incorporation to provide for exculpation of officers from breaches of fiduciary duty to the fullest extent permitted by the General Corporation Law of the State of Delaware (the "Officer Exculpation Proposal"). CORPORATE GOVERNANCE ISSUER 52675.000000 0 FOR 52675.000000 FOR Rhythm Pharmaceuticals, Inc. 76243J105 US76243J1051 06/24/2025 Approval of an adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes at the time of the Annual Meeting to approve the Officer Exculpation Amendment. CORPORATE GOVERNANCE ISSUER 52675.000000 0 FOR 52675.000000 FOR ARS Pharmaceuticals, Inc. 82835W108 US82835W1080 06/25/2025 To elect the four nominees for Class II director named in the proxy statement to serve for three-year terms until the 2028 Annual Meeting of Stockholders: Richard Lowenthal DIRECTOR ELECTIONS ISSUER 507222.000000 0 FOR 507222.000000 FOR ARS Pharmaceuticals, Inc. 82835W108 US82835W1080 06/25/2025 To elect the four nominees for Class II director named in the proxy statement to serve for three-year terms until the 2028 Annual Meeting of Stockholders: Peter Kolchinsky DIRECTOR ELECTIONS ISSUER 507222.000000 0 WITHHOLD 507222.000000 AGAINST ARS Pharmaceuticals, Inc. 82835W108 US82835W1080 06/25/2025 To elect the four nominees for Class II director named in the proxy statement to serve for three-year terms until the 2028 Annual Meeting of Stockholders: Brenton L. Saunders DIRECTOR ELECTIONS ISSUER 507222.000000 0 WITHHOLD 507222.000000 AGAINST ARS Pharmaceuticals, Inc. 82835W108 US82835W1080 06/25/2025 To elect the four nominees for Class II director named in the proxy statement to serve for three-year terms until the 2028 Annual Meeting of Stockholders: Peter A. Thompson DIRECTOR ELECTIONS ISSUER 507222.000000 0 WITHHOLD 507222.000000 AGAINST ARS Pharmaceuticals, Inc. 82835W108 US82835W1080 06/25/2025 To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2025. AUDIT-RELATED ISSUER 507222.000000 0 FOR 507222.000000 FOR Praxis Precision Medicines, Inc. 74006W207 US74006W2070 06/26/2025 To elect the Class II Directors to serve until the 2028 Annual Meeting of Stockholders and until their respective successors have been duly elected and qualified: Jeffrey Chodakewitz, M.D. DIRECTOR ELECTIONS ISSUER 105047.000000 0 WITHHOLD 105047.000000 AGAINST Praxis Precision Medicines, Inc. 74006W207 US74006W2070 06/26/2025 To elect the Class II Directors to serve until the 2028 Annual Meeting of Stockholders and until their respective successors have been duly elected and qualified: Merit Cudkowicz, M.D. DIRECTOR ELECTIONS ISSUER 105047.000000 0 FOR 105047.000000 FOR Praxis Precision Medicines, Inc. 74006W207 US74006W2070 06/26/2025 To ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025. AUDIT-RELATED ISSUER 105047.000000 0 FOR 105047.000000 FOR Praxis Precision Medicines, Inc. 74006W207 US74006W2070 06/26/2025 To approve, on an advisory (non-binding) basis, the compensation of the named executive officers as disclosed in the Company's proxy statement for the 2025 Annual Meeting of Stockholders pursuant to the applicable compensation disclosure rules of the SEC, including the compensation tables and narrative discussion. SECTION 14A SAY-ON-PAY VOTES ISSUER 105047.000000 0 AGAINST 105047.000000 AGAINST TScan Therapeutics, Inc. 89854M101 US89854M1018 06/30/2025 To elect three Class I directors to the Company's Board of Directors: Stephen Biggar DIRECTOR ELECTIONS ISSUER 498008.000000 0 FOR 498008.000000 FOR TScan Therapeutics, Inc. 89854M101 US89854M1018 06/30/2025 To elect three Class I directors to the Company's Board of Directors: Gavin MacBeath DIRECTOR ELECTIONS ISSUER 498008.000000 0 FOR 498008.000000 FOR TScan Therapeutics, Inc. 89854M101 US89854M1018 06/30/2025 To elect three Class I directors to the Company's Board of Directors: Garry Nicholson DIRECTOR ELECTIONS ISSUER 498008.000000 0 WITHHOLD 498008.000000 AGAINST TScan Therapeutics, Inc. 89854M101 US89854M1018 06/30/2025 To ratify the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025 AUDIT-RELATED ISSUER 498008.000000 0 FOR 498008.000000 FOR